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While the effectiveness and benefits of statin medications have been demonstrated in 
numerous studies, adherence to statin therapy is still less than optimal. Psychosocial factors are 
attributed to a variety of health behaviors, but the study of their impact on statin medication 
adherence is limited. This study aimed to (1) investigate the effect of self-regulatory mechanisms 
impacting patients’ adherence to statin medications, (2) assess the effect of a regulatory fit 
intervention on the behavior, and (3) investigate how optimism may play a role in adhering to 
statin medications. 
Adults taking a statin medication were recruited from a Midwestern University health 
system and were randomized into two study groups. Each study group was primed with 
messages that were framed either as promotion or prevention; another randomization followed 
into three groups for each. Patients were primed with implementation intentions framed as 
promotion or prevention and one group served as the control receiving no implementation 
intentions. The Regulatory Focus and Fit Theories were used to design the intervention. The 
behavior of statin medication adherence and patient psychosocial factors were assessed via a 
series of questions delivered in two questionnaires two weeks apart. Conditional indirect 
processing models were designed to test the relationships between the psychosocial factors and 
the behavior of statin medication adherence. 
A total of 326 patients completed both surveys. Patients’ prevention compared to 
promotion orientation positively and significantly impacted the behavior of statin medication 
adherence directly and indirectly via behavioral intentions and motivational intensity. At weak 
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patient psychosocial factors, the Fit intervention resulted in higher statin medication adherence 
levels compared to the non-fit or control groups. Patients’ optimism levels positively impacted 
the behavior of statin medication adherence by significantly influencing behavioral intentions 
and motivational intensity, when levels of self-efficacy and outcome expectations were low or 
moderate. 
Patient psychosocial factors present an area of opportunity to explain the behavior of 
medication adherence and design interventions that will motivate patients to successfully engage 
in medication adherence. Future studies are needed to further investigate the effect of these and 
other psychosocial factors in a variety of medications and populations. 
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 - LITERATURE REVIEW AND BACKGROUND Chapter 1
Introduction 
 
Medications are one pathway by which the health of individuals and populations at large 
could be improved. From the Hippocrates’ times to the invention of penicillin to the discovery of 
DNA to today - the development and use of new medicines to ameliorate and/or cure various 
diseases is promising. Along with these positive promises come many challenges.  
One challenge is the complex biological system of the body unique to each individual. 
Another challenge is the complex psychosocial system, again unique for each individual. A 
person’s biological makeup interacting with the psychosocial environment subsequently 
influences the decisions and lifestyle a person engages in on a daily basis.  
In the pursuit of health, many individuals affected by either an acute or chronic condition 
will choose to take one or more medications during their lifetime. This decision may or may not 
be coupled with choosing to engage in other behaviors that could improve one’s health; a 
decision that is impacted again by a multitude of factors. Although many medications are being 
prescribed by health care providers to their patients, a decline in taking the prescribed medication 
as recommended is seen over time. This is called medication non-adherence, and this behavior 
serves as the focus of this study. 
In the next sections of this chapter the focus is on unwrapping the challenge of 
medication adherence. Specifically, medication adherence is being investigated in cardiovascular 
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patients who have been prescribed statin medications. This chapter begins with providing an 
overview of medication adherence followed by discussing the issue of statin medication 
adherence among cardiovascular patients. Next, it examines contributing factors and 
interventions focused on improving statin medication adherence followed by examining theories 
used to improve other health behaviors. Gaps and opportunities to improve medication adherence 
are identified and a theoretical framework for this study is created with the goal to potentially 
bridge the existing gaps. This chapter ends with an outline of the aims and hypotheses for the 
study. 
Medication Adherence 
The World Health Organization (WHO) reports that medication adherence in the 
developed world among patients with chronic diseases averages to 50%.
1
 Investing millions of 
dollars in developing new drugs will help only if patients adhere to their medications. As C. 
Everett Koop simply stated “drugs don’t work in patients who don’t take them”.
2
 This section 
will present how medication adherence is defined, why it is important, how it is measured, and 
describe the challenges associated with the behavior of adhering to medications. 
Medication adherence is defined as the extent to which a patient takes a prescribed 
medication according to the prescribed schedule by their health care provider.
2-5
 The terms 
adherence and compliance are often used interchangeably. Some studies differentiate adherence 
as primary or secondary.
1
 Primary adherence refers to the behavior of filling new prescription 
medications while secondary adherence refers to the behavior of taking the medication as 
prescribed once the prescription has already been filled. The term medication persistance refers 
to whether or not a patient stays on the prescribed therapy. Both, adherence and persistence to a 
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prescribed treatment, are complex behavioral processes influenced by the patient, providers, and 
their internal and external environments.  
Understanding medication adherence accross conditions in various populations is 
important for several reasons. One, there are negative conequences associated with medication 
non-adherence. Examples of consequences of medication non-adherence are: worsening of the 
disease, poor clinical outcomes, poor quality of health, high morbidity and mortality rates, and a 
heavy economic burden on the health care system.
1,2,4,6-8
 Specifically for the US health care 
system, non-adherence translates to a $290 billion of annual health care expenditures.
6
 It is also 
known that low adherence to placebo is linked to increased risk of death.
8
 Therefore, adherence 
to medications leads to improved patient outcomes via the effect of the medications or via the 
overall healthy adherer effect. This leads to the second reason why medication adherence is 
important. The positive outcomes of improved medication adherence are better health and 
quality of life for the patients, lower mortality rates across various conditions, and reduced health 
care costs. Hence, improving medication adherence across conditions and in various populations 
is a worthwhile goal. 
The need to improve medication adherence is clear. The strategies used to measure the 
behavior of medication adherence vary. There are more than 12 types of tools to measure 
medication adherence, ranging from specific statistical tools used in secondary analyses to pill 
counts to various questionnaires/scales and direct patient interviews.
1
The tool of choice used to 
measure medication adherence for each study varies depending on how medication adherence is 
defined and the scope of the project.  
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Measures of medication adherence, can be simplified in two categories: subjective and 
objetive measures.
1
 Subjective measures involve evaluation of medication-taking behavior either 
at the patient or provider level usually in the form of self-report. Objective measures are 
biochemical measures of the drug in the body, pill counts, electronic monitoring, and secondary 
database analyses. Other studies clasify the measures as either direct or indirect; biochemical 
measures representing the direct measures and the self-report measures representing the indirect 
ones.
1,3,5
 Strenghts and limitations are found in each measure. For example, the direct measures 
of medication adherence are usually costly with the potential bias of the white coat adherence 
and not feasible to be performed in large numbers. The indirect measures of medication 
adherence present recall and social desirability biases and in some cases communication 
challenges between the patient and the health care providers. Because perfect adherence where 
patients adhere to the treatment regimen 100% of the time is difficult and unrealistic, adherence 
to medications 80% of the prescribed doses or higher is often used as a benchmark when 
measuring medication adherence.
5,8
 However, the best strategy to measure medication adherence 
is to use a combination of methods, as not one tool is considered the gold standard.   
Among the multitude of medication adherence measures, some are utilized more 
commonly than others. Andrade et al., summarized in a review all the current known methods 
used to assess medication adherence and persistence. Among the multitude of choices of 
medication adherence measurements, the most common measure reported in this study is the 
medication possession ratio (MPR).
3
 MPR is a tool used to investigate medication adherence in 
secondary database analyses and can be defined generally in two ways. It may be defined as the 






In terms of questionnaires, with a 93% sensitivity and 53% specificity, the eight-item 
Morisky Medication Adherence Scale (MMAS-8) seems to be the most accepted self-report 
measure of medication adherence to medications. Its shorter version, the four-item Morisky 
Medication Adherence Scale (MMAS-4), is the most widely used scale for research as it is quick 
to administer and score.
1
 
Another valid and reliable measure of medication adherence is the single-item visual 
analogue rating scale (VAS). VAS asks individuals to estimate along a continuum from 0 to 
100% the percentage of medication dosages taken as prescribed during a specified period of 
time. It demonstrated similar adherence estimates to unannounced pill counts, electronic 
medication monitoring, and self-reported recall.
9,10
 This tool may serve best when medication 
adherence is investigated and measured among other factors.  
Challenges to ideal medication adherence involve medication, patient, provider, and 
health system factors.
4
 Medication factors include a complex regimen, side effects, and high out-
of-pocket costs. Patient factors may include a patient’s demographic characteristics such as race, 
marital status, ethnicity, socio-economic status; a patient’s health literacy; psychological and/or 
social challenges; perceived benefit of the medication; beliefs about the medication; patient’s 
motivation; and others. Provider factors may include poor communication, empathy, and 
compassion strategies offered to the patient. And lastly, health system factors may include 
insurance coverage and access to a health care facility. 
Addressing these challenges at all points of care: medication, patient, provider, and health 
system is important towards the improvement of medication adherence. Suggested by the WHO, 
medication adherence is based on three main pillars: patient information, motivation, and 
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behavioral skills, out of which motivation is considered to be most important.
4
 Patient’s 
motivation to engage in a behavior along with patient-provider communication and relationship 
are considered by other researchers, as well, as two key factors to consider when improving the 
quality of medication use.
2,11
 
Therefore, this study focuses on investigating a variety of patient-related factors, 
including motivation, affecting medication adherence. Specifically, the study focuses on statin 
medication adherence. The next section describes statin medications and their aid in 
cardiovascular health.   
Cardiovascular Health 
Since 1900, cardiovascular diseases (CVDs) have posed a public health challenge every 
year since except for 1918 and have accounted for more deaths in the United States than any 
other cause.
5
 A total of 83 million American adults are affected by CVDs.
12
 The total annual 
costs for CVDs and stroke are reported to be $316.6 billion, out of which $193.1 billion 
represent direct costs and $123.5 billion represent indirect costs.
13
 In 2010 the American Heart 
Association (AHA) stated its goal to improve the cardiovascular health of Americans by 
reducing deaths from cardiovascular diseases and strokes by 20% by 2020.
13,14
 To achieve this 
goal, various efforts are needed for cardiovascular health promotion and disease prevention, 
spanning from patient behaviors, to basic clinical research, to public policy programs.  
For an individual to achieve ideal cardiovascular health, one must engage in ideal health 
behaviors and attain ideal health factors.
13,14
 The considered ideal health behaviors are: 
nonsmoking, a body mass index of <25kg/m2, physical activity at goal levels, and a diet 
consistent with guideline recommendations. The ideal health factors to be attained are: total 
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cholesterol levels of <200 mg/dL, blood pressure levels of <120/80 mmHg, and fasting glucose 
of <100 mg/Dl in the absence of drug treatment.
13,14
 If any of the health factors are less than 
optimal, health care providers recommend an appropriate treatment guideline tailored for each 
patient. For example, if one’s cholesterol levels are too high, and ideally after all other tried 
health behaviors have failed, a patient is prescribed a cholesterol lowering medication.   
Lowering the cholesterol levels has been shown to reduce the incidence of Coronary 
Heart Disease (CHD).
5
 CHD is one type of Cardiovascular Disease (CVD), and it is described as 
atherosclerotic disease of the arteries. It is the leading cause of heart disease caused by plaque 
buildup in the arteries that supply blood to the heart. It is also named as coronary artery disease 
(CAD).
5
 Therefore, using various strategies to lower cholesterol levels and reduce the incidence 
of CHD via various health behaviors, including statin medications, is essential. 
Statin Medication Adherence 
To achieve cardiovascular health, one of the health behaviors individuals engage in is 
taking cholesterol lowering medications with the focus on reaching one of the ideal health factors 
of total cholesterol levels of <200 mg/dL. Cholesterol lowering medications have proven to 
prevent and reverse the progression of high cholesterol, known as hypercholesterolemia.
15
 
Statins are one class of cholesterol lowering medications and are currently the most commonly 
prescribed medications used to manage cholesterol levels.  
Statins play a critical role in the treatment (secondary) and prevention (primary) of heart 
disease and reduction of cardiovascular mortality.
5,16,18
 They have been shown to effectively 
lower cholesterol levels, have been proven to reduce cardiovascular mortality, and to 
substantially reduce plaque in coronary arteries. Although considered safe and effective, statin 
8 
 
non-adherence is documented in numerous studies.
16-18
 Specifically, taking statin medications as 
prescribed is known to be as low as 25% for primary prevention, 36% for coronary heart disease 
and 40% for acute coronary syndrome. The current statin medication adherence of 25-40% is 
suboptimal in view of the general targeted medication adherence goal of 80% or greater. 
Therefore, finding ways to better understand and increase statin medication adherence is of vital 
importance to decreasing cardiovascular events and disease. 
Contributing Factors  
There are four main categories of factors contributing to statin medication adherence: 
health system factors, health care provider, patient, and medication factors. Interactions between 
these factors influence patients’ adherence to statin therapy. Variability exists among research 
when identifying predictors for statin non-adherence in each of these categories. This variability 
may be due to various designs of research studies, different patient population, and diverse 
methodologies used. In the next four sub-sections, factors affecting statin medication adherence 
in each category are examined utilizing synthetized information from review and individual 
studies. 
Health System factors. Health system factors most often include the feasibility of access 
to care and costs.
5
 Although the cost of statin medications has been made more patient friendly 
over the years, studies still report that unfavorable co-payment structures to the patient and high 
out-of-pocket costs to be associated with lower adherence to statin therapy.
16,18,19
 Interestingly, 
increased lipid testing has been associated with better statin medication adherence.
16
 This may be 
due to patient’s being more educated and knowledgeable of potential risks of high cholesterol 
thus leading to better adherence.  
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Health care provider factors. Within the health care system, health care providers play 
an essential role contributing to statin medication adherence. The specialty of the health care 
provider influences patients’ behavior of adherence to statin therapy. It is found that certain types 
of physicians: cardiologist, primary care physician, and US medical graduate are associated with 
higher statin medication adherence.
20
 This may be due to the degree of trust the patient has in 
their health care provider and the strength of the patient-physician relationship developed. This 
trust has the potential to be strengthened at the patient and provider level. Patient reluctance to 
freely express his/her thoughts in regards to statin therapy during the patient-physician 
interaction may be due to views of the physician as the authority figure.
18
 Empowering patients 
with confidence in shared decision making in regards to their therapy may improve the patient-
physician relationship. This of importance as Chee et al. specifically reported that a poor 
physician-patient relationship was found to negatively affect adherence to statin therapy.
21
 This 
poor patient-physician relationship was expressed via patient dissatisfaction with the physician’s 
explanation in regards to disease, therapy, and potential adverse events and limited amount of 
time spent with the patient during consultation.
18,21
 Patient dissatisfaction with the physician’s 
explanation may be a perceived lack of effective communication. This is noteworthy as 
healthcare professionals have an opportunity to improve and tailor communication strategies 
with their patients according to their needs in regards to their behavior of taking statin 
medications.  
Patient factors. There are a multitude of patient factors that may influence the behavior 
of statin medication adherence, either in a positive or negative way. Specifically, for statin 
medication adherence, the most common predictors are: age, gender, race, income, health-
literacy, comorbidities, perception/beliefs, and lifestyle factors.
5,16,18,20-23
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Older patients of >70 years or greater and youngest patients of <50 years are found to 
have lower adherence to statin therapy compared to patients with ages between 50 to 69 years of 
age.
16,20,21
 Women are more likely to be more non-adherent to statin therapy than men.
16,20,22,24
 
Minorities are less likely to be adherent to statins compared to Caucasians.
16,20,22,24 
Higher 
income is associated with higher statin medication adherence
16,20,21
 while low health-literacy is 
associated with lower statin adherence.
18,21
 Lower educational attainment and high poverty levels 
are associated with statin non-adherence.
24
 
When it comes to comorbidities, there is a mix of findings on how they affect statin 
adherence.
16,21
 For example, patients with a history of cardiovascular disease and hypertension 
are more likely to be adherent to statin therapy. Conversely, patients with depression are found to 
be less adherent to statin therapy. And patients who have a history of diabetes present conflicting 
results when it comes to statin medication adherence; some studies report better adherence while 
others worse.
16,21
 It is also known, that first time statin users are less likely to be adherent 
compared to experienced statin users.
16
   
Lack of perceived benefits that statin therapy offers, low perceived need for statin 
therapy, perceived side-effects, overestimation of the effectiveness of the dietary change, 
previous negative experiences with pharmacological treatments, psychological challenges, and 
cognitive impairment - all were found to be a hindrance to adherence to statin therapy.
18,21
 For 
example, some concerns expressed by patients about statins were being uncertain about benefits 
or about statin importance, being inconvenienced by taking the a medication, being restricted to 
not drinking grapefruit juice, while other concerns were related to information of statin adverse 
events patients likely gathered from the internet.
18
 Based on the Theory of Planned Behavior, 
side-effects associated with statins are one of the perceived barriers to statin therapy, with 
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approximately 20% of patients discontinuing therapy due to myalgia.
21
 Other perceived barriers 
are costs of statin - increase in copayment for statin results in a 7% decrease in adherence, 
dissatisfaction with relationship between patient and physician – due to poor treatment 
explanation and short consultations, and reliance on diet control alone – many patients have the 
perception that it is sufficient for managing dyslipidemia.
21
     
Additionally, lifestyle factors were found to influence statin medication adherence.
23
 
Specifically, being overweight or obese and former smoking were found to be associated with 
better statin medication adherence, while risky drinking behaviors and a cluster of lifestyle risk 
factors were found to be associated with statin nonadherence. The cluster of lifestyle risk factors 
may include a high BMI, low physical activity, high alcohol consumption, and current smoking.  
Medication factors. In regards to regiment complexity, a pattern of high number of 
medications that are non-cardiovascular is linked to low statin adherence while a high number of 
cardiovascular medications is associated with statin adherence.
16
 Switching to generic statins 
lead to improved adherence to statin therapy.
19
 Statin medication adherence over time could drop 
significantly from 50% at 6 months to 30-40% at 12 months and cost for statin therapy may be a 
barrier to optimal adherence.
16,25-27
 
To conclude, all factors affecting statin medication adherence are important. Addressing 
all factors for all patients is neither feasible nor applicable, as some factors are relevant to some 
patients and not for others. Therefore, finding which factors influence statin medication 
adherence for a patient or a group of patients may be best in regards to finding interventions and 
solutions to helping patients improve their adherence to statin therapy. 
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For this study, we chose to focus on patient-related factors. Specifically, we chose to 
investigate how patients’ psychosocial factors such as patients’ motivation, intentions, optimism, 
self-efficacy beliefs, outcome expectations affect the behavior of statin medication adherence. 
Motivation is considered by WHO as a main pillars of medication adherence WHO.
4
 Hence, 
understanding patients’ motivational factors to engage in the behavior of statin medication 
adherence is important as it will bring insights on how to improve the patient-provider 
communication in future studies. Therefore, the findings of this study have the potential to help 
the patient, provider, and by improving outcomes the health care system as a whole.   
Interventions  
Interventions to improve statin medication adherence have been tested in various 
studies.
27-35
 Methods and result varied. Table 1.1 provides an overview of these studies and this 
section highlights findings as well as suggestions to moving forward. 
The studies reviewed tested interventions aimed at improving statin medication adherence 
focusing either on the entire class of statins, a single statin, and in some cases a combination 
therapy consisting of a statin and other medications. The duration of interventions and follow-up 
ranged from 4 months to 2 years. The majority of studies used usual care as the control group, 
with one study using data from a national pharmacy claims database to assess statin adherence as 
the control group. The most common measure for statin medication adherence in these studies 
was MPR; other measures included pill and packet counts, refill records, MEMS records, and 
self-report questionnaires.   
Interventions included patient-pharmacist counseling, patient-physician counseling, 
telephone counseling and reminders, and mailing of educational materials. The majority of 
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interventions, except two, resulted in better adherence to statin therapy.
27-35
 The ones resulting in 
better statin therapy all involved counseling with a health care professional, either a pharmacist 
or physician, in person or via the telephone. One intervention that resulted in no significant 
increase in statin medication adherence consisted of mailing video educational materials.
34
 
Furthermore, one study that included both telephone and postal reminders, in addition to 
physician counseling, resulted only in significant association between statin medication 
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These studies suggest that patient contact by a health-care professional in regards to statin 
therapy is essential in improving adherence. Pharmacists serving as health-care professionals 
with direct contact with the patients are prime candidates for these interventions and have proven 
to serve effectively in this cause. Future studies are needed to investigate best approaches to 
counseling tailored to patients’ needs and motivation to improve the behavior of statin 
medication adherence. This study focuses on investigating patient motivational factors that affect 
statin adherence. In the next section theories addressing patient-related factors and various health 
behaviors are discussed. 
Theories and Concepts Addressing Patient Psychosocial Factors and Health Behaviors 
The focus of this study is to understand how patient related factors affect the behavior of 
statin medication adherence. Specifically, patient-related factors related to motivation, such as a 
patient’s regulatory orientation, intentions, self-efficacy, outcome expectations, and optimism 
were investigated in this study. Some of these factors have been studied in the context of 
medication adherence while others have been extensively studied and applied in other health 
behaviors. Next, theories and concepts related to these patient factors are described followed by 
their importance in studying the behavior of statin medication adherence. 
Regulatory Focus and Fit Theories 
Regulatory Focus Theory. The first patient related factor described is patient’s 
regulatory focus, also called regulatory orientation. The concept of regulatory focus originates 
from the regulatory focus theory proposing that all goal-directed behaviors are regulated by two 
independent motivational systems, namely promotion (self-regulation to strong ideals) and 
prevention (self-regulation to strong oughts).
36-39
 Higgins generated the concept while exploring 
how and why individuals are able to manage themselves in pursuit of a goal. More specifically, 
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he was interested to better understand how a person’s orientation affects perceptions, judgments, 
decisions, and behavior.  
The regulatory focus theory proposes that the promotion and prevention self-regulatory 
motivational systems operate differently according to specific human need.
36-39
 The human 
promotion motivational system operates to meet the survival need of nurturance (nourishment) 
and is characterized by ideals including hopes, wishes, and aspirations as maximal goals to be 
reached. Ideal self-regulation then is concerned with the presence or absence of positive 
outcomes and involves promotion-focus concerns, such as advancement, aspirations, and 
accomplishments. The human prevention motivational system operates to meet the survival need 
of obtaining security and is characterized by oughts including duties, obligations, and 
responsibilities as minimal goals to be met. Ought self-regulation is concerned with the presence 
or absence of negative outcomes and involves prevention-focus concerns, such as protection, 
safety, and responsibilities. Additionally, situations involving gain-nongain induce a promotion 
focus while situations with loss-nonloss induce a prevention focus.
36 
Higgins explains gain and 
loss originating from the child-caretaker relationship. For example, nongain would be 
withdrawing love from a child by the caretaker to communicate an undesired state of the child’s 
actions, such as lack of advancement or accomplishment.
40 
The prospect theory suggests that 
individuals respond differently to messages that are framed as gain or loss.
41 
 For example, in the 
context of smoking and dental health, gain-framed messages resulted in increased interest in 
plaque-fighting mouth rinse and in increased abstinence from smoking compared to loss-framed 
messages.
41,42
 The regulatory focus theory consists of message framing as well, with promotion 




Higgins suggests via the regulatory focus theory that the two systems, promotion and 
prevention, have distinct strategic means of regulating behavior towards desired end-states or 
end-goals.
36,37,39
 Promotion focused individuals use approach-eagerness strategic means and 
prevention focused individuals use an avoidance-vigilant strategic means to achieve a goal. 
Approach strategic means are described by strategically approaching matches to desired end-
states and ensuring hits and against errors of omission. Avoidance strategic means are described 
by strategically avoiding mis-matches to desired end-states, ensuring correct rejections and 
against errors of commission.  
A person’s regulatory focus may be chronic or situational and it can be induced.
36,38
 
Individuals with a chronic or situationally induced regulatory focus are inclined to utilize that 
approach’s (promotion or prevention) strategic means in order to achieve a goal. The chronic 
regulatory focus is measured with the Regulatory Focus Questionnaire (RFQ) and is associated 
with styles of child-caretaker interaction and socialization processes.
43
 The chronic orientations 
are not bipolar constructs; a patient may be high or low in both.
39
 The situational regulatory 
focus is experimentally manipulated using a priming technique. The priming technique involves 
framing worded statements as either promotion or prevention. For example, priming for 
promotion focus would include ideals, such as dreams, hopes and aspirations a patient may have 
in regards to their goal of cardiovascular health and priming for prevention focus would include 
oughts, such as duties, obligations, and responsibilities a patient may have in regards to their goal 
of cardiovascular health.  
In the context of the behavior of medication adherence, a patient that is at high risk for 
cardiovascular disease and has a promotion focus will have a goal to have great cardiovascular 
health and will engage in nutrition, exercise, and medication behaviors including taking their 
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statin medication as indicated by their health care provider that will lead to reducing risks and 
achieving the goal of cardiovascular health. A patient with a prevention focus with the same goal 
will be careful to fulfill and know the required information about cardiovascular disease and 
avoid anything that will hinder achieving this goal, including not taking their statin medication as 
directed by the health care provider.  Taking the statin medication as directed and engaging in 
additional behaviors leading to cardiovascular health represent promotion orientation while 
fulfilling requirements and avoiding any potential hindrances represent prevention orientation. 
The promotion-prevention orientations co-exist within every person and when activated via 
priming tend to alter perception and behavior.
43
  
The Regulatory Focus Questionnaire (RFQ) that measures chronic orientation was 
developed by Higgins. It consists of eleven items, six of which are promotion scale items and 
five of which are prevention scale items. It exhibits good internal reliability (alpha=0.73 for 
promotion and 0.80 for prevention) and excellent fit (0.95). There was no correlation found 
between the promotion and prevention scales.
38
 
Studies on regulatory focus investigated the effect of orientation on decision-
making.
36,37,39
  Specifically, the value derived from various outcomes and from fit was 
determined. For the value from outcomes studies, findings indicate that decision makers in a 
promotion focus treat promotion relevant outcome dimensions, such as emotional appraisal and 
object evaluation, as more important than prevention relevant outcome dimensions, and vice-
versa. For example, one study demonstrated that promotion individuals value the dimensions of 
luxury and innovation of a car product while prevention individuals value the dimensions of 
protection and reliability of the same car product.
39
  The value of fit studies focus on how the 
match between individual’s orientations and strategic means affect emotions or object 
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evaluation. Findings indicate that a match, defined as fit, results in better feelings about a choice 
or decision and higher value assigned to a product.
36,39
   
This study focuses on how regulatory focus as a motivational system drives the behavior 
of adhering to one’s prescribed medication. Specifically, we are interested whether promotion or 
prevention will affect statin medication adherence similarly or different. Understanding under 
which regulatory orientation system a patient operates will equip us to tailor medication 
adherence messages and communication according to each patient’s orientation in future 
research. The next section examines the Regulatory Fit Theory to explain how a match between a 
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Regulatory Fit Theory. The regulatory fit principle encompasses and goes beyond the 
regulatory focus theory proposing that motivational strength to obtain a goal is enhanced when 
the strategy used sustains the current regulatory orientation.
37,44,45
 In other words, a match 
between a person’s orientation (promotion/prevention) towards a goal and the means (approach-
eagerness/avoidance-vigilance) that a person uses to achieve the goal produces a state of 
regulatory fit, which in turn creates a feeling of rightness. This feeling of rightness increases the 
person’s engagement in the task necessary to accomplish the goal. Regulatory fit operates 
independently of one’s expectancies and value assigned to a goal and leads to not only higher 
motivation in goal pursuit, but also to feeling better and more alert about a decision, and to 
enjoying goal pursuit more.
37
 
To demonstrate the applicability of the regulatory fit theory, an example of students 
working towards the goal of attaining an A in a course is considered.
37
  All students in the course 
if achieve the goal of receiving an A will have outcome benefits; however the means to achieve 
the goal may be different for different students. Some students in the course may have a 
promotion orientation and see the goal of obtaining the A as an accomplishment, while others 
may have a prevention orientation and see the goal of obtaining the A as a responsibility. Hence, 
the promotion oriented students may read material beyond the assigned readings as the means to 
attain the A and the prevention students may be careful to fulfill all course requirements as the 
means to attain the A. The fit here exists between students’ regulatory orientations and goal 
pursuit means. Reading extra material fits an accomplishment orientation. Fulfilling course 
requirements fits a responsibility orientation. Independent of the value from the worth of 
obtaining the A in the course, students will experience a regulatory fit when they use goal pursuit 
means that fit their regulatory orientation. This regulatory fit increases the value of what they are 
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doing and increases their motivation to accomplish the goal. Higgins reports that goal 




Considering goals in the context of improving health behaviors, health care providers can 
be trained via different strategies to enhance communication. For example, considering the 
health behavior of interest in this study, medication adherence, pharmacists can frame health 
messages as promotion or prevention according to each patient’s regulatory orientation, and/or 
prime a patient’s regulatory orientation to match the strategic means to achieve better medication 
adherence and ultimately better health outcomes. By tailoring communication to create 
regulatory fit, patients’ motivation to engage in pursuits towards accomplishing the goal will be 
increased. Testing and applying the regulatory fit theory in communication strategies utilized by 
health care providers when interacting with their patients to improve medication adherence is a 
future research goal to be pursued. Understanding how to tailor communication is an important 
first step. Thus, the ramifications of this study are to better understand and enhance the 
effectiveness of tailored messages targeting medication adherence using the regulatory fit theory.  
The next section will examine how the regulatory fit theory has been studied in the context of 
tailored messages and human behaviors thus far. 
 Regulatory Fit in Human Behaviors 
Regulatory focus theory and the regulatory fit principle can be used to increase the 
effectiveness of health messages and health behavior. The behaviors studied in the context of the 
regulatory fit theory include physical activity, fruit and vegetable consumption, writing, 
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Findings indicate that tailored messages that fit individuals’ regulatory focus lead to 
greater physical activity participation and more positive feelings than non-fit messages.
46
 
Regulatory focus studies on fruit and vegetable consumption show that participants who 
experienced fit (promotion/benefits and prevention/costs) ate about 20% more fruits and 
vegetables compared to participants experiencing non-fit (promotion/costs and 
prevention/benefits participants).
44
 Furthermore, tailored messages targeting increase of fruit and 
vegetable consumption at the 4
th
 month follow-up were more efficacious when congruent with 
participants’ regulatory focus.
47
  Similarly, promotion/eagerness and prevention/vigilance 
participants are found to be 50% more likely to turn in their written reports during their leisure 
time than promotion/vigilance and prevention/eagerness participants.
44
 Regulatory fit increases 
an individual’s motivational intensity to engage in changing strong unhealthy snacking habits.
48
 
Prevention regulatory fit with worry leads to engagement in cancer detecting behaviors while a 
promotion regulatory fit leads to use of stimulants in order to achieve academic goals.
50
 When 
supplementing with omega-3 products, findings indicate that prevention outcome expectations 
are strengthened at high levels of self-efficacy.
49
 
Examples of a promotion and prevention-focused messages in the context of physical 
activity are:” Scientists say to accumulate physical activity throughout the day to stay healthy or 
improve your health” and” Scientists say failing to accumulate enough physical activity 
throughout the day can lead to poor health”.
46
 Examples of promotion and prevention-focused 
messages in the context of fruits and vegetable consumption are: ”Optimize your health: eat 5 to 
9 fruits and vegetables every day; add chopped green peppers, mushrooms, and onions to your 
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scrambled eggs or omelet – they add fiber, which promotes optimal colon function; so, achieve 
the 5 to 9 goal every day to look and feel your best; promote your health: eat more fruits and 
vegetables today” and ”Protect your health: eat 5 to 9 fruits and vegetables every day; add 
chopped green peppers, mushrooms, and onions to your scrambled eggs or omelet – they add 
fiber, which helps to prevent colon cancer; meet the 5 to 9 guideline every day to protect your 
health; prevent disease: eat more fruits and vegetables today”.
47
 
Next, in order to better understand the methodology used in these studies, a detailed 
description is provided for each study investigating regulatory focus/fit in the context of the 
specific behavior studied. 
Specific Example of Behaviors Examined via Regulatory Fit: Turning in Reports and 
Eating more Fruits and Vegetables. Spiegel et al. examined via two experiments how regulatory 
fit enhances motivational strength during goal pursuit.
44
 The first experiment examined whether 
students with a chronic promotion or prevention focus who used strategic means that fit their 
regulatory state would be more likely than those who used non-fitting strategic means to write 
and turn in a report. The second experiment examined whether students who read a promotion or 
a prevention framed message that encouraged eating more fruits and vegetables would eat more 
over the course of a week if they imagined the benefits they might get by complying or the costs 
they might incur via non-compliance. These two tasks are common in life and considered to have 
a practical value in addition to the theoretical significance.  
For the first experiment, a total of 71 Columbia undergraduate students participated. They 
received $5 for the first part completing a Self-Guide Strength measuring people’s ideal 
(promotion) and ought (prevention) selves and $7 when turning the report of minimum 100 
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words. The ‘ideal’ self was defined as the type of person they ideally would like to be. The 
‘ought’ self was defined as the type of person they believed they ought to be. Participants were 
asked to list in a random order, 3 ideals and 3 oughts. They were asked to rate from 1-4 (slightly, 
moderately, a great deal, extremely) the extent to which they ideally like for their ideals or the 
extent they ought for their oughts. They were also asked to rate the extent to which they actually 
possessed the attribute on the same scale. A total ideal strength score and ought strength score 
were calculated by summing the ideal/ought attribute and the extent reaction times.  
The strategic means in this experiment refer to implementation intentions. Participants 
were asked to imagine certain steps that they might take in writing the report: when, where, and 
how participants planned to write. For the when/eagerness manipulation, participants were asked 
to imagine a good convenient time when they would be able to write their reports while for the 
when/vigilance manipulations, participants were asked to imagine times that were bad or 
inconvenient for writing their reports, such as when they were busy, so that they could avoid 
those times. For the where/eagerness manipulation, participants were asked to imagine a 
comfortable, quiet place where they might write their reports while for the where/vigilance 
manipulation, participants were asked to imagine places that were uncomfortable or with lots of 
distractions so that these places could be avoided when writing their reports. For the 
how/eagerness manipulation, participants were asked to imagine capturing as many details as 
they could and creating their reports as vivid and interesting as possible while the how/vigilance 
manipulation, participants were asked to imagine not forgetting to leave any details out and 
being very careful not to make their reports bland or boring.  
A 3-way chi-square with dominant regulatory focus (promotion/prevention), strategic 
means (eagerness/vigilance) and whether participants turned in their report (yes/no) revealed that 
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74% of participants who experienced a fit turned in their reports compared to 54% in 
promotion/vigilance and 46% in prevention/eagerness groups (p<0.05). This result indicates that 
the presence of regulatory fit between students’ chronic regulatory orientation and the type of 
plans they mentally stimulated was found to have a significant impact on the likelihood that they 
would complete the goal of writing and turning in a report. No main effects were found between 
regulatory focus or implementation intentions on participants turning in their reports; only the fit 
between regulatory focus and implementation intentions exerted an influence on students’ 
behavior.  
The second experiment extended the test by manipulating participants’ regulatory focus 
instead of measuring the chronic state. Additionally, rather than varying the plans of mental 
stimulations, participants were asked to imagine possible outcomes (the benefits of compliance 
or costs of non-compliance). The explanation of this design is based on the idea that a recipient’s 
behavioral response to a health message may be a function of both the strategic framing of the 
outcomes to be imagined and the pre-existing psychological perception of the health issue. 
Specifically, this experiment investigated how the fit between regulatory focus and strategic 
outcome framing influences the effectiveness of health messages in changing the behavior of 
eating more fruits and vegetables. 
Participants consisted of 150 Columbia undergraduate students. The experiment consisted 
of two sessions. In session 1, participants were given a booklet that had a cover letter, the food 
habits questionnaire, a health message, and an item measuring their confidence level “if you 
wanted to change your current diet by including more fruits and vegetables, how confident are 
you that you could make such a change?” (1=not at all to 7=extremely). This last measure was 
included as a way to rule out the possibility that the effect of regulatory fit on the behavior is 
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mediated by students’ beliefs. Session 2 consisted of students completing a daily nutrition log 
booklet for 7 days.  
Regulatory focus was manipulated by imagining either the benefit or the cost of eating or 
not eating the right amounts of fruits and vegetables consumed daily. Examples of promotion 
regulatory focus framing: ‘If you eat the right amount of fruits and vegetables daily, you can 
experience an overall sense of feeling good about yourself’ and “If you eat the right amount of 
fruits and vegetables, you can actively help keep yourself safe from illness and obtain overall 
good health”. Examples of prevention regulatory focus framing: ‘If you do not eat the right 
amount of fruits and vegetables, you cannot experience an overall sense of feeling good about 
yourself’ and “If you do not eat the right amount of fruits and vegetables, you cannot actively 
help keep yourself safe from illness and facilitate overall good health”. The health message was 
150 words in length and was either promotion or prevention focused. The promotion message 
emphasized accomplishments while the prevention one emphasized safety. The health message 
outcome framings were expected to interact with regulatory focus to predict behavioral change. 
Results of a 2x2 ANOVA with regulatory focus and outcome framing indicated no 
significant effects on participants’ confidence that they could change their eating habits. 
Therefore, confidence was not a mediator of the fit effects on fruits and vegetable consumption. 
The main findings of the second session were that participants with regulatory fit between their 
regulatory focus and outcome framing ate 21% more servings of fruits and vegetables during that 
one week. This behavior change occurred only as a function of the fit between the strategic 
direction of outcome framing and the regulatory orientation of the participants. This finding can 





Other Behaviors Examined via Regulatory Fit. The behavior of physical activity, 
snacking habits, supplementing with omega-3 products, and that of health care-taking were 
studied in the context of regulatory fit as well.
46,48-50
 Another study examined whether tailored 
messages to individual’s regulatory focus increased the persuasiveness of messages encouraging 
greater fruit and vegetable intake.
47
 In this study tailored messages as promotion or prevention 
were mailed to participants who were randomly assigned to promotion and prevention groups. 
The first study on fruit and vegetable consumption manipulated regulatory focus as well, the 
approach being with framing the health message outcomes as either benefits or costs while this 
study framed the goal and the means to achieve the goal. The behavior was measured via self-
report over the telephone at 1month and 4month after the study. Findings of this study indicate 
that at 4 months individuals with a fit between their orientation and framed messages resulted in 
increased likelihood of adhering to the fruit and vegetable intake guideline compared to non-fit.   
Similar findings were found for the behavior of physical activity.
47
 The intervention 
consisted in tailored messages delivered via the telephone that fit an individual’s regulatory 
focus resulted in greater physical activity participation and more positive feelings than non-fit 
messages. This is true for both promotion and prevention messages; promotion group was the 
only one with statistical significance. The behavior was assessed two weeks after the delivery of 
the intervention via a telephone interview. Tam et al. examined whether matching 
implementation intentions to people’s regulatory orientation affected the effectiveness of 
changing unhealthy habits in undergraduate students.
48
 Results showed that participants with 
weak unhealthy snacking habits consumed more healthy snacks when forming implementation 
intentions that matched or mismatched with their regulatory orientation compared to no 
implementation intentions formed. Participants with strong unhealthy habits, however, consumed 
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more healthy snacks only when forming implementation intentions that fit their regulatory 
orientation: promotion-focused participants with promotion implementation intentions or 
prevention-focused participants with prevention implementation intentions.
48
  
Tudoran et al. investigated how regulatory focus, self-efficacy, and outcome expectations 
serve as drivers of motivation to consume omega-3 supplements and omega-3-enriched food 
products.
49
 The researchers of this study assessed how self-efficacy interacted with promotion 
and prevention outcome expectations to determine an individual’s motivation to engage in the 
behavior of adopting health food products. Findings indicated that the relationship between 
prevention outcome expectations impacted intentions directly and interacted with self-efficacy 
beliefs, while promotion outcome expectations had a significant main effect on intentions 
independently of self-efficacy. This study suggests that consumers’ motivation to adopt healthy 
food products needs to be encouraged by stimulating promotion outcome expectations. When a 




Uskul et al., investigated the fit between prevention regulatory focus and tendency to 
worry about ill health and fit between promotion regulatory focus and tendency to perceive 
thrilling activities as pleasurable.
50
 The health-related behaviors investigated were: vigilant 
health care-taking such as cancer detection vs eager disregard of health in pursuit of academic 
goals. Main findings from this study indicate that prevention individuals that are high in worry or 
who have had worry about health triggered in the moment were more likely to engage in health 
care-taking behaviors, such as cancer detection. Conversely, promotion individuals were more 
likely to use stimulants (caffeine, cold remedies) to overcome physical weakness in pursuit of 
academic goals. This suggest that regulatory fit can result in both, positive and negative 
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behavioral outcomes, such as cancer detection and a tendency to engage in negative detrimental 
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In summary, these studies suggest that the motivational regulatory fit theory applied to 
various health related behaviors results in positive outcomes. Specifically, when applying the 
principle of regulatory fit, positive outcomes were identified in behaviors such as: improved 
writing and turning academic reports, increase of physical activity, more fruit and vegetable 
consumption, changing in unhealthy snacking habits, engagement in cancer detection behaviors, 
and the use of stimulants (caffeine, cold remedies) to achieve academic goals.
44,46-50
 The 
definition of regulatory fit varied across studies. Regulatory fit was defined as the fit or non-fit 
between regulatory focus and strategic means used to affect a behavior, between regulatory focus 
and tailored messages/outcome message framing, between regulatory focus and implementation 
intentions, and between regulatory focus and thrill seeking or worry about health behaviors. The 
majority of studies manipulated regulatory focus,
44,46,48,50
 others measured an individual’s 
chronic regulatory focus,
44,47
 and one study measured both the chronic and manipulated 
regulatory focus with similar findings among the two.
48
 Additionally, in one study the 
relationship between three factors including outcome expectations, self-efficacy, and intentions, 
where outcome expectations were manipulated (promotion and prevention), indicated that self-
efficacy affects one orientation (prevention) to impact intentions and not the other; promotion 
outcome expectations impact intentions independently of self-efficacy.
49
   
The effect of regulatory focus and fit has not yet been studied to our knowledge in the 
behavior of medication adherence. Using a similar strategy described in some previous studies, 
the effect of regulatory fit on the behavior of statin medication adherence was investigated. 
Regulatory fit in this study was defined as patients’ regulatory focus matched with 
implementation intentions. Furthermore, this study sought to better understand how this effect is 
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influenced by a patient’s motivation and behavioral intention (mediators) to engage in the 
behavior of adherence, and the concepts of self-efficacy and outcome expectations were tested as 
potential moderators affecting the behavioral outcome. 
Next, a description of the mediators and moderators used in the study along with theories 
behind them is provided. 
Behavioral Intentions 
Behavioral intentions served as a mediator in this study. Behavioral intentions are derived 
from The Theory of Reasoned Action and The Theory of Planned Behavior, both designed by 
Ajzen to predict and explain human behavior in specific contexts.
51
 They capture a person’s 
motivational factors that influence behavior and are an indication of how hard a person will try in 
order to achieve the behavior. 
Theory of Reasoned Action.
51 
In social psychology, the majority of human behavior is 
thought to be goal-directed. To achieve a goal, action must be taken. Actions, in turn, are 
controlled by intentions. However, not all intentions are transformed into action. The Theory of 
Reasoned Action explains causal links of intentions and behavior. The theory suggests that a 
person’s intention is determined by personal and social factors. The personal factor is the attitude 
towards the behavior defined as the positive or negative evaluation of performing the behavior. 
The social factor is one’s perceived perception of social pressures to perform or not the behavior, 
termed subjective norm. The intention to perform a behavior is determined by the positive 
evaluation and the salient beliefs that important others think.  
Why people hold certain attitudes and subjective norms is important to understand. 
Attitude towards a behavior is determined by a person’s salient beliefs, which in turn link the 
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behavior with a valued outcome. A person’s attitude is determined by the evaluation of 
outcomes. If one believes that performing the behavior will lead to positive outcomes, the 
attitude towards performing the behavior will be favorable; conversely, a belief of the behavior 
being linked to negative outcomes will produce an unfavorable attitude. These beliefs are termed 
behavioral beliefs. Subjective norms are associated with one’s beliefs of what others think; these 
are termed normative beliefs. Therefore, behavior is determined by intentions, intentions are 
determined by attitude towards the behavior and subjective norms, and attitude and subjective 
norm are determined by behavioral and normative beliefs. Beliefs represent information one 
holds, whether correct or incorrect, about their world. Hence one’s behavior is determined by 
this information. 
The theory is applicable to a variety of behavioral domains. Generally, people act in 
accordance to their intentions. There are many factors and anticipated events that can influence 
intentions. For example, events such as sudden illness, death in the family, loss of a job, effects 
of time, new information, confidence and commitment, individual differences, and long-range 
prediction can change one’s intention to engage in a specific behavior. One way to ensure the 
stability of intentions is to measure intentions immediately prior to the observation of the 
behavior. The stability of intentions influences the accuracy of behavioral predictions.  
A person’s volitional control influences the behavior towards a goal. Volitional control 
considers one’s perception of their ability to control events in their lives, as opposed to 
environmental factors. Beliefs in personal control over behaviors are related to internal factors 
such as individual differences, information, skills, abilities, will power (strength of character), 
emotions and compulsions, and to external factors such as time and opportunity, and dependence 
on other people.  
36 
 
The Theory of Planned Behavior (TPB)
51
 (Figure 1.2). Based on the Theory of 
Reasoned Action, behavioral intention is best defined as the intention to attempt to perform a 
certain behavior, given all the internal and external factors influencing the behavior. If an 
intention predicts attempts to perform a behavior and fails to predict the attainment of the 
behavioral goal, then factors that are outside one’s control (nonvolitional factors) block one in 
carrying out the intention. Control is related to developing a plan to achieve a behavioral goal. A 
plan may consist of intentions and possible alternatives, considering successes versus failures in 
achieving the goal.   
When the behavior is under complete volitional control, the theory of reasoned action 
applies. However, when internal and/or external factors influence successful performance of 
behavior and the possibility of failure is a consideration, its necessary to go beyond the theory of 
reasoned action to the theory of planned behavior. The theory of planned behavior allows study 
of behaviors influenced by internal and/or external factors when volitional control is limited. The 
difference between the theory of reasoned action and the theory of planned behavior is the 
introduction of the concept of perceived behavioral control. The concept of perceived behavioral 
control is determined by control beliefs and facilitates the implementation of behavioral 











































Attitudes, subjective norm, and perceived behavioral control, predict intentions 
differently across behaviors and situations.
52
 Examples of behaviors that have been studied in the 









 and medication use.
57,58
 
Application of the TPB to different behaviors resulted in insights into what influences 
parents’ feeding behaviors.
53
 Findings indicate that peers have more influence than dietary 
guidelines in parents’ decision on what to feed their children.  In an attempt to improve nutrition, 
the TPB was applied to explain dietitians’ intentions to promote whole-grain foods.
54
 Findings 
indicate that dietitians are overall positive about the health benefits associated with whole-grain 
foods, however many were found to have low levels of knowledge and self-efficacy in helping 
clients eat more whole-grain products. When investigating weight control, TPB was found to 
have a modest explanation between variables and as a model as a whole to explain only 11% of 
the variation in weight control.
55
 For physical activity, perceived behavior control strongly 
predicted physical activity and a person’s attitude was influenced by one’s intention to engage in 
exercise.
56
 Subjective norms were most influential when individuals had no intention to engage 
in exercise. In the context of medication adherence, subjective norms were found to be 
associated with increased adherence to antipsychotic medications in a sample of schizophrenic 
patients of Mexican American origin; attitudes and perceived control were not.
57
 The TPB was 
found to be effective in identifying factors that influence intentions to adhere to treatment among 
HIV-positive immigrant Latinos in a specific program.
57
 These studies indicate that the TPB and 
its concepts are useful when investigating human behaviors.  
This study utilized the concept of behavioral intentions from the TPB to better understand 
the behavior of medication adherence. The specific behavior is adherence to statin medications in 
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American adults who have been prescribed a statin medication. The uniqueness is that the 
concept in this study is examined as a mediator between patients’ regulatory focus and their 
actual behavior of adhering to statin medications.  
Although the theory of planned behavior is effective in identifying factors that lead to 
certain behaviors, often intentions may not be carried out. Development of plans to implement 
intentions can help transform the intention into actual behavior. Next, formation of 
implementation intentions is discussed. 
Implementation Intentions 
Implementation intentions are simple plans that help a person translate their goal into 
action.
56
 They are most helpful when people encounter challenges in their goal-intention such as 
failing getting started, becoming distracted, or falling into bad habits. Behavioral intentions by 
themselves, although found to predict behaviors, do so at a modest level. Only 20 to 30% of the 
variance in behavior is accounted to intentions.
59
 Therefore, formation of plans to implement an 
intention may serve as an effective self-regulatory tool for people who are motivated to 
overcome challenges and achieve their goal-directed behaviors. 
The purpose of implementation intentions is to promote attainment of a goal, specified in 
goal intention. They do so by automatizing action initiation, linking goal-directed responses to 
situational cues that elicit responses when encountered.
59 
When the pursuit of a goal is planned 
ahead of time, goal-directed behaviors can be more easily initiated once a situation is 
encountered. For example, a person will think of a situation X and link it to behavior Y by 
thinking when X occurs, I will perform response Y. Making specific decisions of when, where, 
and how will help in taking action to perform the Y behavior.
59-61
A specific example in the 
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context of medication adherence: people with the goal intention to adhere to their medications 
can form implementation intentions specifying when, where, and how they will take their 
medications; thus making behavior be under direct control of situational cues rather than it being 
under conscious and effortful control. 
Implementation intentions have proven to be effective in completing personal goals and 
in taking immediate action. The mechanism suggested by which implementation intentions do so 
is by heightened mental representation of a potential situation which leads to easier recognition, 
recall, and engagement in that situation when it comes.
59-61
 Initiation and engagement of action 
in that situation suggests that implementation intentions help resist temptation, fight bad habits, 
and create instant potentially good habits.
59,60
 
In the context of health promotion and health prevention behaviors, implementation 
intentions are found to be effective in a variety of behaviors. Examples of such behaviors are: 




 weight loss for overweight and obese women,
66





 reduction in drinking among undergraduate students,
70
 
increase in cervical screening,
71
 and self-monitoring of blood glucose.
72
 
Findings indicate that implementation intentions are an effective tool for promoting the 
inclusion of healthy foods, such as more fruits, in one’s diet, but less so for reducing unhealthy 
snacks in one’s diet.
62
 Implementation intentions are also effective in increasing physical activity 
in children.
63
 Moreover, when combining implementation intentions and a motivational theory 
based intervention, such as a decision balance sheet, a dramatic effect on exercise behavior was 
seen.
64,65
 Motivational intervention on itself produced significant effects on intentions only, not 
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on the exercise behavior itself.
64
 Simply forming implementation intention plans has proven to 
be effective in reducing dietary fat intake during a period of one month, to achieving greater 
weight loss among obese women, and to reducing of drinking and smoking.
66-70
 Furthermore, 
implementation intentions led to increased attendance for cervical screening for those forming 
implementation intentions compared to control, despite equivalent motivation to attend.
71
 
Interestingly, some studies tested implementation intentions on their own compared to a 
control group while other studies tested implementation intentions coupled with other 
motivational interventions. In both cases implementation intentions were found to have a 
positive effect on behavior either when tested on their own or coupled with a motivational 
strategy. In the case of self-monitoring blood glucose, implementation intentions together with 
implementation desire were tested as mediators between goal intentions and the behavior.
72
 Both 
were found to mediate this relationship.  
In one study, the role of implementation intentions was examined on healthy snacking 
behavior when the presence of fit or non-fit exists, where the fit condition was a match between 
regulatory orientation (promotion/prevention) and formed implementation intentions 
(promotion/prevention).
48
 Findings indicated that people who formed implementation intentions 
that matched their regulatory orientation experienced regulatory fit, which in turn heightened 
motivational intensity to attain a specific goal. To better understand the mechanisms of the 
behavior of statin medication adherence, similar approaches have been implemented. This study 
specifically investigated the role implementation intentions play when a match versus a 
mismatch is formed with regulatory focus on the behavior of medication adherence. 
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Additionally, this study considered the effect of one’s self-efficacy and outcome 
expectations on this relationship between regulatory fit/non-fit and statin medication adherence. 
These concepts are discussed next. 
Self-Efficacy and Outcome Expectations  
The concept of self-efficacy and that of outcome expectations originates from Bandura’s 
Social Learning Theory.
73,74
 Bandura defined the role of self-efficacy in the context of a person 
engaging in a behavior with a consequent outcome. The outcome, such as behavior change, is a 
function of one’s expectations about the outcome and one’s ability to engage in behavior 
(Figure1.3). 
Outcome expectations is defined as the belief about the likelihood of the behavior leading 
to certain outcomes.
73,75
 Self-efficacy is defined as one’s belief about his/her ability to 
successfully perform specific behaviors in particular situations to produce the outcomes.
73,75
 The 
two concepts operate independently of each other. One may believe that a specific action to 
produce a certain outcome, however if doubt about performing the behavior is included, then the 
belief will not be strong enough to influence the behavior. Furthermore, Maddux et al., 
determined that when a behavior is challenging to perform, if individuals believe that the 
behavior will result in favorable outcomes, they express greater confidence in their ability to 
perform the behavior.
75
 Conversely, individuals who have a weak relationship in their belief that 
the behavior will result in favorable outcomes, they express less confidence in their ability to 
perform. 
Self-efficacy is a major determinant of one’s choice of activities, effort, and persistence 
when stressful situations arise.
73
 Moreover, self-efficacy is found to be an accurate predictor of 
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performance on tasks of varying difficulty and an important determinant of health behavior 
change.
74,76,77
 Both self-efficacy and outcome expectations are found to be predictors of 
behavioral intentions.
78
 In a review of the effect of self-efficacy and outcome expectations on 
health practices, such as cigarette smoking, weight control, contraception, alcohol abuse, and 




In the context of regulatory focus, one specific study investigated how self-efficacy 
beliefs interact with different types of outcome expectations (prevention or promotion) to affect 
an individual’s behavior of adopting an omega-3 supplement or an omega-3 enriched food 
product.
49
 Findings indicate that outcome expectations and intention to engage in behavior were 
significantly enhanced by high levels self-efficacy beliefs only when a prevention frame was 
used. In this case only intentions and not the behavior itself were investigated.  
This study advances research of the two concepts, self-efficacy and outcome 
expectancies, by examining how the two moderate the relationship between behavioral intentions 
and the behavior itself, where behavioral intentions act in turn as a mediator between regulatory 
focus and the measured behavior of statin medication adherence.  
Next, the concept of optimism is described in this study. We examined whether patients’ 


































The concept of optimism refers to a person’s generalized favorable expectations for the 
future.
79
 Optimists expect good outcomes, even when things are hard. Pessimists expect the 
opposite. These expectations affect how optimists and pessimists approach the world and 
influence their behaviors. Individuals range from being very optimistic to very pessimistic. The 
theoretical basis for the concept of optimism comes from the expectancy-value theories of 
motivation,
79
 suggesting that in pursuit of goals, the more important the goal, the greater its value 
and likelihood of engaging in a behavior that would result in the desired end state or action. 
Optimism is a trait-like concept pertaining to life in general, rather to a specific context.  
The concept of optimism was measured in a multitude of studies and is found to be 
associated with multiple favorable behavioral outcomes. It is associated with better emotional 
well-being, more effective coping strategies, with better outcomes in physical health, with 
persistence in educational efforts, with higher income, and with better relationships.
79
 It is also 
linked to higher levels of engagement coping, better subjective well-being in times of difficulty, 
and greater likelihood that an individual will take proactive steps to protect one’s health.
79
 
In the context of behavioral and cardiovascular health, optimists tend to know more about 
risk factors related to heart attack.
79
 Optimism has also proven to have a protective effect on all-
cause cardiovascular mortality in old age,
80
 was found to be associated with a lower risk of 
stroke in older adults,
81
 and is associated with lower rates of rehospitalization after coronary 
artery bypass graft surgery.
82
 Furthermore, individuals who are optimistic were found to have a 
faster rate of physical recovery after coronary artery bypass surgery during the period of 
rehospitalization and faster rate of return to normal life activities once discharged from the 
hospital.
83
 Optimistic patients participating in a cardiac rehabilitation program have greater 
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success in achieving lower levels of saturated fat and body fat and overall coronary risk.
84
 
Among post-CABG treatment, optimists responded at higher rates to depression treatment.
85
 
Optimistic women are less likely to develop coronary heart disease, to die from coronary heart 
disease related causes, and have lower mortality due to all causes.
86
 
As demonstrated, optimism, as a trait-like concept, has favorable outcomes for 
cardiovascular patients. Many cardiovascular patients, to protect their heart health engage in the 
behavior of taking medications, including statins. Patients’ general expectations for the future 
(optimistic or pessimistic) may influence their intention or motivation to engage in the behavior 
of taking their statin medication as prescribed. This study examined whether optimism influences 
the behavior of statin medication adherence. Specifically, optimism levels of an individual were 
measured and determined whether it influenced one’s behavioral intentions or motivation leading 
to the behavior of statin medication adherence, considering a person’s self-efficacy and outcome 
expectancies. This is also the first study to our knowledge thus far where optimism is examined 
in the context of statin medication adherence. 
To measure optimism, the Life Orientation Test Revised (LOT-R) tool was used in this 
study.
87,88
 This is the most widely used and validated optimism measure thus far. The LOT-R is a 
10-item scale that was adapted from the LOT instrument developed to asses individual 
differences in generalized optimism versus pessimism. The LOT-R scale was constructed by 
eliminating two items dealing with coping style rather than with positive expectations for future 
outcomes. The items in the LOT-R consist of 3 positive worded items, 3 negative worded items, 
and 4 filler items. The higher the value implies higher optimism; scores ranging from 0-13 
indicate low optimism, 14-18 moderate optimism, and 19-24 high optimism. The LOT-R has 
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good internal consistency with a Cronbach’s α=0.78 and its test-retest reliability is 0.68 at 4 
months and 0.79 at 28 months.  
Concluding Remarks  
In summary, patient related factors are important in the context of human behavior. 
Regulatory focus, behavioral intentions, implementation intentions, self-efficacy, outcome 
expectations, and optimism have all been studied in the context of different behaviors and 
determined that each plays a role in behavioral goal decision-making. The review of this 
literature leads to the conclusion that identifying an individual’s regulatory focus and using 
means or tools, such as implementation intentions, that fit that individual’s orientation leads to 
increased motivation to engage in a behavior and ultimately to improved or changed behaviors. 
Furthermore, intentions to engage in a behavior have proven to be a significant predictor of 
behavior. In this study, the effect of intentions on behavior was examined. Specifically, 
intentions were chosen to be tested as mediators between an individual’s orientation and 
behavior. Beliefs about the likelihood of the behavior leading to certain outcomes (outcome 
expectancies) and beliefs in ability to successfully perform specific behavior (self-efficacy) are 
all linked to positive behavioral intentions or behavioral outcomes. In this study, it was tested 
whether the concepts of self-efficacy and outcome expectancy influenced a person’s behavioral 
intentions to engage in the actual behavior of taking statin medications as prescribed. Favorable 
outcomes of one’s generalized favorable expectations for the future, termed as optimism, were 
tested as a predictor of statin medication adherence for the first time in research’s history. Based 
on these theories and concepts, a conceptual model was developed and is described in the next 




Gaps and Opportunities  
The needs to improve medication adherence across conditions and to improve the 
cardiovascular health of patients across the nation are well established. Even though a multitude 
of studies focused to better understand factors contributing to medication nonadherence and 
interventions to improve both adherence and cardiovascular health exist, no one study or 
intervention can possibly explain all causes for these two needs. This is due to the multifactorial 
complexity of what constitutes health and that of medication adherence. 
The commonality across diseases and the challenge of medication adherence is the 
interaction of the patient seeking to improve their health with their health care professional. One 
health care professional of particular relevance to medication adherence is the pharmacist. The 
pharmacist serves as an ideal candidate to be an agent of positive change in improving 
medication adherence and help patients achieve their health goals. With tailored communication 
addressing the specific needs of each patient, this interaction can result in increased patient 
motivation to engage in the behavior of adherence. This study presents an innovative approach in 
better understanding patient motivational factors affecting the behavior of medication adherence. 
The patient motivational factors examined are derived from theories successfully used in the 
social-psychology literature to investigate other behaviors.  
The regulatory focus and fit theories provide a strong foundation in better understanding 
human motivation and strategies used to engage in goal-directed behaviors. The promotion and 
prevention self-regulatory motivational systems provide an explanation of how different 
individuals self-regulate either with ideals or oughts to meet specific needs. When individuals’ 
motivational system match their strategic means used to engage in a specific goal-directed 
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behavior, regulatory fit results. The fit effect results in greater motivation to engage in a task 
needed to accomplish a goal and has been proven effective in a variety of health behaviors. To 
our knowledge, the two theories have not yet been applied to the behavior of medication 
adherence. This study focuses on a unique opportunity of applying the two theories to the 
behavior of medication adherence, specifically on the behavior of adhering to statin medications 
prescribed to cardiovascular patients. This represents an important milestone in the field of 
medication adherence, as this study will present a better understanding of patient motivational 
factors to engage or not engage in the behavior of taking medications as prescribed. Furthermore, 
understanding under which regulatory orientation system a patient operates will equip us to tailor 
medication adherence messages and communication according to each patient’s orientation in 
future research. 
Before a patient engages in the behavior of adhering to statin medications, an intention to 
engage in the behavior is formed. Referred to as behavioral intentions, this concept captures a 
person’s motivation and indicates the degree of effort one will exert to achieve a behavior. 
Intentions originate from the Theory of Planned Behavior and have been applied to a variety of 
behaviors. Only a small percentage of the variance in behavior is accounted to intentions. 
Therefore, this study presents a unique approach to investigating how a person’s intentions 
mediate the relationship between one’s motivational orientation and the actual behavior of 
adhering to statin medications. This relationship is further tested to identify whether other patient 
psychosocial and medication-related factors, such as a patient’s self-efficacy, outcome 
expectations, insurance for drug therapy, duration of therapy, and others influence intentions to 
engage in the behavior. Self-efficacy and outcome expectations both are determinants of health 
behavior change and are found to be predictors of behavioral intentions. Examining whether the 
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two influence this relationship between intentions and the behavior statin medication adherence 
is important, as this will provide a better understanding on the specific patient psychosocial 
related factors that influenced medication adherence. Furthermore, the moderating effect of self-
efficacy and outcome expectations on behavioral intentions and motivational intensity was tested 
on the relationship between optimism and statin medication adherence.  
In order to achieve a behavioral goal, plans must be formed that will help one achieve the 
goal. These plans are often termed as implementation intentions and have been utilized as a 
helpful tool in goal attainment. In this study implementation intentions are coupled with a 
person’s motivational orientation in order to create fit or non-fit. Previously, this concept was 
tested in the behavior of healthy vs unhealthy snacking. Implementation intentions will be 
applied in this study to the behavior of statin medication adherence for the first time.  
In summary, this study is innovative and unique in combining concepts and theories 
across the social-psychology and health-pharmacy fields to better understand the behavior of 
statin medication adherence. Utilizing the motivational self-regulatory and fit principles as well 
as potential patient-related factors, such as their beliefs, expectations, and optimism levels, with 
the application of the tools of implementation intention, this study presents a novel way of 
studying medication adherence and understanding patient psychosocial factors influencing the 
behavior of adherence. This study is important in helping to better understand the behavior of 
statin medication adherence, with the hope to designing more effective interventions in future 
studies.   
Proposed Theoretical Framework 
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The theoretical framework used in this study combines the concepts of regulatory focus, 
regulatory fit (regulatory focus and implementation intentions), optimism, motivational intensity, 
behavioral intentions, self-efficacy and outcome expectations from the theories described in 
previous sections and medication-related factors to better understand the complexity of the health 
behavior of medication adherence (Figure 1.4).  
In this conceptual model the effect of regulatory focus, regulatory fit, and optimism on 
statin medication adherence was tested. In the first aim, the effect of Regulatory Focus 
(promotion/prevention) on statin medication adherence was tested with Motivational Intensity or 
Behavioral Intentions serving as the mediator and the concepts of Self-Efficacy, Outcome 
Expectations, or a Medication-related factor serving as the moderator. In the second aim, the 
effect of a Regulatory Fit intervention on statin medication adherence was tested. Specifically, 
interaction effects of Regulatory Fit, Non-fit, and Control were tested between high (strong) and 
low (weak) behavioral intentions, motivational intensity, self-efficacy, and outcome 
expectations. In the third aim, the effect of Optimism on statin medication adherence was tested 
with Motivational Intensity or Behavioral Intentions serving as the mediator and the concepts of 
Self-Efficacy or Outcome Expectations serving as the moderator.  
Figure 1.4 shows the conceptual framework used in the study. The squares/rectangles 
designate primary predictors and outcomes, including regulatory focus, regulatory fit (regulatory 
focus and implementation intentions), optimism, and statin medication adherence. The lines 
indicate causal pathways. The diamonds represent mediating variables or alternatively causal 
pathways between the predictor and behavior. The circles indicate the potential moderators of the 
causal relationships. Next, the overall objective, aims, and hypotheses for the study are 























































Overall Objective and Central Hypothesis 
The overall objective of this study was to test the effect of patient psychosocial factors on 
the behavior of statin medication adherence. The central hypothesis was that patient psychosocial 
factors will predict the behavior of statin medication adherence via a conditional indirect effect 
and that a Fit intervention will result in greater statin medication adherence compared to non-fit 
and control groups. 
Study Aims and Hypotheses 
Aim 1 (Regulatory focus): To test the conditional indirect effect of patients’ regulatory 
focus on statin medication adherence with behavioral intentions/motivational intensity as the 
mediator and patients’ self-efficacy/outcome expectations/ medication-related factors (time on 
statin, insurance coverage, and the number of non-prescription medications) as the moderator.  
Aim 2 (Regulatory fit): To test the effect of fit versus non-fit versus control on the 
behavior of statin medication adherence at weak versus strong behavioral intentions, 
motivational intensity, self-efficacy, and outcome expectations.  
Aim 3 (Optimism): To test the conditional indirect effect of patients’ optimism on statin 
medication adherence with behavioral intentions/motivational intensity as the mediator and with 
self-efficacy/outcome expectations as the moderator. 
Hypotheses for aim 1: Regulatory focus 
H1a: The regulatory focus of a person will influence behavioral intentions to engage in the 
behavior of statin medication adherence the higher the self-efficacy. 
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H1b: The regulatory focus of a person will influence behavioral intentions to engage in the 
behavior of statin medication adherence the higher the outcome expectations.  
H1c: The regulatory focus of a person will influence behavioral intentions to engage in the 
behavior of statin medication adherence the longer the statin therapy. 
H1d: The regulatory focus of a person will influence behavioral intentions to engage in the 
behavior of statin medication adherence if insurance is present. 
H1e: The regulatory focus of a person will influence behavioral intentions to engage in the 
behavior of statin medication adherence the higher the number of non-prescription medications 
present.  
H2: The stronger the behavioral intentions the greater the statin medication adherence levels. 
H3a: The regulatory focus of a person will influence motivational intensity to engage in the 
behavior of statin medication adherence the higher the self-efficacy. 
H3b: The regulatory focus of a person will influence motivational intensity to engage in the 
behavior of statin medication adherence the higher the outcome expectations. 
H3c: The regulatory focus of a person will influence motivational intensity to engage in the 
behavior of statin medication adherence the longer the statin therapy. 
H3d: The regulatory focus of a person will influence motivational intensity to engage in the 
behavior of statin medication adherence if insurance is present. 
H3e: The regulatory focus of a person will influence motivational intensity to engage in the 
behavior of statin medication adherence the greater the number of non-prescription medications. 
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H4: The stronger the motivational intensity the greater the statin medication adherence levels. 
Hypotheses for aim 2: Regulatory fit 
H1: There is no difference between regulatory fit, non-fit, and control groups when it comes to 
statin medication adherence. This hypothesis was tested with four different independent 
variables: motivational intensity, behavioral intentions, self-efficacy, and outcome expectations.  
H2: There is no difference between the weak and strong independent variable groups when it 
comes to statin medication adherence. This hypothesis was tested within each regulatory fit 
group (fit, non-fit, control). 
H2a1: There is no difference in statin medication adherence levels between the motivational 
intensity groups (weak vs strong) within the fit group. 
H2a2: There is no difference in statin medication adherence levels between the motivational 
intensity groups (weak vs strong) within the non-fit group. 
H2a3: There is no difference in statin medication adherence levels between the motivational 
intensity groups (weak vs strong) within the control group. 
H2b1: There is no difference in statin medication adherence levels between the behavioral 
intention groups (weak vs strong) within the fit group. 
H2b2: There is no difference in statin medication adherence levels between the behavioral 
intention groups (weak vs strong) within the non-fit group. 
H2b3: There is no difference in statin medication adherence levels between the behavioral 
intention groups (weak vs strong) within the control group. 
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H2c1: There is no difference in statin medication adherence levels between the self-efficacy 
groups (weak vs strong) within the fit group. 
H2c2: There is no difference in statin medication adherence levels between the self-efficacy 
groups (weak vs strong) within the non-fit group. 
H2c3: There is no difference in statin medication adherence levels between the self-efficacy 
groups (weak vs strong) within the control group. 
H2d1: There is no difference in statin medication adherence levels between the outcome 
expectations groups (weak vs strong) within the fit group. 
H2d2: There is no difference in statin medication adherence levels between the outcome 
expectations groups (weak vs strong) within the non-fit group. 
H2d3: There is no difference in statin medication adherence levels between the outcome 
expectations groups (weak vs strong) within the control group. 
Hypotheses for aim 3: Optimism 
H1: The greater the optimism the greater the intentions to engage in the behavior. 
H2a: Behavioral intentions will influence the behavior of statin medication adherence the greater 
the self-efficacy. 
H2b: Behavioral intentions will influence the behavior of statin medication adherence the greater 
the outcome expectations. 
H3: Optimism affects statin medication adherence directly. 
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H4: The greater the optimism the greater the motivational intensity to engage in the behavior. 
H5a: Motivational intensity will influence the behavior of statin medication adherence the 
greater the self-efficacy. 
H5b: Motivational intensity will influence the behavior of statin medication adherence the 
greater the outcome expectations. 
H6: Optimism affects statin medication adherence directly. 
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 - PAPER 1: REGULATORY FOCUS’ EFFECT ON STATIN MEDICATION Chapter 2
ADHERENCE 
Abstract 
Background: Medications are one effective tool used to improve health. Despite their 
effectiveness, medication adherence in the developed world among patients with chronic 
diseases is reported to be less than optimal, and efforts to improve statin medication adherence 
have been moderately successful. Regulatory focus, as a human motivational system, has been 
studied in various health-behaviors; however, its effect on the behavior of statin medication 
adherence has not been investigated. Understanding how regulatory focus affects statin 
medication adherence may provide important insights into designing new interventions to 
improve adherence.  
Aim: The aim of this study was to investigate the conditional indirect effect of regulatory focus 
on statin medication adherence.  
Methods: Patients were recruited from a large university health system to participate in the study. 
Data were collected from patients via two online questionnaires. Questionnaire one assessed the 
psychological and environmental variables and questionnaire two, sent two weeks later, 
medication adherence. The conditional indirect effect between regulatory focus and statin 
medication adherence was analyzed via the PROCESS macro tool. 
Results: The conditional indirect effect of regulatory focus on statin medication adherence was 
established when time on statin and insurance coverage were the moderators and behavioral 
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intention was the mediator. Furthermore, the conditional indirect effect of regulatory focus on 
statin medication adherence was seen when self-efficacy and the number of non-prescription 
medications served as moderators and motivational intensity as the mediator.  
Conclusion: Regulatory focus was a significant predictor of statin medication adherence, 
influencing the behavior directly and indirectly via several patient and medication-related 
factors.  
Introduction 
As the saying goes ‘Health is wealth’. Viewed as a resource for everyday life, health is 
pursued by people across all nations and cultures. In the pursuit of this valuable resource, 
individuals chose to engage in various health-promising behaviors, one of which is the behavior 
of taking medications. Medications serve as an effective tool in preventing, treating, or curing 
diseases. Despite the positive outcomes associated with the behavior of taking medications, 
challenges in taking medications as prescribed (adherence) or staying on the prescribed therapy 
(persistence) arise.
1-4
 These challenges are complex multifactorial behavioral processes.  
The challenges can present themselves at various levels including factors related to the 
medication, patient, health care provider, and health care system.
3
 Examples are: complex 
regimen and side effects; demographic, psychological, social characteristics and beliefs; 
communication and empathy with and towards the patient; insurance coverage and access to a 
health care facility; for each level. Addressing challenges at all levels is desirable, yet 
impractical. Therefore, for this study we focused on patient and medication-related factors. 
Specifically, we chose to investigate how certain patient and medication-related factors affect the 
behavior of statin medication adherence. In the next sections we describe the challenges with 
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medication adherence, in general and statin specific in the context of cardiovascular diseases. 
Then, we describe patient motivational factors and intentions to engage in goal behaviors and 
medication factors influencing the behavior of statin medication adherence, ending with the aims 
and hypotheses of the study.  
Medication adherence among patients with chronic diseases is reported by the World 
Health Organization (WHO) to be on average 50% in the developed world.
5
 The low adherence 
levels pose consequences, such as worsening of disease, poor clinical outcomes, poor quality of 
health, mortality, and an economic burden of $290 billion USD in annual health 
expenditures.
1,3,5-8
 Therefore, efforts to improve medication adherence are worthwhile.  
Medications are an essential tool in managing chronic diseases, including cardiovascular 
diseases (CVDs). CVDs are the leading cause of morbidity and mortality in developed nations; 
by year 2030 they are projected to be the leading cause of death globaly.
9-11 
To improve the 
cardiovascular health of Americans, the American Heart Association aims at reducing CVDs and 
strokes by 20% by the year of 2020.
12
 To attain cardiovascular health one must seek to engage in 
health behaviors and to attain ideal health factors. One of the factors is a cholesterol level of 
<200 mg/dL. Attaining this cholesterol level can be done via one or more behavioral tools 
including diet, exercise, and taking medications. We are focusing on the behavior of taking 
medications. Specifically, our focus is on the most commonly prescribed medications used to 
lower cholesterol levels, statins.  
Statins have proven to be effective and safe. A systematic review over a 10year period of 
statin adherence and persistance reported that reduction in CVD and mortality are a result of 
adherence and persistance to statin therapy.
13
 Despite their benefits, statin medication adherence 
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levels have been reported to be between 25 to 48%.
14-17
 The most recent review documents statin 
medication adherence levels between 18.3% to 91.9% represented as percentage of patients 
achieving MPR ≥80%.
13
 Factors contributing to statin medication non-adherence present 
themselves at the medication, patient, patient-health care provider, and health system levels. 
Interventions to improve statin medication adherence thus far have included patient-pharmacist 
counseling, patient-physician counseling, telephone counseling and reminders, and mailing 
educational materials.
18-26 
The results of these interventions suggest that statin medication 
adherence improves for patients who are counseled by a health-care professional, a pharmacist or 
physician, in person and/or over the telephone. Developing best practices for counseling to 
improve statin medication adherence is the next step. In order to do that, we must first identify 
and understand the factors that affect patient motivation and intention to engage in the behavior 
of medication adherence.  
Patient motivation is considered by the World Health Organization (WHO) to be the most 
important pillar of medication adherence.
3
 Other research similarly suggests that patient 
motivation and patient-provider relationship serve as two key factors to improve the medication 
experience for patients.
1,27 
These research findings reinforce the need to develop best counseling 
strategies for patients. Our strategy to do so is by focusing first on better understanding patient 
motivational factors in the context of medication use. Next, we describe human motivation, 
intentions, and other factors potentially affecting our behavior of interest.  
Human motivational factors have been studied in a variety of health behaviors. 
Regulatory focus (RF) theory explains two self-regulatory motivational systems under which 
individuals operate to achieve a goal-directed behavior. The two motivational systems are:  




The two motivational systems are independent of one another and meet different human needs. 
The promotion motivational system meets the need of nurturance and is characterized by ideals 
(hopes, wishes, and aspirations). The prevention motivational system meets the need of security 
and is characterized by oughts (duties, obligations, and responsibilities). The mechanisms of 
promotion and prevention self-regulation differ in the presence and absence of positive versus 
negative outcomes, respectively.  
A person’s regulatory focus may be chronic or situational and it can be induced.
28,30
 For 
the chronic regulatory focus, a patient may be high or low in both promotion and prevention 
regulatory focus, as the two chronic orientations are not bipolar constructs.
31
 Chronic regulatory 
focus is associated with styles of child-caretaker interaction and socialization processes
32,33
 and 
is measured with the Regulatory Focus Questionnaire (RFQ).
30
 The situational regulatory focus 
is experimentally manipulated using a priming technique, which involves framing worded 
statements as either promotion or prevention. The focus of this study is to understand whether or 
not patients’ regulatory focus affects the behavior of statin medication adherence. Patients’ 
situational regulatory focus was primed with promotion or prevention framed messages. 
Understanding patients’ self-regulatory system when making a decision in regards to their 
medications will help us design better patient counseling strategies. 
The process of engaging in a behavior to achieve a goal is complex. When considering 
goal-directed behaviors, such as taking statin medications to improve cardiovascular health or 
avoid a cardiovascular event, patients often form intentions. Behavioral intentions serve as an 
indicator of how hard an individual will try to achieve the goal-directed behavior.
34
 They 
originate from the Theory of Reasoned Action and Theory Planned Behavior, and have been 
examined in the context of various behaviors.
35-41
 Intentions have proven to explain only 20 to 
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30% of variance in a behavior.
42
 Therefore, in our study in addition to intentions we are 
investigating other factors that may influence and explain the behavior of medication adherence. 
The factors chosen were patients’ beliefs (self-efficacy and outcome expectancy), duration of 
medication therapy, presence of drug insurance, and the number of over-the-counter medication 
products taken. Next, we describe each of these factors.  
Research studies have found that both self-efficacy and outcome expectancy beliefs are 
predictors of behavioral intentions.
43
 Self-efficacy is defined as one’s belief to successfully 
perform a specific behavior in particular situations and outcome expectancy is defined as one’s 
belief about the likelihood of the specific behavior change leading to certain outcomes.
44
 Self-
efficacy is identified as a determinant of health behavior, health behavior change, and 
maintenance.
45.46
 It is an indicator of the amount of effort and persistence one would engage in 
the face of obstacles and adverse experiences.
47
 Self-efficacy has been examined in the following 
behaviors: exercise, weight control, contraceptive use, alcohol abuse, and cigarette smoking.
45
 
Findings indicate that self-efficacy has a strong relationship with health behavior change and 
maintenance. Self-efficacy and outcome expectancies were both studied in the context of 
regulatory focus and the behavior of adopting omega-3 foods and supplements.
48
 Findings 
indicate that high self-efficacy beliefs enhanced intention to engage in the behavior only for the 
prevention framed message of outcome expectations, but not for the promotion outcome 
expectation framed messages.
48
 In our study we framed promotion and prevention regulatory 
focus messages and investigated the how self-efficacy and outcome expectancy beliefs 
moderated patients intentions or motivation to engage in the behavior of adhering to statin 
medications. Another difference is that our study measured actual behavior, while the omega-3 
study measured only intentions.  
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In addition to these patient-related factors affecting the behavior, we included several 
medication specific factors that are known to influence the behavior. Specifically, statin 
medication adherence research has demonstrated that over time adherence to statin medications 
could drop significantly from 50% at 6 months to 30-40% at 12 months and that cost of 
treatment may be a barrier to optimal statin medication adherence.
49-52
 Therefore, in our study we 
investigated whether or not duration of therapy and cost may influence patients’ intentions and 
motivation to engage in the behavior of adhering to statins. Knowing this information will help 
us better understand whether the two medication-related factors influence intentions and 
motivation. This will add to the knowledge of medication adherence research and help in future 
intervention design. 
Next we also included non-prescription medications as a medication-related factor. Our 
patient population consists of older adults on a cholesterol lowering medication. National survey 
reports that 42% of older adults ages 57 to 85 years, take one or more non-prescription 
medications and 81% at least one prescription medication.
53
 We investigated how the number of 
non-prescription medications taken in addition to the statin medication affected patients’ 
intention and motivation in the context of regulatory focus. Specifically to statin therapy, non-
prescription medications such as red yeast rice or plant sterols may be sought by patients 
experiencing myopathy.
54,55 
Both red yeast rice and various plant have been demonstrated to 
reduce LDL and total cholesterol levels.
54,55
 With approximately 10% of patients on statin 
therapy experiencing myopathy,
54
 muscle side-effects, these alternatives may be used 
concurrently. As well, the availability of over-the-counter medication products may add value to 
patients’ health in a cost-effective way, as each dollar spent on non-prescription medications 
saves $6 to $7 for the US health care system.
56
 Including non-prescription medication use will 
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help us better understand how prescription and non-prescription medications taken 
concomitantly affect patient psychosocial factors.  
The aims of this study are to better understand patients’ intention and motivation to 
engage in the behavior of statin medication adherence. Specifically, the relationship between 
patients’ regulatory focus and statin medication adherence was tested via a conditional indirect 
effect with behavioral intentions and motivational intensity serving as mediators, and self-
efficacy, outcome expectancy, time on statin, insurance coverage, and the number of non-
prescription medication products serving as moderators.   
Aim 1 tested behavioral intentions as the mediator and aim 2 tested motivational intensity 
as the mediator between regulatory focus and statin medication adherence. Several moderators 
(self-efficacy, outcome expectations, time on statin, insurance coverage, number of non-
prescription medication products) were tested for each aim. The supporting hypotheses for aim 1 
were the following:  
H1a: The regulatory focus of a person will influence behavioral intentions to engage in the 
behavior of statin medication adherence the higher the self-efficacy. 
H1b: The regulatory focus of a person will influence behavioral intentions to engage in the 
behavior of statin medication adherence the higher the outcome expectations.  
H1c: The regulatory focus of a person will influence behavioral intentions to engage in the 
behavior of statin medication adherence the longer the statin therapy. 
H1d: The regulatory focus of a person will influence behavioral intentions to engage in the 
behavior of statin medication adherence if insurance is present. 
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H1e: The regulatory focus of a person will influence behavioral intentions to engage in the 
behavior of statin medication adherence the higher the number of non-prescription medications 
present.  
H2: The stronger the behavioral intentions the greater the statin medication adherence levels. 
H3a: The regulatory focus of a person will influence motivational intensity to engage in the 
behavior of statin medication adherence the higher the self-efficacy. 
H3b: The regulatory focus of a person will influence motivational intensity to engage in the 
behavior of statin medication adherence the higher the outcome expectations. 
H3c: The regulatory focus of a person will influence motivational intensity to engage in the 
behavior of statin medication adherence the longer the statin therapy. 
H3d: The regulatory focus of a person will influence motivational intensity to engage in the 
behavior of statin medication adherence if insurance is present. 
H3e: The regulatory focus of a person will influence motivational intensity to engage in the 
behavior of statin medication adherence the greater the number of non-prescription medications. 
H4: The stronger the motivational intensity the greater the statin medication adherence levels. 
Methods 
Research Design 
This was a randomized controlled field experiment. Patients prescribed a statin medication 
from a university health system were recruited to participate. Those who agreed to participate 
had the opportunity to complete two questionnaires (Appendices A and B) and were randomized 
to two experimental conditions of promotion or prevention. The assignment to the two groups 
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was done randomly via a computer generated system. One group of patients received the 
promotion regulatory focus manipulation while the other group received the prevention 
regulatory focus manipulation. The mediating, moderating, and dependent variables were 
measured variables in our questionnaires. The hypotheses for this study were tested via the 
conditional indirect effect analyses developed by Hayes (Appendix C).
57
 The variables in our 
research design, presented in Figure 1, are the following: 
1. A dichotomous manipulated independent variable (X) indicating exposure to one of the 
two experimental conditions of promotion or prevention regulatory focus. The promotion 
experimental condition was coded +1 and the prevention experimental condition was 
coded -1. 
2. Two continuous mediating variables (M) that were behavioral intentions or motivational 
intensity were tested in two different models. 
3. Five moderator variables (W), four of which are continuous: self-efficacy, time on statin 
therapy, number non-prescription medications, and one is dichotomous: insurance 
coverage for the statin therapy. 
4. One continuous dependent variable (Y), reflecting patients’ self-reported adherence to  
statin therapy.  
Manipulation. The promotion focus manipulation consisted of priming patients with two 
promotion framed questions. Specifically, patients were asked to think and write down three past 
and three present hopes, aspirations, and dreams. For each of the three, patients were asked to 
indicate how strong each hope, aspiration, or dream was for them personally, with answer 
options ranging from not at all strong to very very strong. The prevention focus manipulation 
consisted of priming patients with two prevention framed questions. Specifically, patients were 
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asked to think and write down three past and three present duties, obligations, and 
responsibilities. For each of the three, patients were asked to indicate how strong each duty, 
obligation, or responsibility was for them personally, with answer options ranging from not at all 
strong to very very strong.  
Participants and Procedures 
Participants were recruited from a large university health system. A total of 1700 
potential participants were invited to participate in the study using an initial mail contact. The 
inclusion criteria for the study were taking a statin medication at the time of the survey, 18 years 
of age or higher, and proficiency in the English language. The total number of participants with 
complete responses for all variables of interest was n=326. 
Participants who agreed to participate in our study were asked to complete two online 
questionnaires, one at baseline and the second one two weeks later. The initial mail contact 
consisted of a cover letter inviting patients to participate in the study. The cover letter conveyed 
the purpose of the study, procedures for completing the two questionnaires, and incentives for 
completing the questionnaires. A $2 bill incentive was included with the cover letter. The 
incentive for completing the first questionnaire was $20 and the incentive for completing 
questionnaire two was $5. At the bottom of the cover letter a link to the first questionnaire was 
provided as well as a unique personal passcode for respondents to access the questionnaire. 
When participants completed the first questionnaire they were asked to enter their email address 
via which they received the second questionnaire two weeks later. This study was approved by 




Several measures were used in this study. 
Independent variable. The independent variable, regulatory focus, was manipulated. The 
manipulation consisted of a priming technique of framed questions. The questions were framed 
as promotion or prevention. For promotion, the priming technique consisted of questions framed 
as hopes, dreams, and aspirations while for prevention, the priming technique consisted of 
questions frames as duties, obligations, and responsibilities.  
Mediating variables. The mediated relationship between regulatory focus and statin 
medication adherence was tested via two mediators including behavioral intentions and 
motivational intensity. Each mediator was measured via two questions. The behavioral intention 
questions asked patients their intention and plans to take their statin medication as directed by 
their health care provider within the next two weeks. The answer options ranged from strongly 
disagree to strongly agree. The motivational intensity questions asked patients how motivated 
and determined they were to take their statin medication as prescribed. Answer options ranged 
from not at all to extremely. The two questions for each mediator were averaged to obtain one 
score for behavioral intentions and one score for motivational intensity. 
Moderator variables. The variables tested as moderators were: self-efficacy, outcome 
expectancy, time on statin, statin insurance and the number of non-prescription medications.  
Self-efficacy was measured via two questions asking patients on a scale from not at all to 
extremely how confident and certain they were able to take their statin medication as directed. 
Outcome expectancy was measured via two questions asking patients on a scale from not at all 
to extremely how promising and likely they were able to take their statin medication as directed.  
The time on statin and number of non-prescription medications questions were open ended. The 
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insurance coverage question had answer options of yes, no, and I don’t’ know. The no and I 
don’t’ know answer options were grouped as ‘no’.  
Dependent variable. The dependent variable, statin medication adherence (SMA), was 
measured via the single-item visual analogue rating scale (VAS). It was a single item asking 
patients to estimate along a continuum the percentage of medication dosages taken as prescribed 
during the past two weeks.
58-60
 Patients’ SMA was measured at baseline in the first questionnaire 
and two weeks after the intervention in the second questionnaire.      
Analysis Approach  
The conditional indirect effects were tested via the PROCESS macro tool,
57 
and two 
models were tested (Figure 1). First, the mediator variable model was determined by the 
interaction effects of the independent variable (X) and the moderator (W) on the mediator (M). 
The following equation represents the mediator variable model:  
M=β10+β11X+β12W+β13X(W)+ε1                                                                                                                                                  (1) 
Second, the outcome variable model was determined by the effect of the mediator (M) on the 
outcome variable (Y) and by the direct effect of the independent variable (X) on the outcome 
variable (Y). The following equation represents the outcome variable model:  
Y=β20+β21X+β22M+ε2                                                                                                                                                                             (2) 
There were some assumptions associated with these two equations. The assumptions were that 
the mediator and moderator variables were mean centered and that the residuals were normally 
distributed, independent, and had a common variance. The conditional indirect effect between 
the independent variable (X) and the outcome variable (Y) was considered successful when the 
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pathway from the independent variable (X) to the mediator (M) (β13) and the pathway from the 
mediator (M) to the outcome variable (Y) (β22) were statistically significant (Figure 1). Figure 1 
presents pictorially the models of the study. [Figure 1a and 1b are similar, with one difference 
being the mediator variable tested. In Figure 1a the mediator variable is behavioral intentions 
while in Figure 1b the mediator variable is motivational intensity. In both figures the 
independent variable (X) is regulatory focus, the dependent variable (Y) is statin medication 
adherence, and the moderator variables (W) are self-efficacy, outcome expectancies, time on 
statin, insurance coverage, and the number of non-prescription medications.] 
Results 
From the 1700 potential participants, a total of 32.65% patients responded to the first 
questionnaire. A total of 58.74% of patients who responded to the first questionnaire completed 
the second one. The total number of complete responses for our variables of interest was n=326. 
There were no statistical significant differences between respondents to both questionnaires and 
respondents to the first questionnaire only, except for health insurance (Appendix E). 
Patient demographic characteristics indicate that the majority of participants were white 
(87.1%) and 60 years of age or older (69.3%) (Table 2.1). Approximately half of participants 
were female (40.2%) and had an annual income of $60,000 or higher (56.8%). The majority of 
participants, 88.7%, reported their health to be good to excellent. Only 11.5% reported an overall 
health of fair to poor. A total of 91.7% of participants received a diagnosis from their health care 
professional of high cholesterol and 11.3% of patients experienced a heart surgery/procedure 
during their lifetime. A total of 87.4% of participants had been on a statin medication for 4 or 
more years for up to 30years. About half of participants (46.03%) were on 1 or 2 non-
prescription medications; some participants were not taking any (14.1%), and others were taking 
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5 of more non-prescription medications (15.3%). A total of 22.1% of participants reported taking 
a medication for depression. Results of chi-square and t-tests indicated that there was no 
difference among all demographic and clinical characteristics between the promotion and 
prevention groups. 
The reliability of variables in the study was measured via the Cronbach alpha (α). A 
general reliability value of ≥.70 is considered good. All study variables exhibited good 
reliability:  α(behavioral intention) = .71, α(motivational intensity) = .93, α(self-efficacy) = .85, 
α(outcome expectancy) = .86, α(regulatory focus promotion) = .82, α(regulatory focus 
prevention)=.74. The distribution of the dependent variable, statin medication adherence, was 
skewed (mean = 96.3 ± 13.74). The statin medication adherence variable was transformed via a 
log-transformation and a two-step approach with results being slightly better towards normality; 
however, not statistically significant (indicated by the Kolmogorov-Smirnov and Shapiro-Wilk 
tests). Hence, we decided to use the original statin medication adherence results. The mean statin 
adherence at baseline was 95.67% ± 14.21. Intentions to engage in the behavior were explored as 
a possible dependent variable as well. The distribution of intentions was skewed (mean 4.85 
±.524). In the end, the behavior of adhering to statin medication was chosen as the dependent 
variable. Table 2.2 presents the results from the PROCESS analysis for conditional indirect 
effect between regulatory focus and statin medication adherence with behavioral intentions 
serving as the mediator. Table 2.3 presents the results from the results from the PROCESS 
analysis for conditional indirect effect between regulatory focus and statin medication adherence 
with motivational intensity serving as the mediator. Table 2.4 presents the conditional indirect 




The results for the conditional indirect effect of regulatory focus on statin medication 
adherence with behavioral intentions serving as the mediator and the five moderators are shown 
in Figure 2.1a; Tables 2.2, and 2.4. Results indicate that behavioral intentions partially mediated 
the impact of patients’ regulatory focus on statin medication adherence. Regulatory focus was a 
direct and indirect predictor of statin medication adherence. The direct effect showed that for one 
unit change in prevention regulatory focus there was a 1.73 units change in statin medication 
adherence (b=-1.73, p=.01). Prevention regulatory focus had a positive effect on statin 
medication adherence, when compared to promotion regulatory focus.  
For the indirect effect, among all the moderators, time on statin therapy (b=.01, p=.03) 
and insurance coverage (b=.26, p=.00) moderated the relationship between regulatory focus and 
behavioral intentions at a statistical significant level. The longer the time on the statin therapy 
(95% CI .08, 2.66) and presence of insurance coverage (95% CI 1.07, 7.83), both, interacted with 
patients’ regulatory focus resulting in higher behavioral intentions to engage in the behavior.  
The results for the conditional indirect effect of regulatory focus on statin medication 
adherence with motivational intensity serving as the mediator and the five moderators are shown 
in Figure 2.1b; Tables 2.3 and 2.4. Results indicate that, similarly to behavioral intentions, 
motivational intensity partially mediated the impact of patients’ regulatory focus on statin 
medication adherence. Regulatory focus served as a predictor of statin medication adherence 
directly and indirectly. The direct effect showed that for one unit change in prevention regulatory 
focus there was a 1.84 unit change in statin medication adherence (b=-1.84, p=.01). Prevention 




For the indirect effect, among all the moderators, self-efficacy (b=.08, p=.05) and number 
of non-prescription medications (b=-.05, p=.01) moderated the relationship between regulatory 
focus and motivational intensity. Higher self-efficacy (95% CI .01, 1.38) and lower number of 
non-prescription medications (95% CI .38, 2.19), both, interacted with prevention regulatory 
focus resulting in higher motivation to engage in the behavior. The number of prescription 
medications was tested as a moderator and was found to have no significant effect (the results are 
not shown).  
In summary, regulatory focus is a significant predictor of statin medication adherence 
affecting the behavior directly and indirectly. The direct effect is positively influenced by 
prevention regulatory focus. The indirect effect is mediated by intentions or motivation and 
moderated by different medication and patient-related factors. Duration of therapy and insurance 
coverage influence patients’ intentions while self-efficacy and  number of non-prescription 
medications influence patients’ motivation.   
Discussion 
Behavioral intentions and motivational intensity were mediating variables between 
patients’ regulatory focus and statin medication adherence. Both are important factors in the 
decision-making process towards the goal-pursuit of cardiovascular health. Other factors 
influencing the behavior were patients’ beliefs in their own ability to engage in the behavior, 
length of time on the statin medication, insurance coverage for statin, and the number of non-
prescription medications.  These factors interacted with patients’ prevention regulatory focus, 
when compared directly to promotion regulatory focus, to influence either behavioral intentions 
or motivational intensity to engage in the behavior and ultimately influencing the behavior of 
SMA at a significant level.  
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Our study showed that that patients’ prevention and promotion orientation impacts the 
behavior of statin medication adherence differently.  Patients’ prevention orientation in 
comparison to promotion positively impacted statin medication adherence. This finding is 
important as our behavior of interest of medication adherence is related and often framed in 
terms of ‘preventing’ a disease or condition or a future unwanted event from occurring. For 
example, statements related to heart disease on the Centers for Disease Control and Prevention 
website are worded as preventing heart disease with a focus on steps a patient must take to 
reduce risks for heart disease or tips to healthy living habits that patients need to consider to 
prevent heart disease.
61
 Therefore, health care professionals are most likely to communicate with 
patients the recommended steps needed to reduce the risk for heart disease. Reducing the risk for 
heart disease or preventing heart disease are both statements that have a prevention regulatory 
focus associated with them, of avoiding unwanted events.  In this case, the unwanted event 
would be a potential future heart attack or potential future diagnosis of cardiovascular disease. 
Specifically, pharmacists may encourage patients to take their statin medication to avoid any 
potential future heart disease. Therefore, this may be a likely explanation for why patients’ 
prevention orientation, when compared to promotion, showed significant positive changes in 
statin medication adherence in our study. 
Additionally, we identified that patients’ behavioral intentions and motivational intensity 
were impacted by different patient and medication-related factors. Presence of insurance 
coverage for the drug and consistent behavior of taking the medication for long periods of time 
positively influenced behavioral intentions to take the statin medication as prescribed. In other 
words, behavioral intentions to adhere to statin medications were impacted by insurance related 
factors. Previous research findings indicate that adherence to statin medications drops over time 
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and cost of treatment can potentially be a barrier.
13,49-52
 Cost is a known significant predictor for 
statin medication adherence.
62
 Specifically, Piette et al. identified high out-of-pocket costs as a 
significant risk for non-adherence for both low and high trust levels between the patient and 
physician.
63
 Furthermore, cost-related underuse of medications was related to patient trust in 
his/her physician.
63
 For example, rates of underuse for patients with low trust in their physician 
were reported within the range of 4% to 30%.
63 
The rest may be attributed to other factors, 
including patient psychosocial factors. Piette et al., states that patients who were non-adherent 
due to cost, reported other reasons for non-adherence, such as depressive symptoms. Considering 
the implications of cost for our sample population, a total of 91.72% of our patients had statin 
insurance and 25.5% reported an annual income of 100k or greater. Therefore, cost of therapy, 
most likely was not a barrier for majority of our patients. Identifying additional determinants, 
such as psychosocial patient factors, of statin adherence adds to our understanding on various 
ways to improve adherence once cost needs have been met for patients. Also, finding ways to 
eliminate the cost barriers for patients who cannot afford therapy treatment, by ensuring 
insurance coverage for statin therapy is essential as it may result in greater intentions for patients 
to adhere. Greater intentions to adhere may improve statin medication adherence over long 
periods of time.  
Patients’ motivational intensity was also impacted by different patient and medication 
factors. The greater patients’ confidence in their ability to follow the prescribed therapy and the 
lower the number of non-prescription medications, the greater was the motivation to adhere to 
statin therapy. Self-efficacy has been studied in the context of intentions in other research and 
was found to predict intentions in general. Our study presents a novel finding where patients’ 
self-efficacy impacted patients’ motivational intensity to engage in the behavior of adhering to 
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statins, but not their behavioral intention.  This may be due to the way we define self-efficacy, as 
one’s confidence in his/her ability to engage in a behavioral goal. Hence, the self-efficacy 
construct influences one’s motivation and determination to engage in a behavior instead of one’s 
intention. The non-prescription medication finding may be due to the possibility that patients’ 
motivation to take their statin medication as prescribed to manage their cardiovascular health 
eliminates the need to rely on other medication products that are sold without a prescription from 
a health care provider. This may be attributed to the effectiveness of statin therapy for our 
sample population. The high adherence levels and long duration of statin therapy indicates that 
majority of patients most likely have not experienced myopathy; hence reliance on statin therapy. 
Identifying the two drivers, higher self-efficacy and lower number of non-prescription 
medications, of patients’ motivational intensity helps us better understand what factors contribute 
to patients’ motivation to take medications as prescribed.  
Our study makes important contributions to research in two meaningful ways. One, our 
research adds value to the medication adherence research. Regulatory focus is a new concept 
being investigated in the context of medication adherence research. Additionally, we have 
investigated the relationship between regulatory focus and statin medication adherence via a 
novel analytic technique, the conditional indirect effect analysis. This allowed us to test the 
effect of regulatory focus on medication adherence directly and indirectly with potential 
mediating and moderating variables. Our findings suggest that patients’ prevention regulatory 
focus positively affects the behavior of statin medication adherence directly, when compared to 
promotion, and is partially mediated by patients’ motivational intensity (the greater the self-
efficacy and the lower the number of non-prescription the greater the motivational intensity) or 
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behavioral intentions (the greater the length of time on statin therapy and presence of insurance 
coverage the greater the behavioral intentions). 
The second meaningful contribution of our study to the body of research is addition of a 
new behavior to the regulatory focus research. This is the first study to our knowledge applying 
the theory of regulatory focus to the behavior of medication adherence. So far, the regulatory 
focus theory has been studied in the context of decision-making and problem solving in various 
tasks, but not yet in the context of the behavior of medication adherence. One behavior it was 
applied was the behavior of supplementing with omega-3 products.
48
 Findings indicate that 
prevention outcome expectations significantly interacted with self-efficacy to impact behavioral 
intentions to engage in the behavior of supplementing with omega-3 supplements and enriched 
foods. Promotion outcome expectations did not interact with self-efficacy beliefs, but did directly 
impact behavioral intentions.
48
 In our study, prevention regulatory focus compared to promotion 
regulatory focus impacted the behavior of statin medication adherence and self-efficacy 
interacted with patients’ motivational intensity to impact the behavior. This study did test the 
effect of outcome expectations as a moderator in both models; however no significant impact 
was found.  
Applying the concept of regulatory focus to medication adherence and better 
understanding the mediating and moderating mechanisms involved in the process, helps us 
identify key variables that affect the behavior. This will help in intervention design to improve 
medication adherence.  For example, if we know that prevention regulatory focus positively 
impacts statin medication adherence compared to control, pharmacists could frame medication 
messages with a prevention focus when communicating with patients about their statin 
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medication in order to activate patients’ prevention orientation. In doing so, based on this study’s 
findings, we expect statin medication adherence levels to improve.  
Our study’s findings also contribute to pharmacy practice. First, our results of prevention 
regulatory focus, when compared to promotion regulatory focus, leads to positive changes in 
statin medication adherence levels. Additional studies are needed to compare prevention 
regulatory focus to control and promotion regulatory focus to control.  These studies will help us 
identify framing strategies for messages. For example, framing messages in terms of prevention - 
avoiding a risk- may be more effective than framing messages in terms of promotion – 
approaching a hope or desire related specifically to the behavioral goal, or vice versa. Framing 
strategies of avoiding risk may take a similar approach to loss framing while those of 
approaching a hope may take a similar approach to gain framing. Investigating which approach 
may work best for the behavior of medication adherence in the context of cardiovascular health 
for different patients will be helpful for pharmacy practice. 
Additionally, our findings indicate that insurance coverage for statins is important and 
that the longer patients take their statin therapy the better. These two factors led to greater 
behavioral intentions to adhere to medications. Pharmacists as health care professionals that have 
direct contact with patients have an opportunity to help patients with insurance coverage 
questions or challenges they may have in regards to continuing on statin therapy for a long 
period of time to ensure optimal health outcomes. And lastly, focusing on patients’ belief in their 
ability to take their statin medication as indicated, pharmacists’ have the opportunity to increase 
patients’ motivational intensity to improve behavior.  
 Future research needs to test whether prevention regulatory focus positively affects 
medication adherence for other medications and conditions. For example, the behavior of taking 
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a statin medication targets reduction of a cardiovascular risk factor to prevent heart disease. Will 
similar results be found for depression medications or medications treating a cold/virus? These 
questions will be interesting to be investigated.  
 In this study, we utilized a technique consisting of priming individuals with framed 
messages as promotion or prevention. Knowing which orientation affects a specific behavior in a 
positive way, we can tailor communication with framed messages that match a particular 
orientation. For example, health care professionals, such as pharmacists, during patient 
consultation interactions can frame the communication messages as prevention in order to 
positively affect adherence levels. Additionally, pharmacists may ask patients about their 
confidence in their ability to take their statin medication as directed. By doing so, if, for example 
the pharmacist identifies that the problem is a lack of information about the medication, he/she 
would provide the information to increase patients’ self-efficacy beliefs. Increasing patients’ 
self-efficacy beliefs will in turn increase patients’ motivational intensity to engage in the 
behavior; therefore the patient would be more likely to adhere to the medication.  
Additionally, next research steps are to develop and test the idea of regulatory focus and 
strategic means by investigating the effect of fit versus non-fit on the behavior of statin 
medication adherence. This will provide a better understanding on whether a fit between 
patients’ regulatory focus and a strategic means positively affect the behavior of statin 
medication adherence or not. Fit studies in other behaviors have proven to improve outcomes, 
therefore testing whether or not a fit intervention will positively affect the behavior of statin 





Our study has several limitations. One limitation of the study is the generalizability of our 
results. The findings of the study apply to our sample population consisting of older adults, 
mostly white, in the higher income bracket, who are part of a university health system. In our 
study, participants were randomly assigned to the two groups, promotion and prevention. 
Therefore, it is unlikely that any differences were attributed to preexisting characteristics. 
Secondly, in our study comparison of prevention or promotion groups can be done 
relative to each other. However, in order to be able to conclude how prevention or promotion 
orientations each operate, inclusion of a control group where neither manipulation is given to 
patients is needed. This will allow us to identify whether promotion or prevention framed 
messages are most effective to affect the behavior of statin adherence. 
Another limitation of this study is the recall and social desirability biases potentially 
present. This is due to the nature of data collection method used, as data were collected via 
questionnaires. Therefore, the potential of failure to remember specific information and the 
desire to respond differently than the actual reality is possible is possible. It is most likely that 
the most adherent patients respond to studies; therefore it is more challenging to detect 
differences among variables between adherent and non-adherent patients.  
The strength of our study was measuring the actual behavior of adhering to statin 
medications. The behavior was measured two weeks after the intervention to test its effects. The 
levels of adherence in this study were very high. The discrepancy between the published 
literature results and our findings, may be due to the social desirability and recall bias, or it may 
be possible that our sample population is adherent to the statin therapy indeed. Statin medication 
adherence was measured via a single-item, the visual analogue scale (VAS). VAS is proven to be 
as effective as unannounced pill-counts
58,59
 and was chosen to capture adherence levels while 
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reducing response burden. Including additional items would have increased response burden in 
this study, but could be pursued in future studies. With different statin medication adherence 
results we may detect different mediation and moderation relationships between variables of 
interest. It is also possible that our results may look different for a more diverse population 
sample in age, gender, race, and income. Our present sample represented mainly white older 
individuals with moderate to high income. 
Conclusion 
Patient psychosocial factors, such as patients’ regulatory focus, behavioral intentions, and 
motivational intensity have a significant impact on the behavior of statin medication adherence. 
Additional patient and medication factors - patients’ self-efficacy beliefs, duration of therapy, 
insurance coverage, and non-prescription medications taken concomitantly with prescription 
medications – play an essential role influencing patients’ behavioral intentions or motivational 
intensity to engage in the behavior. Our study provides insights for future research on improving 
the behavior of medication adherence. Specifically, our research provides insights on potential 
aspects of patient psychosocial factors pharmacists may focus on when interacting with patients 
or thinking of strategies for interventions to improve patients’ medication adherence.  
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Table 2-1. Respondent Demographic and Clinical Characteristics (N=326) 
Characteristic  Percentage  
Age 
   ≥60years 
 
69.3 
Gender (Female) 40.2 
Race  




 ≤19,999/year 8.3 
      $20,000 - $39,000 12.6 
 $40,000 - $59,999 17.8 
 $60,000 - $79,999 15.3 
      $80,000 - $99,000 16.0 
 ≥$100,000/year 25.5 
Had heart disease 25.2 
Had a heart surgery 11.3 
Diagnosed with high cholesterol 93.6 
Insurance coverage for cholesterol medication 91.7 
Taking a medication for depression 22.1 
Time on statin  
   1 
   2-3 
   4-6 
   7-10 







Number of daily Rx 
   1 
   2-3 
   4-7 






Number of non-Rx 
   0 
   1 
   2 
   3 








   Excellent 
   Very good 
   Good 
   Fair 







Rx - prescription medications; non-Rx – non-prescription medications.  Note: Chi-square and t-
test results indicate that there was no difference found among all these variables between the 
promotion and prevention groups 
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Figure 2-1. Theoretical and Analytical Framework for Regulatory Focus Predicting Statin 
Medication Adherence 
a The Conditional Indirect Effect of Regulatory Focus on Statin Medication Adherence with 













b The Conditional Indirect Effect of Regulatory Focus on Statin Medication Adherence with 

















































Table 2-2. Conditional Indirect Effect of Regulatory Focus on Statin Medication Adherence 
with Behavioral Intentions as the Mediator 






























M=β10+β11X+β12W+β13X(W)+ε1 b p b p b p b p b p 
X: manipulation β11 .00 .92 .00 .99 .01 .59 .01 .61 .01 .68 
W: moderator β12 .08 .00* .08 .00* .00 .77 -.12 .19 .03 .03* 
X*W: interaction β13 .01 .64 -.01 .64 .01 .03* .26 .00* -.00 .89 
Outcome variable (Y) Statin Medication Adherence (SMA) 
Outcome Variable Model R
2
=.23, p=.00 
Y=β20+β21X+β22M+ε2 b p 
X: manipulation β21 -1.73 .01* 
M: behavioral intentions β22 13.84 .00* 


















Table 2-3. Conditional Indirect Effect of Regulatory Focus on Statin Medication Adherence 
with Motivational Intensity as the Mediator 




















M=β10+β11X+β12W+β13X(W)+ε1 b p b p b p b p b p 
X: manipulation β11 -.00 .93 -.02 .52 .05 .22 .04 .34 .04 .35 
W: moderator β12 .36 .00* .41 .00* .02 .00* -.26 .10 .02 .42 
X*W: interaction β13 .08 .05* .07 .09 .01 .33 .18 .26 -.05 .01* 
Outcome variable (Y) Statin Medication Adherence (SMA) 
Outcome Variable Model (R
2
=.17, p=.00) 
Y=β20+β21X+β22M+ε2 b p 
X: manipulation β21 -1.84 .01* 
M: behavioral intentions β22 6.93 .00* 




















Table 2-4. Conditional Indirect Effects for Behavioral Intentions and Motivational 
Intensity as Mediators 
































































































SMA - statin medication adherence, M – mediator, W – moderator (+1 low, 0 moderate, -1 high, 
levels), SD - standard error,  
Effect – conditional indirect effect, 95% CI – bootstrap 95% confidence intervals for conditional 














Table 2-5. Regulatory Focus Study Hypotheses and Results 
 Hypothesis Finding 
H1a The regulatory focus of a person will influence intentions to 
engage in the behavior the higher the self-efficacy. 
H1a is not supported. 
(β13 =.01, p=.64) 
H1b The regulatory focus of a person will influence intentions to 
engage in the behavior the higher the outcome expectancies. 
H1b is not supported. 
(β13 =-.01, p=.64) 
H1c The regulatory focus of a person will influence intentions to 
engage in the behavior the longer a person has been on a statin. 
H1c is supported. 
(β13 =.01, p=.03*) 
H1d The regulatory focus of a person will influence intentions to 
engage in the behavior if insurance is present. 
H1d is supported. 
(β13 =.26, p=.00*) 
H1e The regulatory focus of a person will influence intentions to 
engage in the higher the number of non-Rx medication 
products. 
H1e is not supported. 
(β13 =-.00, p=.89) 
H2 The stronger the behavioral intentions the greater the statin 
medication adherence levels. 
H2 is supported. 
(β22 =13.84, p=.00*) 
H3a The regulatory focus of a person will influence motivation to 
engage in the behavior the higher the self-efficacy. 
H3a is supported. 
(β13 =.08, p=.05*) 
H3b The regulatory focus of a person will influence motivation to 
engage in the behavior the higher the outcome expectancies. 
H3b is not supported. 
(β13 =.07, p=.09) 
H3c The regulatory focus of a person will influence motivation to 
engage in the behavior the longer a person has been on a statin. 
H3c is not supported. 
(β13 =.01, p=.33) 
H3d The regulatory focus of a person will influence motivation to 
engage in the behavior if insurance is present. 
H3d is not supported. 
(β13 =.18, p=.26) 
H3e The regulatory focus of a person will influence motivation to 
engage in the behavior the higher the number of non-Rx 
medication products.  
H3e is supported. 
(β13 =-.05, p=.01*) 
H4 The stronger the motivational intensity the greater the statin 
medication adherence levels. 
H4 is supported. 
(β22 =6.93, p=.00*) 











 - PAPER 2: THE EFFECT OF A REGULATORY FIT INTERVENTION ON Chapter 3
STATIN MEDICATION ADHERENCE 
Abstract 
Background: Regulatory Fit between a person’s orientation and strategic means used to 
accomplish a goal leads to higher motivation in goal pursuit, to greater enjoyment during the 
goal pursuit, and to better feelings in the process of decision making. For example, regulatory fit 
would be achieved when a promotion regulatory orientation matches a promotion strategic 
approach to achieve a goal; same for prevention. Regulatory fit, applied to various health 
behaviors from academic writing to cancer detection results in positive outcomes. This principle 
of regulatory fit has not been yet studied in the behavior of medication adherence. Applications 
of regulatory fit interventions could improve the behavior of adhering to medications.  
Aim: Investigate the effect of a regulatory fit intervention on the behavior of statin 
medication adherence.  
Methods: Patients taking a statin medication participated in a randomized, prospective 
field experiment. The three study groups were fit, non-fit and control. Patients completed two 
online questionnaires designed to capture patient variables and deliver the intervention, and two 
weeks later to assess subsequent behavior. The intervention consisted of manipulations priming 
patients with framed messages that created a fit or non-fit between patients’ motivational 
orientation and implementation intentions. ANOVA pairwise comparisons were run to determine 
the significance of between and within group differences. 
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Results: Patients in the regulatory fit group experienced greater statin medication 
adherence levels compared to the patients in the non-fit and control groups. When patients’ 
motivational intensity, behavioral intentions, self-efficacy, and outcome expectancies were 
strong, there was no difference in statin medication adherence levels between the fit, non-fit, and 
control groups. A statistical significant difference was detected among the fit and non-fit and fit 
and control groups for the weak condition for both intention and motivation. A difference 
between only the fit and non-fit groups was seen when patients’ outcome expectancies were 
weak. Regardless of the strength of self-efficacy, there was no difference between any of the 
groups in statin medication adherence levels. Within group differences between the weak and 
strong points of intentions and motivation were detected only for the non-fit and control groups.  
Conclusions: Patients receiving the Fit intervention had higher statin medication 
adherence, when patients’ intention, motivation, self-efficacy, or outcome expectation were 
weak. Therefore, there is an opportunity to improve the behavior of statin medication adherence, 
when patient-related factors are weak, as there were significant differences found between the Fit 
and Non-fit/Control intervention groups. 
Introduction 
Goals and the pursuit of goals are part of everyday life for most people.  Whether it’s 
pursuing an academic, career, personal, health, or an organizational goal – in its pursuit we make 
decisions and engage in actions. While exploring how and why individuals are able to manage 
themselves in goal pursuit, Higgins developed the concept of regulatory focus, proposing two 





The two human motivational systems defined by Higgins are: promotion and 
prevention.
1-4 
The promotion and prevention orientations operate to meet different human needs. 
The promotion motivational system operates to meet the survival need of nurturance 
(nourishment) while the prevention motivational system operates to meet the survival need of 
obtaining security. Therefore, the promotion focus is characterized by “ideals” which include 
hopes, wishes, and aspirations as maximal goals to be reached. Prevention focus, on the other 
hand, is characterized by “oughts” which include duties, obligations, and responsibilities as 
minimal goals to be met.  
The needs of nourishment and security are present in all people in different degrees 
leading to chronic individual differences, with some individuals being more promotion oriented 
and others more prevention oriented.
5
 Some studies suggest that the two chronic orientations are 
not bipolar constructs.
4
  Therefore, the orientations can be activated momentarily in different 
situations.
1,5
 The activation technique involves manipulating the regulatory orientation via the 
framing of messages with either promotion or prevention words, also called priming. All people 
can be primed with both promotion and prevention focus, at different points in time.
5 
We utilized 
this priming technique to activate patients’ promotion/prevention orientation.  
What is also notable is that when a person’s orientation towards a goal – either promotion 
or prevention – matches the strategy used to pursue a goal, then a state of regulatory fit is 
produced.
2,5,6 
This state of regulatory fit creates a feeling of rightness that leads to higher 
motivation to engage in the tasks necessary to accomplish a goal. In addition, a state of 






The regulatory fit theory has been studied in the context of a variety of behaviors, such as 
physical activity, fruit and vegetable consumption, writing, unhealthy snacking habits, 
supplementing with omega-3 products, and cancer detection.
7-11
 The definition of regulatory fit 
among studies differs with regulatory focus (promotion and prevention) being constant while the 








While motivation is important, translating goals into actions can be challenging. One 
strategic self-regulatory tool used to overcome obstacles in goal-pursuit is implementation 
intentions.
12 
Proven to be effective in completing personal goals and in taking immediate action, 
the mechanism suggested by which implementation intentions do so is via a heightened mental 
representation of a potential situation which leads to easier recognition, recall, and engagement 
when the specific situation arises.
12-14 
In other words, implementation intentions make action 
initiation easier by linking a goal-directed response to a situation or situational cues.
12 
For 
example, linking a situation X to behavior Y by thinking when X occurs, I will perform response 
Y, a person will make specific decisions of when, where, and how to engage in the behavior, so 
that action is automatized.
12-14 
Specifically to statin medications, a patient would think when I 
wake up in the morning, I will take my statin medication as soon as I wake up, in the kitchen, as I 
prepare my morning coffee/tea.  
Studied in the context of a variety of behaviors,
 
implementation intentions serve as an 
effective tool in reducing dietary fat intake, in achieving greater weight loss among obese 
women, in reducing drinking and smoking, in increasing attendance for cervical screening, in 
increasing physical activity in children, and in increasing the inclusion of healthy foods, such as 
more fruits in one’s diet.
 15-24  
Moreover, when combining implementation intentions with a 
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motivational theory-based intervention, such as a decision balance sheet, a dramatic effect in 
increased exercise behavior was seen.
17,18 
Motivational intervention by itself produced significant 
effects on intentions only, yet not on exercise behavior.
17 
Studied in the context of self-
monitoring blood glucose, implementation intentions together with implementation desire were 
found to be mediators between goal intentions and the blood glucose monitoring.
25
 
Together with regulatory focus, implementation intentions were studied in the context of 
the behavior of healthy snacking.
9 
A match between implementation intentions and regulatory 
focus was defined as regulatory fit and a mis-match as non-fit. Findings indicate that formation 
of implementation intentions that match regulatory orientation results in a state of regulatory fit, 
which in turn heightens motivational intensity to attain a specific goal. Similarly, our study 
investigated the effect of implementation intentions together with patients’ regulatory focus on 
the behavior of medication adherence, when a match versus a mis-match exists. 
The specific medication adherence behavior in this study was statin medication 
adherence.  Medication adherence is defined as the extent to which a patient takes a prescribed 
medication according to the prescribed schedule by their health care provider.
26-29 
Being adherent 
to statin medications has proven to be effective in the treatment and prevention of cardiovascular 
diseases and reducing cardiovascular mortality.
29-31 
Despite their effectiveness, patients have 
challenges in continuing to take statin medications, with adherence rates ranging from 25 to 
48%.
31-33 
SMA levels, measured as the percentage of patients achieving MPR ≥80%, were 
reported in the most recent review to be between 18.3% to 91.9%.
34
 Statin medication adherence 
is thus considered a goal behavior. 
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Predictors to better understand the behavior of statin medication adherence have been 









Yet, no one single variable or factor on its own can explain the reason behind 
statin non-adherence in all patients. Therefore, identifying the factors influencing statin 
medication adherence for a patient or a group of patients may be a good strategy to start with 
when thinking of solutions or design of interventions. For this study, we chose to focus on 
patient psycho-social factors to better understand the behavioral goal of statin medication 
adherence.  
The patient psycho-social factors chosen were motivational intensity, behavioral 
intentions, self-efficacy, and outcome expectancies. We chose motivational intensity because 
regulatory fit produces a feeling of rightness and leads to higher motivation.
2
 Motivational 
intensity, to our knowledge, has not yet been investigated in the behavior of medication 
adherence. This will be the first study to do so. Behavioral intentions are included in our study as 
they capture a person’s motivational factors that influence behavior and are an indication of the 
effort one will invest in to achieve a goal. Behavioral intentions are part of the Theory of Planned 
Behavior and it has been used to study medication use.
41-43 
Their focus is to predict and explain 
behavior; however they do so at modest levels of 20 to 30% of variance.
12 
Pairing behavioral 
intentions with implementation intentions, therefore, is essential in helping patients translate 
their intentions into actions to achieve a goal. We have included both, behavioral intentions and 
implementation intentions, in this study.  
Next, in addition to intentions, we included patient beliefs, such as self-efficacy, and 
patients’ outcome expectancies, to better understand the behavioral goal of taking statin 





is a function of the person’s beliefs about one’s ability to engage in the behavior, termed as self-
efficacy (SE), and of the person’s expectations about the outcome, termed as outcome 
expectations (OE).  
Self-efficacy, described as the belief in one’s abilities to perform in behavioral domains, 
encompasses personal competencies and self-regulation.
46
 Self-efficacy influences directly or 
acts as a mediator for a variety of behaviors including cigarette smoking cessation, condom use, 
alcohol use, exercise, recovery from bulimia, weight reduction, coping with severe and chronic 
illness, recovery from myocardial infarction, and disease management.
45-49
 Individuals with 
higher self-efficacy levels may be more likely to sustain healthy behaviors.
49
 
 Self-efficacy is also known to predict medication adherence to some medications as 
several measures have been designed to assess the concept of self-efficacy in certain conditions 
and in specific populations. Examples of such measures are  MASES – Medication Adherence 
Self-Efficacy Scale in hypertensive African Americans,
50
  LTMBSES – Long-Term Medication 
Behavior Self-Efficacy Scale tested in adhering to an immunosuppressive regimen,
51
 SEAMS – 
Self-efficacy for Appropriate Medication Use developed to assess medication self-efficacy in 
chronic disease management,
52
 MUSE- the Medication Understanding and USE Self-Efficacy 
Scale to determined medication use,
53
 SEOMA – Self-Efficacy for osteoporosis medication 
adherence.
54
 OEOMA – Outcome Expectations for osteoporosis medication adherence was 
developed and tested as a reliable and valid measure of medication adherence.
54
 Self-efficacy 
beliefs and outcome expectancies are both predictors of behavioral intentions
55 
and of behavior 
change.
45,56 
Investigating the role of self-efficacy and outcome expectancies on the behavior of 
statin medication adherence as moderators will help us better understand how psycho-social 
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factors affect the behavior of adhering to medications. This in turn will help us design better 
interventions targeted to improve medication adherence.  
In summary, this study designed an intervention based on the Regulatory Fit Theory and 
tested it on the behavior of adhering to statin medications. The objective of the study was 
investigate how Regulatory Fit affects the behavior of statin medication adherence compared to 
Non-Fit and Control considering several patient psycho-social factors serving as mediators or 
moderators.  Regulatory Fit was defined as a match between one’s manipulated regulatory 
orientation and framed implementation intentions.  The study’s hypotheses are the following:  
H1: There is no difference between regulatory Fit, Non-Fit, and Control groups when it comes to 
statin medication adherence at weak versus strong variables of motivational intensity, behavioral 
intentions, self-efficacy, and outcome expectations.  
H2: There is no difference between the weak and strong motivational intensity/behavioral 
intentions/self-efficacy/outcome expectations variable groups when it comes to statin medication 
adherence within each of the regulatory Fit, Non-Fit, and Control group.  
Methods 
Design 
The effect of regulatory fit and non-fit was evaluated in older adults taking a statin 
medication as part of a field experiment using a randomized design (Figure 3.1). The experiment 
consisted of two Qualtrics® questionnaires with priming manipulations. The manipulations in 
this study were priming patients’ regulatory focus and formed implementation intentions. 




Patients were randomly assigned by the Qualtrics® survey system into two groups, 
promotion or prevention. The promotion group was primed with promotion framed messages, 
while the prevention group was primed with prevention framed messages. The formation of 
implementation intention plans was manipulated as well. Patients in the two orientation groups, 
promotion and prevention, were randomly assigned by the Qualtrics® survey system into three 
groups: promotion implementation intentions, prevention implementation intentions, and no 
implementation intentions.  
The research study was approved by the University’s Institutional Review Board 
(Appendix D). 
Participants 
Participants in the study were recruited from the University of Michigan Health System. 
The inclusion criteria for the study were being 18 years of age or higher, ability to speak English, 
and taking a statin medication at the time of participation in the study.  
Data Collection 
Data were collected via two online Qualtrics® questionnaires. A cover letter was mailed 
to 1,700 potential participants meeting the inclusion criteria inviting them to participate in the 
study. The letter, addressed to each patient, described the purpose of the study and an invitation 
to participate. A link to survey one was provided in each cover letter and a $2 bill was included 
as an incentive. Patients who chose to participate and completed survey one received a $20 visa 
gift card in the mail as an appreciation for their time and participation. Patients who completed 
survey one were invited to complete survey two by asking them to provide an email address. 
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Survey two was emailed two week later, and patients who completed survey two received an 
additional $5 reward. 
Questionnaires (Appendices A and B) 
The two questionnaires were designed based on theories and concepts used in the social-
psychology and pharmacy fields to better understand goal-pursuit and behavior change. 





 respectively. The concept of behavioral intentions was derived from 
the theory of planned behavior.
43
 The concepts of self-efficacy and outcome expectancies were 
derived from Bandura’s social learning theory.
44,45
 
Questionnaire one was distributed via Qualtrics® and consisted of 47 questions for the 
promotion and prevention groups and of 45 for the control group. It included questions that 
determined eligibility to participate in the study, questions about medications and overall health, 
and demographic questions. Patients were asked two questions to determine their statin 
medication adherence via the visual analogue rating scale.
57,58
 Patients’ regulatory focus was 
primed via two questions and then measured with the promotion or prevention regulatory focus 
questions. The regulatory focus questions were derived from the Regulatory Focus Questionnaire 
designed by Higgins and modified by Bagozzi.
3,9
 Patients’ intentions, motivation, self-efficacy, 
and outcome expectations were measured with two questions each. Patients were primed with 
implementation intentions framed as either promotion or prevention. One group of patients 
served as the control group, therefore receiving no implementation intentions.  
Questionnaire two consisted of four questions. Similarly to the first questionnaire, two 





 Question three was designed to capture potential reasons for statin medication 
non-adherence. And the last question asked patients of their intention to adhere to their statin 
medication in the next two weeks.  
Measures 
Regulatory Focus (RF). Regulatory focus was manipulated. Manipulation consisted of 
priming patients with two promotion or two prevention framed questions. The promotion framed 
questions asked patients to think about past and present hopes, aspirations, and dreams and list 
three of them.  The prevention framed questions asked patients to think about past and present 
duties, obligations, and responsibilities and list three of them. Question one for each 
manipulation focused on the past and question two focused on the present. The success of the 
manipulation was checked with nine promotion or prevention questions derived from the 
Regulatory Focus Questionnaire (RFQ) and designed by Bagozzi.
3,9
 Seven-point scales with 
response options from (1) Does not describe me at all to (7) Describes me extremely well were 
used. The 18 item Regulatory Focus Questionnaire was inspired from the original 11 items RFQ 
developed by Higgins (α=0.91 for the promotion scale; α=0.93 for the prevention scale).
3,9
 
Higgins’ RFQ was modified by eliminating the parental oriented questions such as “how often 
did you obey rules and regulations that were established by your parents?” so that the 
questionnaire is applicable to adult sample populations. A sample item of promotion-focus scale 
is “I am typically able to get what I want out of life” and a sample item of prevention-focus scale 
is “I frequently think about how I can prevent failures in my life”.  
Implementation Intentions (ii). The formation of implementation intention plans has been 
studied and applied in other studies.
12-14 
In this study, implementation intentions were 
manipulated by framing implementation intention messages as promotion, prevention, or none. 
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The promotion and prevention implementation groups each received two questions framed as 
either promotion or prevention. The control group did not receive any implementation intention 
questions.  
In the first question the promotion implementation intentions group was asked to think of 
the benefits of taking their cholesterol medication and to list at least three things that they could 
do that could help them to take their cholesterol medication. In the second question, then they 
were asked to imagine when, where, with whom, and in what situations they will take their statin 
medication. The prevention implementation intention group was asked to think of the drawbacks 
of not taking their cholesterol medication and list three things they could do that would help to 
avoid not taking their cholesterol medication.  
Regulatory Fit (RFit). Regulatory Fit in this study was manipulated and defined as the match 
between a patient’s orientation (RF) and implementation intentions. A fit was experienced when 
a patient with a promotion orientation formed promotion implementation intentions or when a 
patient with a prevention orientation formed prevention implementation intentions. A misfit was 
experienced when a patient with a promotion orientation formed prevention implementation 
intentions or when a patient with a prevention orientation formed promotion implementation 
intentions. Fit was coded 1, Non-Fit -1, and control 0. Control represented groups that formed no 
implementation intentions. 
Behavioral Intention (BI). Behavioral intention was assessed via two questions in this study. 
Participants were asked on a scale from strongly disagree to strongly agree to answer two 
questions on intending and planning to take their cholesterol medication as prescribed during the 
next 2 weeks. The behavioral intentions variable was further dichotomized by averaging strongly 
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disagree, disagree, neither disagree/agree as together as ‘weak’ and averaging agree and 
strongly agree as ‘strong’. The effect of regulatory fit on statin medication adherence was tested 
when behavioral intentions were strong versus weak. 
Motivational Intensity (MI). Motivational intensity was assessed via two questions in this 
study. MI was measured via two constructed questions asking participants how motivated and 
determined they are to take their cholesterol medication as prescribed. The response options 
ranged from not at all to extremely.  Motivational intensity was dichotomized by averaging not 
at all, somewhat, and moderately together as ‘weak’ and very and extremely as ‘strong’. The 
effect of regulatory fit on statin medication adherence was tested when motivational intensity 
was strong versus weak. 
Self-efficacy (SE). Self-efficacy was assessed via two constructed questions asking patients how 
confident and certain they are in their ability to take their cholesterol medication as directed. 
Response options ranged from not at all to extremely confident for each question. Self-efficacy 
was dichotomized by averaging not at all, somewhat, and moderately together as ‘weak’ and 
very and extremely as ‘strong”. The effect of regulatory fit on statin medication adherence was 
tested when self-efficacy was strong versus weak.  
Outcome Expectancies (OE). Outcome expectancies was assessed via two questions by asking 
patients how promising or likely is that their heart will improve or their risk for heart disease will 
be reduced if cholesterol medication will be taken as directed. Response options range from not 
at all to extremely certain. Outcome expectancies was dichotomized by averaging not at all, 
somewhat, and moderately together as ‘weak’ and very and extremely as ‘strong”. The effect of 
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regulatory fit on statin medication adherence was tested when a patient’s outcome expectations 
were strong versus weak. 
Statin Medication Adherence (SMA). Statin medication adherence was measured via the two 
surveys at baseline and two weeks later. The item used to collect data on statin medication 
adherence was the single-item visual analogue rating scale (VAS).
57,58 
The VAS has been 
successfully tested and used to measure adherence to antiretroviral therapy.
59 
VAS is a single 
item visual analogue scale that asks individuals to estimate along a continuum the percentage of 
medication dosages taken as prescribed during a specified period of time. The continuum ranges 
from 0% to 100% of medication doses taken as prescribed. VAS, administrated via a computer, 
demonstrated adherence estimates that paralleled unannounced pill counts, electronic medication 
monitoring, unannounced monthly pill counts, and self-reported recall.
57,58
 
Other Variables. Demographic variables such as gender, age, race, and income were collected 
in this study. Data on clinical variables such as having a diagnosis of heart disease, high 
cholesterol, had heart surgery, currently taking a statin medication, the length of time being on 
the statin medication, insurance coverage, number of Rx medications taken daily, number of over 
the counter products, and perceived overall health were collected as well.  
Summary Design (Figure 3.1) The simple effect analysis variables can be summarized as 
follows: 
1) manipulated variable RFit (X): defined as the match/fit between a patient’s regulatory focus 
orientation and implementation intention plans. Fit was coded 1, Non-Fit -1, and Control 0. 
Control represented groups that formed no implementation intentions, 
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2)  categorical independent variables: motivational intensity (MI), behavioral intentions (BI), 
self-efficacy (SE), and outcome expectancies (OE), 
3)  one continuous outcome variable (Y): statin medication adherence (SMA). 
Analysis 
For analysis, descriptive and frequency distributions were computed to describe 
demographics and health characteristics. Behavioral intentions, motivational intensity, self-
efficacy, and outcome expectancies were recoded as ‘strong’ and ‘weak’. A 2 (independent 
variable: weak vs strong) x 3 (Regulatory: Fit vs Non-Fit vs Control) ANOVA with statin 
medication adherence (SMA) as the dependent variable was conducted. Pairwise comparisons 
were run to determine the significance of differences between groups. For each of the ‘weak’ and 
‘strong’ groups, it was tested whether there was a statistical significant difference in statin 
medication adherence between the Fit, Non-Fit, and Control groups.  
Results 
A total of 1700 patients from a university affiliated health system were invited to 
participate in the study; responses were received from 555 patients to questionnaire one and to 
both questionnaire from 326 patients. Differences in variables of interest were tested between 
respondents to both questionnaires and those who responded to only questionnaire one. Results 
indicated a significant difference between respondents and non-respondents in health insurance 
(Appendix E). Table 3.1 presents patient demographic and clinical characteristics. The majority 
of patients (69.32%) were 60 years of age or higher and identified themselves as white (87.17%). 
Patients’ economic status represented in terms of income ranged from ≤$19k/year (9.2%) to 
$100k/year or ≥ (24.2%); about half of participants had an income of $60k/year or greater. The 
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majority of patients (88.65%) reported to be very good to excellent overall health. A total of 
93.56% reported a high cholesterol diagnosis, with 25.15% having a heart disease/condition and 
11.35% reported to have experienced heart surgery. The respondents were on a statin medication 
for a long period of time, for up to 30 years and they were taking other prescription medications 
in addition to the statin. There was no significant difference between the Fit, Non-Fit, and 
Control groups in demographics or clinical characteristics. 
Overall, the mean for Statin medication adherence (SMA) at two weeks was 96.3% ± 
13.74; while at baseline was 95.67% ± 14.21. The dependent variable was skewed, and it was 
transformed via a two-step approach and a log-transformation. Both transformations resulted in 
slightly better results towards normality; however, the results were not statistically significant 
(indicated by the Kolmogorov-Smirnov and Shapiro-Wilk tests). Therefore, we used the original 
statin medication adherence results for analyses. For each group, SMA was the following: SMA 
(Fit) = 98.25%, SMA (Non-Fit) = 95.64%, SMA (Control) = 94.89% (F=1.81, p=.165). The 
behavior of statin medication adherence (SMA) was predicted as a function of regulatory fit 
(RFit) and independent variables, including motivational intensity (MI), behavioral intentions 
(BI), self-efficacy (SE), and outcome expectations (OE). In addition to statin medication 
adherence, intentions were explored as a possible dependent variable. Intentions’ distribution 
was skewed (mean 4.85 ± .524); therefore the behavior of adhering to statin medication was 
chosen as the dependent variable.  The average promotion and prevention scores were calculated 
to test whether manipulation worked. The manipulation was successful: RF (promotion) average 
score was 5.02 (.90) and RF (prevention) average score was 5.65 (.79). 
Figure 3.2 and Table 3.2 represent the results of the ANOVA analysis of the difference 
between groups (H1). When patients’ motivational intensity, behavioral intentions, self-efficacy, 
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and outcome expectations were strong, there was no difference in statin medication adherence 
levels between the Fit, Non-Fit, and Control groups. When patients’ motivational intensity and 
behavioral intentions were weak, statin medication adherence in the Fit group was higher than in 
the Non-Fit and in the Control group. There was no statistically significant difference between 
the Non-Fit and Control groups. When patients’ self-efficacy was weak, there was no difference 
between any of the groups in statin medication adherence levels. When patients’ outcome 
expectations were weak, statin medication adherence was higher in Fit versus Non-Fit group 
(p=.023).  
Table 3.3 represents the results of the ANOVA analysis of the differences within groups 
(H2). There is a statistical significant difference for the Non-Fit and Control groups for patients 
who have weak versus strong motivational intensity and behavioral intentions, but not for weak 
versus strong self-efficacy. Weak versus strong outcome expectations were significant only in 
the Non-Fit condition. For the Fit group, there is no difference for patients with weak and strong 
aspects of all variables.  
Discussion 
This study examined the effect of a fit intervention on the behavior of statin medication 
adherence. Specifically, the intervention was designed to examine potential strategies patients 
may use in their decision-making process to engage in the behavioral goal of adhering to their 
statin medication. The strategic compatibility between patients’ regulatory focus and formed 
implementation intentions was tested in this intervention. 
Findings indicate that patients who experienced a Fit versus Non-Fit or versus Control 
had greater statin medication adherence levels at weak psychosocial factors such as motivational 
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intensity, behavioral intentions, and outcome expectations. When these patient psychosocial 
factors were strong, there was no statistical significant difference in statin medication adherence 
levels among the groups. Additionally, findings suggest that when patients’ self-efficacy is weak 
or strong there is no difference in statin medication adherence levels between the Fit, Non-Fit, 
and Control groups. These findings indicate that when patients’ motivational intensity, 
behavioral intentions, and outcome expectations are weak, there is an opportunity to improve 
statin medication adherence via a Fit intervention. 
The results of this Fit intervention are similar with findings from with previous regulatory 
fit studies.
1,6-9,11 
The Fit intervention consisted of matching patients’ primed regulatory focus 
with framed implementation intentions. Implementation intentions served as strategic means to 





 taking on eagerness versus strategic approach,
6
 thrill versus 
worry emotional approaches,
11
 and framed implementation intentions.
9
 Regardless of the 
strategic means chosen in each study, the suitability of strategic means to patients’ regulatory 
orientation is what created a ‘value from fit’.
4
 This ‘value from fit’ effect led to a feeling of 
rightness in the decision-making process, increased motivation to engage in the specific 
behavior, and feeling better and more alert about the decision.
4
 In the context of the behavior of 
choice of this study, statin medication adherence, when experiencing a fit, patients would be 
more likely to be motivated to take their medication and feel better as a result of making the 
decision to take their medication as directed by their health care provider.  
Patients’ regulatory focus in this study was manipulated. Other studies manipulated 
participants’ regulatory focus as well,
7,9,11 
while others measured participants’ chronic regulatory 
focus.
6,8 
One study measured participants chronic regulatory focus and also manipulated it; 
124 
 
similar findings were reported for the two.
9 
Since the effect of both measured and manipulated 
regulatory focus was found to be similar, we chose to test the effect of patients’ manipulated 
regulatory focus with promotion and prevention framing messages on the behavior of statin 
medication adherence. Testing the effects of this priming manipulation on the behavior of statin 
medication adherence provides us with an intervention tool that can be applied to improve 
adherence behavior.  
This study adds value to the body of research as it is the first study to investigate the 
effect of the regulatory fit theory on the behavior of statin medication adherence. This study took 
on an intervention approach of manipulating both regulatory focus and implementation 
intentions. One study investigated the behavior of healthy snacking behavior with a similar 
approach and had some similar findings to this study.
9
 Findings indicate that, similarly to statin 
medication adherence, the snacking behavior was affected differently at weak versus strong 
unhealthy snacking habits. The difference being that the healthy snacking behavior was changed 
only at strong unhealthy habits when there was a fit, while at weak habits the behavior was 
changed either when there was a fit or non-fit. For the behavior of statin medication adherence, 
at weak patient psychosocial factors the behavior was greater for the fit versus non-fit and versus 
control, while at strong psychosocial factors the behavior of adhering to medications was similar 
among the groups. These findings indicate that a fit intervention is most effective when 
unhealthy habits are strong and psychosocial factors are weak; hence, more potential for 
behavior change. Applying the theory of regulatory fit via similar fit interventions to other 
medications and/or conditions will help us better understand whether patients’ self-regulatory 




More recent research in medication adherence trajectories is promising. Trajectories of 
non-adherence identified for coronary heart disease, for example are: 1) nearly always adherent 
patients, 2) an early gap in adherence with a later recovery, 3) brief gaps in medication use or 
occasional users, 4) a slow decline in adherence, and 5) a fast decline.
60 
Predictions of statin 
adherence trajectories were identified based on patterns of statin filling over a year following 
therapy initiation.
61
 The best prediction trajectory was using 3 months statin initial adherence and 
worst using just baseline variables. Future studies investigating how our results may be similar or 
different by trajectories of statin adherence are needed in order to identify how patient 
psychosocial factors impact adherence levels at different stages during therapy.  
Implications for pharmacy practice can be drawn from the results of the fit intervention. 
Specifically, the fit design presents an opportunity for future tailored communication between 
the health care provider and the patient. The communication would be tailored to be patient 
specific according to each patient’s regulatory focus (chronic or manipulated). In this context, 
considering the behavior of statin medication adherence, pharmacists would tailor their 
communication by framing strategic means to match patients’ orientation. This approach can be 
applied during a patient consultation or during a motivational interview session. Both encounters 
are opportunities for pharmacists to tap into the motivational sources for patients’ decision to 
engage in the behavior of taking their statin medication. In either encounter, pharmacists would 
inquire about patients’ goals as a result of taking the medication and based on answers received 
would tailor communication. For example, if the patient states his/her goal being to avoid a 
stroke event as a result of taking the statin medication, then the pharmacist would tailor their 
response as ‘avoid stroke, as a result of taking the statin medication’; this representing a 
prevention fit communication between pharmacist and the patient. However, if the patient thinks 
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in terms of promotion outcomes, as a result of chronic or manipulated promotion regulatory 
focus orientation, the pharmacist would tailor communication accordingly. A promotion 
cardiovascular goal may be to ‘improve heart health and live a long life to see my great 
grandkids’. Another approach pharmacists may use is to assess patients’ motivational intensity, 
behavioral intentions, and outcome expectations in regards to their behavior of taking their 
medication. If those are high, then there is no need to tailor communication. However if they are 
low, pharmacists have an opportunity to tap into patients’ intrinsic motivational factors and help 
them move towards positive medication adherence behavior change via tailored ‘fit’ 
communication. 
Future studies investigating the effect of fit interventions in various medications and 
disease conditions will provide us with insights to design messages for patients that will improve 
behavior change for each medication and condition. These fit interventions can be designed to 
deliver tailored communication face-to-face or via mobile technologies. The goal of positive 
behavior change is to improve patients’ overall health and well-being.   
Limitations of this study include the potential patient response bias in the questionnaires. 
The statin medication adherence levels in this study are high compared to the previously reported 
statin adherence levels. This may be due to the self-report nature of the study leading to over-
reporting due to potential social desirability to indicate high adherence values or potentially due 
to recall bias leading to patients inaccurately remembering their adherence behavior.  It may also 
be likely that patients participating in the study were more inclined to seek engagement in 
various health behaviors, including taking statin medications, in pursuit of improving their 
cardiovascular and overall health. Furthermore, statin medication adherence was measured via 
the visual analogue scale (VAS), consisting of a single item. This measure was chosen to capture 
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the adherence levels while reducing response burden. Including additional items could be 
pursued in future studies, but would increase response burden. With different statin medication 
adherence levels, we may detect different results.  
Study generalizability is another limitation. The results of this study are applicable for 
one segment of a specific population, specifically patients on a statin medication in a specific 
geographical area. It is likely, that given a more diverse population sample, our results may have 
been different. For example, a different distribution in race and income may result in different 
statin medication adherence levels as well as different levels in behavioral intentions, 
motivational intensity, self-efficacy, and outcome expectations. Our study design did include 
randomizing patients to different groups and assessed behavior two weeks after delivering the 
regulatory fit intervention. Therefore, the generalizability of the results from our controlled study 
to a similar sample of patients is scientifically sound. Potential future research applications are to 
test the effect of Regulatory Fit interventions in other medications and patient populations and 
design tailored messages delivered by pharmacists face-to-face or via mobile technologies. 
Conclusions 
The regulatory fit intervention resulted in higher statin medication adherence levels for 
the fit versus the non-fit and versus the control groups. Furthermore, when patients’ behavioral 
intentions, motivational intensity, and outcome expectations were weak, differences in statin 
medication adherence levels between the fit and non-fit and between the fit and control groups 
were significant, presenting an opportunity for adherence improvement via interventions.  Future 
research expanding the effect of regulatory fit for various medications and patient populations is 
needed. Pharmacists have a unique opportunity to apply regulatory fit interventions in their 
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Table 3-1. Patient Demographic and Clinical Characteristics by Intervention Group 
Variable Fit Non-Fit Control Total  
Sample size 112 110 104 326 p-value 
Demographics 
   Age (≥60y) 
   Female 
   White 
   Income 






























   Heart disease (yes) 
   Heart surgery (yes) 
   High cholesterol (yes) 
   Depression meds (yes) 
   Rx ≤ 5 
   Time on statin ≤10y 
   Overall health 












































Table 3-2. Mean Differences in Statin Medication Adherence between Weak and Strong 
variables at Different Points of Fit 
Variable Weak Strong 
 mean diff (se) p-value mean diff (se) p-value 
Motivational Intensity     
Fit : Non-Fit 14.3 (3.73) .000* .293 (1.87) .875 
Fit : Control 17.4 (4.36) .000* 2.19 (1.86) .240 
Non-Fit : Control 3.12 (4.53) .492 1.89 (1.84) .304 
Behavioral Intentions     
Fit : Non-Fit 29.5 (8.82) .001* 1.60 (1.70) .349 
Fit : Control 54.5 (9.52) .000* 1.83 (1.73) .289 
Non-Fit : Control 25.0 (9.52) .009 .236 (1.73) .892 
Self-efficacy     
Fit : Non-Fit 4.00 (2.30) .083 .77 (3.04) .801 
Fit : Control 3.90 (2.38) .102 3.14 (3.00) .296 
Non-Fit : Control -.10 (2.43) .968 2.38 (2.91) .414 
Outcome Expectancies     
Fit : Non-Fit 5.62 (2.45) .023* -.598 (2.73) .827 
Fit : Control 3.77 (2.45) .125 2.89 (2.82) .305 
Non-Fit : Control -1.84 (2.52) .465 3.49 (2.75) .205 





Table 3-3. Mean Differences in Statin Medication Adherence between the Fit, Non-Fit, and 
Control groups at Weak and Strong Variables 
Variable (weak vs strong) Fit Non-Fit Control 
 mean diff (se) p mean diff (se) p mean diff (se) p 
Motivational Intensity -5.47 (2.82) .053 -19.48 (3.07) .000* -20.70 (3.81) .000* 
Behavioral Intentions .259 (6.35) .967 -27.64 (6.35) .000* -52.41 (7.30) .000* 
Self-Efficacy -2.33 (2.72) .393 -5.56 (2.66) .038 -3.08 (2.70) .254 





















































































 - PAPER 3: OPTIMISM’S EFFECT ON STATIN MEDICATION Chapter 4
ADHERENCE 
Abstract 
Background: Optimism is linked to positive outcomes in a variety of behaviors, including 
cardiovascular health and medication adherence. The mechanisms via which it does so are not 
yet understood. This is important because it may provide a better understanding for future 
intervention design to improve health behaviors. 
Aim: To test the conditional indirect effect of optimism on statin medication adherence with 
various psychosocial factors mediating and moderating the relationship as potential mechanisms. 
Methods: Adults on a statin medication proficient in English were recruited from a Midwestern 
academic health system to participate in the study. Patients who agreed to participate completed 
two questionnaires assessing various psycho-social factors in questionnaire one and the behavior 
of statin medication adherence in questionnaire two. Optimism was measured via the Life 
Orientation Test Revised tool. The effect of optimism on statin medication adherence was 
determined via a conditional indirect effect using the PROCESS macro tool. 
Results: The conditional indirect effect of optimism on statin medication adherence with 
behavioral intentions serving as the mediator and low-to-moderate levels of self-efficacy or 
outcome expectation levels serving as the moderator was statistically significant. Similarly, the 




























intensity intentions serving as the mediator and low-to-moderate levels of self-efficacy or 
outcome expectation levels serving as the moderator was statistically significant. 
Conclusion: Optimism affected the behavior of statin medication adherence via a conditional 
indirect effect with various patient psychosocial factors serving as mediators and moderators. 
This is a novel predictor for statin medication adherence that should be considered when 
designing interventions to improve medication adherence. Furthermore, our research provides a 
framework for potential mechanisms via which optimism affects behavior.  
Introduction 
Optimism, an inherent part of human nature, is a beneficial psychological characteristic 
defined as the global expectancy that good things will be plentiful in the future and bad things 
scarce.
1,2
 This personality variable categorizes people as optimists or pessimists, with a range 
from very optimistic to very pessimistic. Optimists expect good things to happen to them while 
pessimists expect the opposite.
2
 Optimism is known to influence a variety of behaviors.  
Research indicates that optimism is associated with greater persistence in educational, 
athletic, military, occupational, and political success; benefits in the socioeconomic world; better 
relationships; popularity; better health; and with long life.
 1,2
 Specifically to health behavioral 
outcomes, optimism is linked to higher levels of engagement coping, better subjective well-being 
in times of difficulty, and to greater likelihood of taking proactive steps to protect one’s health.
2
 
In the context of cardiovascular health, optimism is associated with reduced pain, distress, and 
cardiovascular reactivity in healthy adults primed with neutral words.
3
 For older adults, optimism 
has a protective effect on all-cause cardiovascular mortality and the risk of stroke is lower for 





Being optimistic is associated with positive outcomes for patients who have experienced 
one or more cardiovascular events. Specifically, optimism is associated with a faster rate of 
physical recovery after coronary artery bypass graft (CABG) surgery during the period of 
rehospitalization, with a faster rate of return to normal life activities once discharged from the 
hospital, and with lower rates of rehospitalization after CABG surgery.
6
 Moreover, being 
optimistic is linked to higher response rates to depression treatment in depressed post-CABG 
surgery patients,
7
 and to greater success in achieving lower levels of saturated fat, body fat, 
global coronary risk, and higher aerobic capacity in cardiac patients.
8
  
Optimism is a patient characteristic that has been studied little in in the context of 
medication adherence. There is one study that investigated the effect of optimism on medication 
adherence in a sample population of people living with HIV/AIDS.
9
 The finding of this 
dissertation research study indicates that optimism is positively associated with medication 
adherence. Additional factors suggested to influence this relationship are presence of depression, 
quality of life and self-efficacy. The mechanisms of optimism’s effect on the behavior 
medication adherence, however, are not yet examined. Therefore, this study will serve as a 
foundational research in better understanding the mechanisms via which optimism affects the 
behavior of statin medication adherence.  
Approximately 50% of patients with cardiovascular disease are reported to have poor 
medication adherence.
10
 Aligned with the American Heart Association’s goal of improving the 
cardiovascular health of Americans by 10% by the year 2020,
 11,12
 we are interested in improving 
the cardiovascular health of patients. Specifically, we are focusing on improving one of the 
cardiovascular health behaviors patients must engage in to achieve cardiovascular health, that is 
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attaining cholesterol levels of <200mg/Dl.
12
 One pathway to achieve this goal is taking a statin 
medication. Therefore, our focus is on investigating the behavior of statin medication adherence. 
The behavior of medication adherence is an important behavior of focus for several 
reasons. One, with 50% of patients in the US not taking their medications as prescribed,
13
 
medication nonadherence is costing the US between $100 to $300 billion USD annually of 
avoidable health care costs.
10
 In addition to increased health care costs, other negative 
consequences of medication nonadherence are worsening of condition, increased comorbid 
diseases, higher hospitalization rates, and death.
14
 Better medication adherence leads to positive 
outcomes. Examples include lower hospitalization rates and cost offsets of medical costs for 
some chronic conditions,
15
 lower rates of major adverse cardiovascular events and cost savings,
16
 
and improved health outcomes and reduced annual costs for secondary prevention of coronary 
artery disease.
17 
Therefore, improving the behavior of medication adherence is a worthwhile 
goal. 
Adhering to statin therapy is an important clinical issue as statin medications have shown 
to play an essential role in the treatment and prevention of heart disease.
18,19
  Despite being safe 
and effective in reducing cardiovascular mortality and morbidity, half of patients discontinue 
therapy within the first year and statin adherence levels are reported to be as low as 25% and as 
high as 48%.
18,19,20
 The most recent review documents statin medication adherence levels 
between 18.3% to 91.9%; SMA was measured as the percentage of patients achieving MPR 
≥80%.
21
 Consequences for medication non-adherence are poor outcomes, increased healthcare 
utilization, and increased overall costs; specifically, non-adherence for cardiovascular 
medications consequences are increased risks of morbidity and mortality.
22
 Reasons for statin 





 Specific examples for statin discontinuation include adverse effects, lack of efficacy, 
motivation, cost, polypharmacy, drug interactions, age, ethnicity, gender, type of exercise, 
presence of other diseases, adverse publicity in the media, and others.
23
  
This study focused on investigating patient psycho-social factors to better understand the 
behavior of statin medication adherence. Specifically, we focused on investigating how patients’ 
optimism affects the behavior of statin medication adherence with behavioral intentions, 
motivational intensity, self-efficacy, and outcome expectations potentially mediating or 
moderating this relationship. Behavioral intentions, derived from The Theory of Reasoned 
Action and The Theory of Planned Behavior, capture a person’s motivational factors that 
influence behavior and are an indication of how hard a person will try in order to achieve a 
behavior.
24
 The concepts of self-efficacy and outcome expectations originate from Bandura’s 
Social Learning Theory proposing that behavior change is a function of one’s expectations about 
the outcome and one’s ability to engage in behavior.
25,26
 Self-efficacy is defined as one’s belief 
about his/her ability to successfully perform specific behaviors in particular situations to produce 
the outcomes and outcome expectations is defined as the belief about the likelihood of the 
behavior leading to certain outcomes.
25,27
 Motivational intensity measures the degree of 
motivation one would engage in a behavior and it is linked to the self-regulatory fit theory.
28
 
These four patient psycho-social factors are identified as important in goal behaviors. Hence, 
they are included in this study as potential variables investigating the mechanism of optimism on 
statin medication adherence.  
The aims of this study were to understand how optimism affects the behavior of statin 
medication adherence. Specifically, the relationship between patients’ optimism and statin 
medication adherence was tested via a conditional indirect approach with behavioral intentions 
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and motivational intensity serving as mediators, and with patients’ self-efficacy and outcome 
expectancies serving as moderators.   
First, the conditional indirect effect of patients’ optimism on statin medication adherence 
was tested with behavioral intentions as the mediator and the two moderators of self-efficacy and 
outcome expectancies. The hypotheses tested were: 
H1: The greater the optimism the greater the intentions to engage in the behavior. 
H2a: Behavioral intentions will influence the behavior of statin medication adherence the greater 
the self-efficacy. 
H2b: Behavioral intentions will influence the behavior of statin medication adherence the greater 
the outcome expectations. 
H3: Optimism affects statin medication adherence directly. 
Second, the conditional indirect effect of patients’ optimism on statin medication 
adherence was tested with motivational intensity as the mediator and the two moderators, self-
efficacy and outcome expectancies. The hypotheses for this model include: 
H4: The greater the optimism the greater the motivation to engage in the behavior. 
H5a: Motivational intensity will influence the behavior of statin medication adherence the 
greater the self-efficacy. 
H5b: Motivational intensity will influence the behavior of statin medication adherence the 
greater the outcome expectations. 





This was a prospective study and data collection was done via two designed 
questionnaires (Appendices A and B). Questionnaire one focused on patient psychosocial 
factors, and questionnaire two focused on the behavior of adherence to the statin medication.  
Patients who were taking a statin medication during the time of study were identified at a 
large university health care system. A total of 1700 potential patient participants were invited to 
take part of our study. The invitation consisted of a cover letter consisting of the purpose of the 
study and invitation to participate, a link to complete the survey online, and a $2 incentive. The 
link was the same for all potential participants and a unique code was provided for each 
participant to access the survey. Participants who completed the first survey received an 
incentive of $20 and were invited to complete the second survey. The second survey was sent to 
participants’ emails two weeks from completing the first survey. Participants who successfully 
completed the second survey received an additional $5 incentive. University of Michigan 
Institutional Review Board (IRB) approval was granted to initiate and complete the study. 
Participants 
Patients on a statin medication, proficient in English, 18 years of age or higher were 
included in the study. Patients who did not meet our inclusion criteria were excluded from the 
study.  
Measures 
Independent variable: Optimism 
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The independent variable, optimism, was measured via the Life Orientation Test Revised 
(LOT-R).
29,30
 The LOT-R is a 10-item scale that was adapted from the LOT instrument 
developed to asses individual differences in generalized optimism versus pessimism. The LOT-R 
scale was constructed by eliminating two items dealing with coping style rather than with 
positive expectations for future outcomes. The items in the LOT-R consist of 3 positive worded 
items, 3 negative worded items, and 4 filler items. The LOT-R items are scored 1-5, with 1 
indicating strongly disagree, 2 disagree, 3 neutral, 4 agree, and 5 strongly agree. Total score is 
the sum of 6 items; the other four items are filler items. The filler items are its easy for me to 
relax, I enjoy my friends a lot, it’s important for me to keep busy, I don’t get upset too easily.. 
The three negatively worded items are reverse coded before scoring; if something can go wrong 
for me it will, I hardly ever expect things to go my way, I rarely count on good things to happen 
(0=4, 1=3, 2=2, 3=1, 4=0). Specific items 1,3,4,7,9, and 10 are summed to obtain an overall 
score, and the possible range for the total score is 6 to 30. The higher the value implies higher 
optimism. The LOT-R has good internal consistency with a Cronbach’s α=0.78 and its test-retest 
reliability is 0.68 at 4 months and 0.79 at 28 months.  
Dependent variable: Statin medication adherence (SMA) 
Statin medication adherence was assessed using the single-item visual analogue rating 
scale (VAS).
31,32
 It consists of a single item that asked participants to estimate, along a 
continuum of 0 to 100, the percentage of medication dosages taken as prescribed during a 
specified time period.
31,32,33
 VAS was used to successfully measure adherence to antiretroviral 
therapy
33
 and has demonstrated adherence estimates that paralleled unannounced pill counts, 





Statin medication adherence was assessed at baseline and two weeks after completing 
questionnaire one.  
Mediator variables: Behavioral intentions and Motivational intensity 
Behavioral intentions (BI) 
The variable of behavioral intentions served as a mediator in this study and was assessed 
via two questions. The two questions consisted of asking participants to rate on a scale from 
strongly disagree to strongly agree their intention to take the cholesterol medication as 
prescribed in the next two weeks and on a scale from very unlikely to very likely  how likely is 
the intention to take their cholesterol medication as prescribed. The scores for the two questions 
were averaged. The answer options for both questions were on a scale of 1 to 5. 
Motivational intensity (MI) 
The variable of motivational intensity served as a mediator in this study as well and was 
assessed via two questions. The two questions asked participants on a scale of not at all to 
extremely how motivated and determined they were to take their cholesterol medication as 
prescribed.  To obtain one score for the motivational intensity variable, the scores for the two 
questions were averaged. The answer options for both questions were on a scale from 1  to 5. 
Moderator variables: Self-efficacy and Outcome expectancies 
Self-efficacy (SE) 
The variable of self-efficacy served as one of the moderator variables. It was tested via 
two questions asking participants on a scale of not at all to extremely how confident they were 
that their cardiovascular health will improve as a result of taking their cholesterol medication as 
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directed and how certain they were that they will be able to avoid cardiovascular disease as a 
result of taking their cholesterol medication as directed. The average of the two questions was 
calculated into one self-efficacy score. The answer options were on a scale from 1 to 5. 
Outcome expectancies (OE) 
The variable of outcome expectancies served as a moderator in this study as well and was 
measured via two questions. One question asked participants how promising it was that their 
health would improve if they took their cholesterol medication as directed. The second question 
asked participants how likely it was that they will reduce their risk of heart disease if they took 
their cholesterol medication as directed. Both questions had answer options ranging from not at 
all to extremely, and the scores for the two questions were averaged to obtain one score. The 
answer options were on a scale from 1 to 5. 
Participants in the study also answered questions about their overall and cardiovascular 




 (Appendix C) was applied to test the hypotheses in this study. 
Figure 1 represents the model with the variables included in the model. The conditional indirect 
effect of X on Y via mediators M and moderators V is tested via two subset models: the mediator 
variable model and the outcome variable model.  
The mediator variable model is determined by the effect of the independent variable (X) 
on the mediator (M). The equation for the mediator variable model is:  
M=β10+β11X+ε1                                                                                                                                                                                            (1) 
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The outcome variable model is determined by the direct effects of the independent variable (X) 
on the independent variable (Y) and by the interaction effects of the mediator (M) with the 
moderator (V) on the independent variable. The equation for the outcome variable model is:   
Y=β20+β21X+β22M+ β23V+β24M(V)+ε2                                                                                           (2)                                                                                                                                                                                                                                                                                                                                                                    
The conditional indirect effect of optimism on statin medication adherence is found to be 
successful when β11 and the β24 coefficients are statistically significant.  
Results  
Demographic and clinical patient characteristics represented in Table 1 indicate that our 
sample was comprised of predominantly white (87.1%) and ≥60y of age (69.3%) adults. The 
female and male populations were similar in number and approximately half of the sample had 
an annual income of $60k or higher. The majority of patients perceived themselves as being in 
good to excellent health (88.7%). Approximately 1/3 indicated taking a depression medication at 
the time of study completion. Analyses between respondents to both questionnaires versus 
respondents to questionnaire one only indicate no significant differences between majority of 
variables, except health insurance (Appendix E). 
Cronbach alpha (α) tests determined the reliability of the measures in our study. 
Considering the general rule in social sciences of a reliability measure of  ≥.70 being good, all 
variables tested exhibited good reliability:  α(behavioral intentions) = .71, α(motivational 
intensity) = .93, α(self-efficacy) = .85, α(outcome expectancies) = .86, α(optimism) = .81. The 
distribution of the dependent variable Statin medication adherence (SMA) was 96.3% ± 13.74. 
Baseline statin medication adherence was 95.67% ± 14.21. Intentions were considered as a 
potential dependent variable tool. Similarly to statin medication adherence, the distribution of 
152 
 
intentions was skewed (mean 4.85 ± .524). For analyses, we chose the behavior of adhering to 
statin medication as the dependent variable. The two-step and log-transformation approaches 
were used to transform the statin medication adherence variable. Slightly better results towards 
normality resulted. However, the transformation results were was not statistically significant as 
indicated by the Kolmogorov-Smirnov and Shapiro-Wilk tests. The original statin medication 
adherence results were used for analyses. 
Figure 1 represents pictorially the model with the independent variable being optimism 
(X), the mediating variables being behavioral intentions and motivational intensity (M), and the 
moderating variables being self-efficacy and outcome expectancies (V). The three main findings 
from testing the model were:  
1. Optimism did not influence the behavior of statin medication adherence directly. 
2. Optimism did influence the behavior of statin medication adherence via a conditional 
indirect effect with behavioral intentions mediating the relationship and with self-efficacy 
or outcome expectancies serving as moderators.  
3. Optimism did influence the behavior of statin medication adherence via a conditional 
indirect effect with motivational intensity mediating the relationship and with self-
efficacy or outcome expectancies serving as moderators.  
The conditional indirect effect of optimism on statin medication adherence was established 
when behavioral intentions or motivational intensity served as the mediator and when self-
efficacy or outcome expectancies served as the moderator (Figure 4.1; Table 4.2). Specifically, 
behavioral intentions mediated the relationship between patients’ optimism and behavior of 
adhering to statin medications (b=.01, p=.04). Furthermore, self-efficacy or outcome expectancy 
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values moderated the degree to which patients’ intentions influenced the behavior (b=-10.88, p 
=.00). Specifically, low and moderate levels of self-efficacy and outcome expectations interacted 
behavioral intentions to affect statin medication adherence (Table 4.4). Since, there was not a 
direct effect of optimism on the behavior of statin medication adherence, we can say with 
statistical confidence that intentions fully mediated the impact of optimism on statin medication 
adherence in this model.  
Similarly to intentions, motivation was found to fully mediate the impact of optimism on 
statin medication adherence. The conditional indirect effect of optimism on statin medication 
adherence was established when motivational intensity served as the mediator (b=.04, p=.00) and 
when self-efficacy (b=-2.77, p=.00) or outcome expectancies (b=-1.79, p=.048) served as the 
moderator (Table 4.3). Specifically, low and moderate levels of both moderators significantly 
interacted with motivational intensity to affect statin medication adherence (Table 4.4). 
Discussion 
Psychosocial factors are essential determinants of human behaviors. Optimism is a novel 
patient psychosocial factor investigated in the context of the health behavior of statin medication 
adherence. This study sought to test the effect of optimism on the behavior of statin medication 
adherence. Specifically, this study aimed to better understand the mechanisms via which 
optimism may impact the behavior by focusing on patients’ behavioral intentions, motivational 
intensity, self-efficacy, and outcome expectations as potential influencing factors. Our main 
finding was that optimism is a predictor of statin medication adherence and it affects it via a 
conditional indirect effect.   
Our findings provide insights into potential mechanisms of how optimism affects the 
behavior of medication adherence for patients who are at risk for cardiovascular disease. 
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Specifically, our study identified that optimism does not affect the behavior of statin medication 
adherence directly. Utilizing a conditional indirect analysis approach, optimism was identified to 
influence patients’ behavioral intentions and motivational intensity to engage in the behavior of 
taking statin medications as prescribed. This relationship was further influenced by patients’ self-
efficacy and outcome expectations. Low and moderate self-efficacy or outcome expectations 
interacted with patients’ behavioral intentions or motivational intensity to positively affect 
behavior.  
Optimism is associated with a variety of health benefits, including lower risk of stroke;
5
 
reduced all-cause mortality in old age;
2
 greater success in achieving lower levels of saturated fat, 
body fat, and global coronary risk, and with greater success in increasing aerobic capacity;
8
 with 
lower rate and risk of rehospitalization after coronary artery bypass graft (CABG) surgery;
6,7
 
with better physical health;
2
 with benefits in the socioeconomic world;
2
 with more persistence in 
educational efforts and with higher level of income;
2
 with faring better in relationships;
2
 with 
reduced risk of incidence of coronary heart disease;
35
 with positive mood, good morale, 
perseverance, problem solving, success, popularity, good health, long life;
1
 and with medication 
adherence.
9
 The mechanisms for these positive associations of optimism to outcomes are not yet 
fully understood.  
Kim et al., suggests as a potential mechanism that optimism may protect against stroke 
through different pathways, including health behaviors.
5
 This study demonstrated that optimism 
positively affects the behavior of statin medication adherence. The mechanism via which it does 
so is via one’s formed behavioral intentions or via one’s motivational intensity to engage in the 
behavioral goal. Carver et al. further suggests that optimism is associated with taking proactive 
steps to protect one’s health, hence behavioral patterns of optimists may provide models of living 
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for others to learn.
2
 Desirable characteristics linked to optimism are happiness, perseverance, 
achievement, and health.
1
 In addition to focusing on behavioral intentions and motivational 
intensity as approaches to improve behavioral goals, striving to emulate these characteristics may 
be one approach to cultivate optimism. 
Self-efficacy and outcome expectations are known predictors of behavioral intentions.
36 
Tested as potential moderators, low to moderate self-efficacy and outcome expectations 
interacted with behavioral intentions and motivational intensity to impact the relationship 
between patients’ optimism and the behavior of statin medication adherence. Another study 
indicated positive associations between optimism and confidence to take medications.
9 
Hence, it 
may be possible that strong self-efficacy and outcome expectations may serve as mediators of 
optimism and behavior rather than moderators. Future research is needed to investigate further 
the relationship between optimism and these factors.  
It is possible for optimism to be learned, although generally it is described as a trait-like 
characteristic.
2
 The questions that need to be answered are how much of it can be learned for 
what period of time? Cognitive behavioral therapies are one approach to reduce negative 
cognitive distortions and allow room for positive ones.
2
 Cancer cognitive-based intervention 
focused on cognitive and emotional-focused coping strategies and resulted in reduced stress.
37
 
As health care professionals, pharmacists can focus on fostering positive thoughts and affects to 
their patients in regards to their statin medication and cardiovascular health. This can be 
accomplished via questions of patients’ positive expectations as a result of taking their 
medication for their cardiovascular health, well-being, and quality of life in general. Additional 
research is needed to identify exact questions and framing strategies to use during an interaction 
or intervention in order to achieve positive results. By instilling optimism in patients, they may 
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be more likely to adhere to their medication and to take proactive actions to optimize health.
2 
The 
challenge for pharmacists is familiarizing professionals with the ways to instill optimism and 
identify appropriate strategies to nurture optimism in patients at appropriate times.  
This was the first study to our knowledge investigating the effect of optimism on the 
behavior of statin medication adherence with other psychosocial factors influencing this 
relationship. Patients’ behavioral intentions and motivational intensity mediate the effect of 
optimism on the behavior of adhering to statins and both intentions and motivation in turn 
interact with low and moderate self-efficacy and outcome expectations to affect behavior. These 
findings are important for both optimism and health behavior research in the following way. For 
optimism research, we are presenting potential mechanisms via which optimism affects behavior. 
For health behavior research, we are expanding the research on medication adherence by 
presenting novel ways in which psychosocial factors can be studied in the context of this 
behavior. For clinical research and practice, an important patient factor, optimism, is presented to 
potentially be used to design interventions and applied in practice to improve medication 
adherence. 
Our study was faced with some limitations. One limitation is the generalizability of the 
results. The findings of the study apply only to our sample population consisting of older mostly 
white adults that are in the higher income bracket and part of a university health system. These 
findings may be similar or different in other sample populations. Also there may be cultural 
differences in optimism results between North Americans, Asians, and Europeans.
2
 More 
research is needed to investigate the effects of optimism on the behavior of medication adherence 
among different cultural, ethnic, and race groups. Second, there are potential recall and social 
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desirability biases present, both being associated with answering questionnaires. These biases 
most likely contributed to increased reported statin medication adherence levels.  
Furthermore, the measure used for statin medication adherence was a single item. Including 
additional items would increase response burden. Therefore, although not included in this study, 
they could be pursued in future studies. Different statin medication adherence levels may impact 
the results. It is also likely that investigating these psychosocial factors in different sample 
populations, with different race and income distributions, may produce different results. 
Additionally, it may be likely that adherent patients are more likely to volunteer to participate in 
studies compared to nonadherent patients.  
Conclusion 
Optimism is a predictor of statin medication adherence. It influences statin medication 
adherence via a conditional indirect effect with various patient psychosocial factors influencing 
this relationship. Patients’ optimism together with behavioral intentions, motivational intensity, 
self-efficacy, and outcome expectations are important factors to consider when examining the 
behavior of statin medication adherence.  
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Figure 4-1. Theoretical and Analytical Framework for Optimism Predicting Statin 
Medication Adherence 
a The Conditional Indirect Effect of Optimism Regulatory Focus on Statin Medication 











b The Conditional Indirect Effect of Optimism Regulatory Focus on Statin Medication 














































Table 4-1. Respondent Demographic and Clinical Characteristics 
Characteristic  Percentage  
Age 
   ≥60years 
 
69.3 
Gender (Female) 40.2 
Race  
     White-American 





 ≤19,999/year 8.3 
      $20,000 - $39,000 12.6 
 $40,000 - $59,999 17.8 
 $60,000 - $79,999 15.3 
      $80,000 - $99,000 16.0 
 ≥$100,000/year 25.5 
Had heart disease 25.2 
Had a heart surgery 11.3 
Diagnosed with high cholesterol 93.6 
Insurance coverage for cholesterol medication 91.7 
Taking a depression medication 22.1 
Overall Health 
   Excellent 
   Very good 
   Good 
   Fair 

















Table 4-2. Model 1a Conditional Indirect Effect of Optimism on Statin Medication 
Adherence with Behavioral Intentions as the Mediator 
Mediator (M) Behavioral intentions 
Mediator Variable Model R
2
=.01, p=.04 
M=β10+β11X+ε1 b b 
X: Optimism β11 .01 .04* 
Outcome variable (Y) Statin Medication Adherence (SMA) 
Moderator (V) Self-efficacy Outcome expectancies 





Y=β20+β21X+β22M+β23V+β24M(V)+ε2 b p b p 
X: independent variable β21 .13 .43 .21 .22 
M: mediator β22 6.19 .00* 10.98 .00* 
V: moderator β23 1.86 .01* 1.11 .13 
M*V: interaction β24 -10.88 .00* -3.57 .01* 




















Table 4-3. Model 1b Conditional Indirect Effect of Optimism on Statin Medication 
Adherence with Motivational Intensity as the Mediator 
Mediator (M) Motivational intensity 
Mediator Variable Model R
2
=.05, p=.00* 
M=β10+β11X+ε1 b p 
X: Optimism β11 .04 .00* 
Outcome variable (Y) Statin Medication Adherence (SMA) 
Moderator (V) Self-efficacy Outcome expectancies 





Y=β20+β21X+β22M+β23V+β24M(V)+ε2 b p b p 
X: independent variable β21 .15 .41 .19 .29 
M: mediator β22 5.25 .00* 5.92 .00* 
V: moderator β23 .38 .65 -.36 .68 
M*V: interaction β24 -2.77 .00* -1.79 .048* 




















Table 4-4. Conditional Indirect Effects: Optimism and Statin Medication Adherence 









































SMA - statin medication adherence, M – mediator, V – moderator, SD - standard error,  























Table 4-5. Optimism Study Hypotheses and Results 
 Hypothesis Finding 
H1 The greater the optimism the greater the intentions to engage 
in the behavior. 
H1 is supported. 
(β11 =.01, p=.04*) 
H2a Behavioral intentions will influence the behavior of statin 
medication adherence the greater the self-efficacy. 
H2a is not supported.  
(β24 =-10.88, p=.00*)  
H2b Behavioral intentions will influence the behavior of statin 
medication adherence the greater the outcome expectancies. 
H2b is not supported.  
(β24 =-3.57, p=.01*)  
H3a Optimism affects statin medication adherence directly. H3 is not supported. 
(β21 =.13, p=.43) SE 
(β21 =.21, p=.22) OE 
H4 The greater the optimism the greater the motivation to engage 
in the behavior. 
H4 is supported.  
(β11 =.04, p=.00*) 
H5a Motivational intensity will influence the behavior of statin 
medication adherence the greater the self-efficacy. 
H5a is not supported.  
(β24 =-2.77, p=.00*)  
H5b Motivational intensity will influence the behavior of statin 
medication adherence the greater the outcome expectancies. 
H5b is not supported. 
(β24 =-1.79, p=.048*) 
H6 Optimism affects statin medication adherence directly. H6 is not supported. 
(β24 =.15, p=.41) SE 













 - DISCUSSION Chapter 5
This is the first randomized field study focused on investigating unique patient 
psychosocial factors and the effects of a fit intervention on the behavior of statin medication 
adherence.  We created and delivered a fit intervention to better understand its effects on statin 
medication adherence; the results of which will help with future communication intervention 
design. Additionally, our study investigated how unique patient and medication-related factors 
affect the behavior; specifically patients’ regulatory focus and optimism are first in research 
history to be investigated in the context of statin medication adherence. Next, a summary of 
findings for each aim is provided followed by the study’s limitations, potential future directions, 
and conclusions. 
Summary of Study Aims 
Aim1 
Using the theory of regulatory focus, social learning theory, and the theory of planned 
behavior, two questionnaires were created to investigate the effect of patients’ regulatory focus 
on the behavior of statin medication adherence with behavioral intentions, motivational intensity, 
and other medication-related factors serving as mediators and moderators. To test the effect of 
regulatory focus, patients’ orientation was manipulated via messages framed as either promotion 
or prevention. This technique enabled us to prime patients’ orientation into promotion or 
prevention regulatory focus orientation and test the effect of one orientation versus another on 
the behavior of statin medication adherence. The approach of manipulating regulatory focus has 
been successfully applied to a variety of studies and behaviors.
1-9
 Tam et al., is an example of a 
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study where both manipulated and chronic regulatory orientation were examined in behavior 
change.
8
 Findings indicate both approaches to be effective. However, manipulating regulatory 
focus via priming is the preferred method, as measuring chronic regulatory focus may not be 
feasible in a practice setting.  
Our findings indicate that regulatory focus predicted the behavior of statin medication 
adherence. Specifically, prevention orientation positively impacted the behavior when compared 
to promotion.  Future studies need to identify the effect of prevention and promotion regulatory 
focus compared to control. We believe that the reasons for this finding may be related to the 
nature of the behavior of taking medications. For example, our behavior of taking statin 
medications as indicated by a health care provider is one which patients engage in to either 
prevent a cardiovascular event from occurring based on a lab value, usually a high LDL-
cholesterol value, or to prevent another heart event from occurring. Both goals encompass the 
idea of preventing an unwanted event to happen in the future. This prevention orientation is part 
of prevention regulatory focus described by Higgins via the regulatory focus theory. The 
regulatory focus theory distinguishes self-regulation with a promotion from prevention focus.
1
 A 
person’s prevention focus is governed by security needs, strong oughts, and specific situations of 
nonloss-loss and is sensitive to absence of presence of negative outcomes.
1
 When a person is 
prescribed a statin medication, it may automatically imply prevention of an unwanted future 
event. Taking the statin medication may represent to many patients the hope of meeting that 
security need, may represent meeting a responsibility given by their health care provider, and 
may represent the fear of loss of their cardiovascular health as a result of failing to take the statin 
medication.  The promotion focus, conversely, is governed by nurturance needs, strong ideals, 





 When a patient is told that he/she is at high risk of cardiovascular disease, or is 
diagnosed with a heart condition, or has experienced a heart procedure - all may trigger a 
prevention orientation versus promotion.  More studies are needed to determine how each 
promotion or prevention orientation operates when compared to control. Additionally, further 
studies are needed to determine whether these results are similar or different for different 
population samples.  
Furthermore, we found that several patient psychosocial and medication-related factors 
impact the relationship between prevention regulatory focus and statin medication adherence. 
Specifically, patients’ motivational intensity and behavioral intentions partially and separately 
mediate this relationship; each patient factor, in turn, is affected by different medication-related 
factors. As a theory attempting to answer how people are motivated to achieve a goal, 
motivational intensity is a key variable assessed in regulatory focus studies.
4
 Patients’ 
motivational intensity was found to mediate the relationship between regulatory focus and statin 
medication adherence. Furthermore, motivational intensity was influenced by patients self-
efficacy and number of non-prescription medications. Specifically, the greater patients’ self-
efficacy and the lower the number of non-prescription medications, the greater the motivational 
intensity. The higher patients’ confidence in their ability to take their statin medication as 
prescribed, the greater their motivation to engage in the behavior. Similarly, the lower the 
number of non-prescription medications a patient was taking, the greater their motivation to 
engage in the behavior. This may be due to patients’ confidence in the effectiveness of their 
prescribed medication for their specific diagnoses or condition compared to the non-prescribed 
over the counter medications. This confidence may be linked to our patient’s high adherence 
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levels of adherence and long duration of statin therapy, indicating low likelihood of adverse side-
effects, such as myopathy.  
Patients’ intentions too partially mediated the relationship between regulatory focus and 
statin medication adherence. Intentions were influenced by different medication-related factors 
than motivational intensity. Specifically, presence of insurance coverage for statins and duration 
of statin therapy positively influenced intentions to engage in the behavior of statin medication 
adherence. Presence of statin drug insurance and longer time on statin resulted in greater 
intentions. Lower costs for statins and familiarity with drug therapy positively affected patients’ 
intentions to engage in the behavior. Therefore, ensuring affordable costs for statins for all 
patients and encouraging patients to remain on therapy are essential to improving patients’ 
intention to engage in the behavior and ultimately to improve statin medication adherence. 
Intentions, derived from the Theory of Reasoned Actions and the Theory of Planned 
Behavior, control people’s actions via attempts to engage in a behavior and motivational 
intensity measures the degree of motivation one has to make a goal happen.
4,10
  Both factors 
partially interacted with prevention regulatory focus in predicting the behavior of statin 
medication adherence. The mechanisms via which they do so are different. We identified that 
intentions and motivation are driven by different patient and medication-related factors. Peoples’ 
attempts to engage in the behavior of statin medication adherence are determined by drug 
therapy cost and familiarity. Peoples’ motivation to engage in the behavior is determined by their 
confidence and belief in the effectiveness of their medication. 
Similarly to this study, prevention orientation had a positive effect on the behavior of 
taking omega-3 health supplements. The omega-3 study indicated that prevention compared to 
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promotion positively influenced the behavior of supplementing with omega-3 supplements or 
omega-3 enriched products.
11
 The difference between the omega-3 study and this medication 
adherence study is that outcome expectations were framed as promotion or prevention in the 
omega-3 study, while in our study the regulatory focus messages were framed as promotion or 
prevention and outcome expectations were measured via two questions. Findings of the omega-3 
study indicated that the prevention outcome expectations only (not promotion) and intentions 




These are important findings because this is the first study to our knowledge in which the 
regulatory focus theory was applied to the behavior of medication adherence. The theory of 
regulatory focus goes beyond the hedonic principle of people approaching pleasure and avoiding 
pain and explains the two distinct self-regulatory modes of promotion and prevention to achieve 
a goal.
1
 Identifying that one mode of self-regulation, prevention, predicts the behavior of statin 
medication adherence, when compared to promotion, is an important finding in the medication 
adherence research. A better understanding how patients’ self-regulate during the decision-
making process to engage in the behavior of taking medications as prescribed will help health 
care providers, such as physicians and pharmacists to better address patients’ needs. 
Furthermore, patient and statin-medication specific factors found to partially impact patients’ 
self-regulation to adherence. The conditional indirect approach used in this study is a novel 
approach in the medication adherence research thus far. This approach may be applied to 
studying adherence to other medications. As a result, we will better understand whether these 
mediation and moderator factors affect statin medication adherence specifically or adherence to 
other medications as well.  
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Knowing that prevention regulatory focus, when compared to promotion, positively 
predicts statin adherence has implications in practice as well. One implication is that health care 
providers could focus on communicating with patients at risk or diagnosed with cardiovascular 
disease with a prevention frame when encouraging adherence to statin therapy. An example of a 
prevention framed message a pharmacists may be one emphasizing the importance of taking 
statin medications to avoid an unwanted cardiovascular event. A promotion framed message 
emphasizing the importance of taking the statin medication to approach the goal of being healthy 
and live a long life enjoying more time with grandchildren may be less beneficial in this case. 
Ensuring that patients have insurance coverage for their statin medications, finding ways to 
encourage patients to take their statin medication over a long period of time, and assess patients’ 
confidence levels in their ability to take their statin medication as indicated, and inquiring about 
any other non-prescription medication patients’ may be taking at the time of therapy – are action 
steps health care professionals may take to increase patients’ intentions and motivation to adhere.  
Overall, this study was successful at investigating the effect of regulatory focus theory 
via a conditional indirect effect testing various patient and medication-related factors as potential 
mediators and moderators on the behavior of statin medication adherence. This study answered 
the question of how patients who are on statin therapy self-regulate when deciding to take their 
statin medication as prescribed. The next step was to examine patients’ self-regulation and 
strategies used to achieve the goal of statin medication adherence. 
Aim2 
This study sought to examine how various strategies used in the decision making process 
to engage in the behavioral goal of adhering to statin medications interacted with patients’ 
regulatory focus. These strategies are referred to as strategic means. When there is a strategic 
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compatibility between the means and orientation, a fit is experienced. The effect of a fit 
intervention was tested on the behavior of statin medication adherence. 
The fit intervention consisted of experimentally priming patients’ regulatory focus with 
framed promotion or prevention messages and by priming patients with framed (promotion or 
prevention) and non-framed implementation intentions. A fit was defined as a match between 
patients’ orientation (promotion/prevention) and implementation intentions 
(promotion/prevention), such as promotion-promotion or prevention-prevention. The suitability 
of strategic means to patients’ regulatory orientation generates ‘value from fit’ which explains 
how a goal pursuit is carried out.
4
 Consistent with previous studies,
 1,5-9
 regulatory fit resulted in 
greater statin medication adherence levels compared to non-fit and to control. These results are 
promising as we now have a better understanding of best strategies to use for patients with 
different orientations to achieve better statin medication adherence. 
Of equal importance, findings of this study indicated that various patient psycho-social 
factors affected statin medication adherence differently between the fit, non-fit, and control 
groups. Specifically, at weak patient psychosocial factors (intentions, motivation, outcome 
expectations) statin medication adherence levels were significantly different between the fit and 
non-fit and between the fit and control groups. However, at strong levels of the same patient 
psychosocial factors (intentions, motivation, outcome expectations) statin medication adherence 
levels were not significantly different between the fit, non-fit, and control groups. These findings 
suggest that when patients’ motivation, intentions, and outcome expectations are weak, there is 
an opportunity to improve statin medication levels with a Fit intervention. However, when 
patients’ motivation, intentions, self-efficacy, and outcome expectations are strong, statin 
medication adherence levels are similar among all groups.  
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Our findings were similar to a fit intervention study examining the behavior of healthy 
snacking; the behavior was affected differently at weak versus strong unhealthy snacking habits. 
For the weak unhealthy snacking habits, regardless of the kind of implementation intentions 
formed, the healthy snacking behavior was higher compared to when no implementation 
intentions were formed while for strong unhealthy snacking habits, the behavior was broken and 
people snacked more healthfully only when there was a fit between implementation intentions 
and regulatory focus.
8
 Similarly, this study found that statin medication adherence was affected 
differently at weak versus strong factors. At weak behavioral intentions, motivational intensity, 
and outcome expectancies, statin medication adherence was greater when there was a fit between 
regulatory focus and implementation intentions formed compared to when there was a non-fit or 
when no implementation intentions were formed.  
Being the first regulatory fit intervention applied to the behavior of medication 
adherence, research on better understanding the processes through which people decide to adhere 
or not adhere to their medications will inform health care professionals how to best help people 
adhere to their medications and improve their health. Extending similar interventions in other 
medications and conditions will help to better understand whether our findings are statin specific 
or whether they can be applied to other conditions. Additionally, future studies testing the effect 
of patients’ prospective feelings about a choice they make of taking or not taking their 
medication when regulatory fit is higher and examining whether patients’ retrospective 
evaluations of past decisions or goal pursuits are more positive when regulatory fit is higher will 
add to the understanding of the ‘value from fit’ concept in the context of medication adherence.  
This study presented an effective regulatory fit intervention demonstrating improved 
statin adherence levels at weak psychosocial factors as behavioral intentions, motivational 
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intensity, and outcome expectations. Similar future interventions could be applied in population 
samples of patients who may display weak behavioral intentions, motivational intensity, 
expectations of outcomes, and are in need to improve medication adherence levels. The fit 
intervention presents an opportunity for future tailored communication that is patient specific to 
their regulatory focus. In this case, considering the behavior of statin medication adherence, 
health care professionals may tailor communication via framing strategic means that match 
patients’ primed orientation. Tailored communication strategies between the health care 
professional and the patient could be implemented face-to-face during a patient consultation or 
during motivational interviewing. The patient counseling may be extended beyond to just 
purposes of taking the medication to patients’ goals as a result of taking the medication. One of 
the four general principles of motivational interviewing is developing discrepancy between 
present behavior and goals or values that are important to the person.
12
 Identifying patients’ 
goals that are important to them is an essential step.  
Here, pharmacists have an opportunity to identify the goal and tailor communication that 
is aligned with patients’ goals. For example, in the contexts of cardiovascular health and 
medication adherence, the pharmacist would ask the patient what his/her goals are in regards to 
their cardiovascular health and why the mentioned goals are important to them. Then, based on 
the patients’ answers, if, for example the answer is ‘my goal is to avoid a stroke or heart attack’, 
the pharmacist would tailor their communication with that of the patient’s, with the choice of 
words ‘avoid stroke or heart attack as a result of taking your medication’. On the other hand, if 
the patient would mention that his/her goal is ‘to stay healthy and be able to live long and enjoy 
more time with grandchildren’, then the pharmacist would tailor communication with that of the 
patient’s with the choice of words ‘live long and enjoy more time with grandchildren as a result 
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of taking your medication’.  As a result of this tailored communication a fit will be created. 
Therefore, a feeling of rightness will be created in patients, their motivation to take the 
medication will be increased, and it is likely that patients will even feel better and more alert 
about their decision to take their medication as their health care provider has indicated to do. In 
other words this tailored communication strategy will create a ‘value from fit’ effect’
2
 in 
patients’ decision process.  
Motivation is what provides the drive for patients’ focus, effort, energy needed to move 
through processes of change described in the transtheoretical model of intentional human 
behavior change (TTM).
12
 The Fit strategy is likely to increase patients focus, effort, energy at 
all points of behavior change. This is likely to happen by carefully tailoring each stage back to 
patients’ goal mentioned in the developing discrepancy step. 
Assessing patients’ intentions, motivation, self-efficacy, and outcome expectations in 
regards to behavior is important, as we have identified different adherence levels at weak versus 
strong patient psychosocial factors. The last step of motivational interviewing is assessing and 
supporting patients’ self-efficacy. In addition to self-efficacy, pharmacist could assess patients’ 
motivation, and their outcome expectations they have in regards to taking their medication. 
Miller states that when motivational interviewing is done well, then it is the client that gives a 
voice to his/her concerns, reasons for change, self-efficacy, and intentions to change.
12
 In this 
case, the client is the patient and the pharmacist’s role is to tap into patient’s intrinsic 
motivational factors and help the patient move towards positive behavior change. This study 
provides an innovative strategy to tailor communication between the pharmacist and patient that 
can be implemented in the motivational interviewing setting and potentially in other counseling 
environments.   
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In addition to the face-to-face interaction, this study provides the opportunity to tailor 
medication messages via mobile technologies. Future studies will investigate the possibility of 
delivering tailored messages via a fit intervention design. This fit intervention, delivered face-to-
face or via mobile technologies, will help patients improve their medication taking behavior, and 
ultimately improve their health. 
Aim3 
To better understand what other factors may influence the behavior of statin medication 
adherence, this study focused on examining the effect of optimism on the behavior. This effect 
was tested via the conditional indirect approach with motivational intensity or behavioral 
intentions as the mediator and with self-efficacy or outcome expectations as the moderator. This 
is the first study to our knowledge investigating optimism in the context of the behavior of statin 
medication adherence.  
Optimism can be a trait (captures optimism levels generally experienced for each 
individual) or described as a state (captures optimism based on situation or contextual factors).
13
 
Optimism is known to be positively linked to a variety of health benefits;
14-21
 however, the 
mechanisms via which it does so are not yet fully understood. The findings of this study provide 
insights into potential mechanisms via which optimism affects the behavior of statin medication 
adherence.  
Optimism acted as a significant predictor of the behavior of statin medication adherence. 
It affected the behavior via a conditional indirect effect, but not directly. Specifically, patients’ 
behavioral intention or motivational intensity levels to engage in the behavior were positively 
affected by optimism levels, but only when levels of self-efficacy and outcome expectations 
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were low or moderate. From previous research it is known that self-efficacy and outcome 
expectations are predictors of behavioral intentions.
22
 Additionally, one specific study found 
positive associations between optimism and confidence to take medications.
23
 Tested as potential 
moderators, self-efficacy and outcome expectations impacted the relationship between patients’ 
optimism and the behavior of statin medication adherence differently. It may be possible that 
strong self-efficacy and/or strong outcome expectations may act as mediators of patients’ 
positive expectations of the future and behavior. Future research efforts are needed to investigate 
additional mechanisms between these psychosocial factors. 
This study has important implications for both, research and practice. In the realm of 
research opportunities, this is a cornerstone step in investigating the effect and mechanisms of a 
trait/state characteristic in the behavior of statin medication adherence. Future research is needed 
to test how optimism may affect adherence in a variety of medications and conditions. This will 
allow us to further understand the mechanisms via which optimism does affect adherence. By 
doing so, we will be better equipped to design interventions delivered in practice to positively 
influence behavior. 
In the context of cardiovascular health and pharmacy practice, pharmacists have the 
opportunity to foster positive thoughts in patients related to statin medication and cardiovascular 
health. The cognitive behavioral therapy approach focuses on reducing negative cognitive 
distortions, hence making room for positive ones.
15
 Identifying such distortions during 
pharmacist-patient communication and replacing with positive one, may be a good starting point 
in instilling optimism in patients. Research to answer the questions of the feasibility and power 




Our study may present some generalizability challenges as it consisted of a certain 
demographic sample population. Due to the randomized nature of our design, we can generalize 
our findings to similar populations engaging in a similar behavior. Our sample population 
consisted of volunteers; hence it is likely that our participants were already interested in 
improving their medication adherence behavior. Our findings indicate statin medication 
adherence levels were higher than the average levels indicated in previous studies; this could be 
due to the self-report nature of the study, thus presenting the possibility of social desirability and 
recall biases. Or it may be that we truly captured the actual adherence levels representative for 
this population sample. 
Future Directions 
This is the first cutting-edge research investigation to analyze the psychosocial driving 
forces behind the behavior of statin medication adherence. Findings provide insights into 
potential mechanisms, but there is much more to be understood in the realm of the behavior of 
adhering to medications. Considering the importance of patient-centered care and that much of 
human behavior is driven by internal factors, heightened understanding of the role of 
psychosocial factors in adherence will play a vital role in intervention design to improve 
behavioral health outcomes.  
Future research investigating the effect of psychosocial factors in patients from diverse 
backgrounds is warranted. Specifically, research is needed to determine how psychosocial 
factors affect behavior similarly or differently in patients from different cultural, ethnic, racial, 
economic, generational backgrounds. Moreover, understanding the effect of these factors across 
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medications and conditions is important, as the mechanisms may differ depending on type and 
disease severity. 
Driving motivational forces and mechanisms for statin medication adherence identified 
that prevention orientation positively affected the behavior when compared to promotion.  Future 
studies are needed to better understand whether prevention regulatory focus orientation 
positively affects adherence levels similarly or differently in other medications and/or conditions. 
It is also important to understand whether prevention or promotion orientation would positively 
affect the behavior of medication adherence when compared to control. Future regulatory focus 
studies are needed in the domain of medication adherence research. A better understanding of 
patients’ motivational orientation will better equip us to tailor communication more effectively 
between the patient and health care provider.  
Additionally, designing and delivering ‘Fit’ tailored messages for patients during face-to-
face patient-provider interactions or via mobile technologies will aid in improving patients’ 
medication adherence and health outcomes. Moving forward testing Fit interventions across 
populations and conditions is imperative. And finally, a better understanding of how optimism 
affects medication adherence and finding ways to improve patients’ optimism levels will serve as 
an innovative way to improve medication adherence.   
Conclusions 
In sum, this study found that patients’ prevention regulatory focus predicted statin 
medication adherence directly and indirectly via several patient psychosocial and medication-
related factors. Directly, it predicted statin medication adherence with prevention focus 
positively affecting the behavior compared to promotion focus. Indirectly, it predicted statin 
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medication adherence with intentions or motivation serving as mediators and different factors 
serving as moderators (insurance and time on statin for intentions; self-efficacy and number of 
non-prescription medications for motivational intensity). Furthermore, the intervention of 
matching patients’ regulatory orientation with implementation intentions as strategic means was 
found to be an effective intervention that resulted in greatest statin medication adherence levels 
for the fit condition. At weak behavioral intentions, motivational intensity, and outcome 
expectations the greatest the differences between the fit versus non-fit and between fit versus 
control groups; hence, the greatest potential for a fit intervention. Lastly, the behavior of statin 
medication adherence was influenced by patients’ optimism levels via a full conditional indirect 
effect with behavioral intentions or motivational intensity serving as the mediator and 
low/moderate self-efficacy or outcome expectations serving as the moderator. Optimism is an 
important patient psychosocial factor found to positively impact the behavior of statin 
medication adherence when self-efficacy and outcome expectations were low/moderate.  
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A. Questionnaire One  
The next few questions will determine if you are eligible for our study: 
1. Has your doctor ever told you that you have heart disease?  
 yes   no   do not know  
2. Have you had heart surgery?   
 yes   no   do not know  
3. Has your doctor ever told you that you have high cholesterol?  
 yes   no   do not know  
4. Are you currently taking a statin medication to lower your cholesterol?  
 yes   no   
5. Are you currently taking a medication for depression? 
 yes   no   
 For patients who answer Yes to question # 4 and No to question # 5, the following 
message will appear: “Thank you very much! You are eligible for the study. Please 
proceed to the next page.” 
 For patients who answer No to question # 4 and Yes to question #5, the following 
message will appear: “Thank you for your interest to in our study. Unfortunately, you 




























We are doing a research study about cardiovascular health. The purpose of this study is to test 
how people make decisions about their cholesterol medications. Please follow the instructions in 
each section of this survey till your complete it. It will take you approximately 15 to 20 minutes to 
take the entire survey. 
Participating in this study is completely voluntary. There are no foreseeable risks associated with 
your participation. However, if you feel uncomfortable or stressed answering any question you 
may skip it or you can discontinue participation from this study at any point. Your responses and 
all data from this research are completely confidential. The benefit of your participation in this 
study is helping research advance in the area of cholesterol medication adherence and 
cardiovascular health. There are no foreseeable risks associated with this study. 
If you have any questions or comments, please feel free to contact any member of our research 
team.  












If you have questions about your rights as a research participant, or wish to obtain information, 
ask questions or discuss any concerns about this study with someone other than the researcher(s), 
please contact the University of Michigan Medical School Institutional Review Board (IRBMED), 
2800 Plymouth Road, Building 520, Room 3214, Ann Arbor, MI 48109-2800, (734) 763-4768 [or 
(866) 990-0111]. irbmed@umich.edu. 
Ala Iaconi 
PhD student 
University of Michigan 
Email: iaconi@umich.edu 
phone: (734)936-1505 
Drs. Karen Farris & Richard Bagozzi  
Professors 






In the next set of questions we would like to ask you about your medications and health.     
1. How many different prescription medications do you take daily? _______________ 
2. How long have you been on your cholesterol lowering medication? _______________ 
3. Is your cholesterol medication covered by your insurance?  
 yes   no   do not know 
4. How many different over the counter products (those purchased without a prescription)? do 
you take daily_______________ 
5. Overall in the past month, how would you rate your health? 
 Excellent 
 Very good 
 Good 
 Poor 




The next set of questions asks about your cholesterol medication.  
Most people have many medications to take at different times during the day and many find it 
hard to remember to take them. We need to understand what people are really doing with their 
medications. It is okay to tell us exactly how you take your cholesterol medication. Please tell us 
what you are actually doing in your personal situation.  
1. Please put an "X" on the line below, between 0% and 100%, at the point showing your 
best guess about how much of your cholesterol medication you have taken in the last two 
weeks.  
0% means you have taken none of the drug 
50% means you have taken the drug half of the time 





2. Over the last 14 days, how many days were you able to take your cholesterol medication 
exactly as prescribed? 
0 days 1day 2days 3days 4days 5days 6days 7days 8days 9days 10days 11days 12days 13days 14days 
 
3. Now, specifically, in the last 7 days, how many days were you able to take your 
cholesterol medication exactly as prescribed? 
0 days 1day 2days 3days 4days 5days 6days 7days 
 
 For the Regulatory Focus Manipulation participants are randomly assigned to 2 
groups: promotion and prevention. The promotion group receives a promotion 
message, while the prevention group receives a prevention message.   
Promotion: 
For the next few questions please think about your past hopes, aspirations, and dreams and list 3 
of them. Next to each hope, aspiration, or dream, tell us how strong this hope/aspiration/dream is 
for you personally: 










1.Past hope/aspiration 1 2 3 4 5 
2.Past hope/aspiration 1 2 3 4 5 





Now, please think about your current hopes, aspirations, and dreams and list 3 of them. Next to 
each hope, aspiration, or dream, tell us how strong this hope/aspiration/dream is for you 
personally: 












1 2 3 4 5 
2.Current 
hope/aspiration 
1 2 3 4 5 
3.Current 
hope/aspiration 
1 2 3 4 5 
 
Prevention: 
For the next few questions please think about your past duties, obligations, and responsibilities 
and list 3 of them. Next to each duty, obligation, or responsibility, tell us how strong this 
duty/obligation/responsibility is for you personally: 










1.Past duty/obligation 1 2 3 4 5 
2.Past duty/obligation 1 2 3 4 5 





For the next few questions please think about your current duties, obligations, and 
responsibilities and list 3 of them. Next to each duty, obligation, or responsibility, tell us how 
strong this duty/obligation/responsibility is for you personally: 












1 2 3 4 5 
2.Current  
duty/obligation 
1 2 3 4 5 
3.Current 
duty/obligation 













For the next 9 questions, please indicate the extent to which each statement describes you 








  Promotion Focus Does not 
describe 









1. I am typically able to get what I want out of life. 1    2     3  4   5  6 7 
2. I often accomplish things that get me excited or 
motivated to work even harder. 
1    2     3  4   5  6 7 
3. I often do well at different things that I try. 1    2     3  4   5  6 7 
4. When it comes to achieving things that are important to 
me, I find that I don’t perform as well as I would like to 
do. 
1    2     3  4   5  6 7 
5. I feel like I have made progress towards being 
successful in my life. 
1    2     3  4   5  6 7 
6. My job or studies capture my interests and motivate me 
to put considerably effort into them. 
1    2     3  4   5  6 7 
7. I feel that I am succeeding well in terms of goals that I 
have set. 
1    2     3  4   5  6 7 
8. I see myself as someone who is primarily striving to 
reach my “ideal self” to fulfill my hopes, wishes, and 
aspirations. 
1    2     3  4   5  6 7 
9. I frequently imagine how I will achieve my hopes and 
aspirations. 




The next set of questions asks you about your plans to take your cholesterol medication. Please 
indicate how much you agree or disagree with the following questions: 
1. I intend to take my cholesterol medication as prescribed during the next 2 weeks: 





agree strongly agree 
 
2. How likely or unlikely is it that you intend to take your cholesterol medication as 
prescribed during the next 2 weeks: 
1 2 3 4 5 
Very unlikely Likely  neither 
unlikely/likely 
Likely Very likely 
 
  Prevention Focus Does 
not 
describe 









1. I seldom break my obligations. 1   2     3   4   5     6 7 
2. Obeying rules is important to me. 1   2     3   4   5     6 7 
3. I generally fulfill my duties. 1   2     3   4   5     6 7 
4. I find myself doing things that are forbidden or  
  frowned upon. 
1   2     3   4   5     6 7 
5. I usually honor rules and regulations.      1   2     3   4   5     6 7 
6. Being a responsible person is a value I hold. 1   2     3   4   5     6 7 
7. I seldom do things that others disapprove of me doing. 1   2     3   4   5     6 7 
8. I see myself as someone who is primarily striving to 
become the self I “ought” to be  to fulfill my duties, 
responsibilities and obligations. 
1   2     3   4   5     6 7 
9. I frequently think about how I can prevent failures in  
  my life. 
1   2     3 4   5     6 7 
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 For the implementation intention manipulation, among our three groups (promotion, 
prevention, control), only the promotion and prevention groups will receive the 
Implementation Intention Questions. In the promotion group, ½ of the participants 
will receive promotion worded implementation intentions and the other ½ will receive 
prevention worded implementation intentions. Similarly, in the prevention group, ½ 
of the participants will receive promotion worded implementation intentions and the 
other ½ will receive prevention worded implementation intentions. 
Question 1 
According to medication experts, the most effective way to improve taking your cholesterol 
medication is to focus on the benefits of taking your cholesterol medication (drawbacks of not 
taking your cholesterol medication) for you personally and to commit yourself to taking your 
cholesterol medication as directed. Please list at least 3 things you could do that will help you to 






Now, imagine as vividly as possible, when you will take (avoid not taking) your cholesterol 
medication, where you will take (avoid not taking) it, and other details of the situation you 
anticipate to take (avoid not taking) your cholesterol medication. Next we ask you to let us know 
approximately when, where, with whom, and in what situations you will take (avoid not taking) 
your cholesterol medication. 
When? _______________________________________________________________ 
Where? _____________________________________________________________  
With whom? __________________________________________________________ 




The next 10 questions tell us about you.  
Please be as honest and accurate as you can throughout. Try not to let your response to one 
statement influence your responses to other statements.  
There are no ‘correct’ or ‘incorrect’ answers. Answer according to your own feelings, rather than 
how you think ‘most people’ would answer.  
Using the scale below, write the appropriate number beside each statement. 
1 = strongly disagree, 2 = disagree, 3 = neutral, 4 = agree, 5 = strongly agree  
 
1) In uncertain times, I usually expect the best ___________ 
2) It’s easy for me to relax ________ 
3) If something can go wrong for me it will __________  
4) I’m always optimistic about my future _____________ 
5) I enjoy my friends a lot ___________ 
6) It’s important for me to keep busy ____________ 
7) I hardly ever expect things to go my way __________ 
8) I don’t get upset too easily __________ 
9) I rarely count on good things happening to me ____________  







The next set of questions asks you about your cholesterol medication. Please select one answer 
for each question. 
1. How confident are you that your cardiovascular health will improve as a result of taking 
your cholesterol medication as directed?  
a. Not at all confident 
b. Somewhat confident 
c. Moderately confident 
d. Very confident 
e. Extremely confident 
2. How certain are you that you will be able to avoid cardiovascular disease as a result of 
taking your cholesterol medication as directed?  
a. Not at all certain 
b. Somewhat certain 
c. Moderately certain 
d. Very certain 
e. Extremely certain 
3. How promising is it that your heart health will improve if you take your cholesterol 
medication as directed? 
a. Not at all promising   
b. Somewhat promising 
c. Moderately promising 
d. Very promising 
e. Extremely promising 
4. How likely is it that you will reduce your risk of heart disease if you take your cholesterol 
medication as directed? 
a. Not at all likely 
b. Somewhat likely 
c. Moderately likely 
d. Very likely 
e. Extremely likely 
5. How motivated are you to take your cholesterol medication as prescribed? 
a. Not at all motivated 
b. Somewhat motivated  
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c. Moderately motivated 
d. Very motivated 
e. Extremely motivated 
6. How determined are you to take your cholesterol medication as prescribed?  
a. Not at all determined   
b. Somewhat determined 
c. Moderately determined 
d. Very determined 
e. Extremely determined 
 
Please let us know your intention of taking your cholesterol medication as directed during the 
next 2 weeks.  
1. I intend to take my cholesterol medication as prescribed by my health care provider 
during the next 2 weeks: 
1 = strongly disagree  
2 = disagree  
3 = neither disagree/agree 
4 = agree  
5 = strongly agree  
 
In the next set of questions we would like to ask you a bit about yourself.    
1. What is your gender: 
 male   female 
2. What is your age: ________________ 
3. What is your race: 
 Caucasian-American  African-American  Asian-American  Hispanic-American  
prefer not to answer 
4. What is your income:  






 $80,000- $99,000 
 ≥$100,000/year 
 
Thank you for your participation in this survey!  
Please fill out your name and address so we will know where to send your gift card for 
participating in our survey.  
Please tell us your email address so that we can send you the second survey about two weeks 













B. Questionnaire Two 
 
 
This survey has 5 questions about your cholesterol medication.   
Most people have many medications to take at different times during the day and many find it 
hard to remember to take them. We need to understand what people are really doing with their 
medications. It is okay to tell us exactly how you take your cholesterol medication. Please tell us 
what you are actually doing in your personal situation. 
1. Put an "X" on the line below, between 0% and 100%, at the point showing your best 
guess about how much of your cholesterol medication you have taken in the last two 
weeks.  
0% means you have taken none of the drug 
50% means you have taken the drug half of the time 
100% means you have taken every single dose of the drug on each day it is to be taken 
 
 
2. Over the last 14 days, how many days were you able to take your cholesterol medication 
exactly as prescribed? 
0 days 1day 2days 3days 4days 5days 6days 7days 8days 9days 10days 11days 12days 13days 14days 
 
3. Now, specifically, in the last 7 days, how many days were you able to take your 
cholesterol medication exactly as prescribed? 
0 days 1day 2days 3days 4days 5days 6days 7days 
 
4. When you were not able to take your cholesterol medication as prescribed, how many 
days did it happen in the past 7 days for each of the following reasons? 
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0 days 1day 2days 3days 4days 5days 6days 7days 
I had side effects from my cholesterol medicine 
I did not have money to pay for my cholesterol medicine 
I was not comfortable taking it for personal reasons (for example: I was traveling…) 
I was not comfortable taking it for social reasons (for example: I was with friends….) 
I don’t think I need my cholesterol medicine anymore 
I don’t think that my cholesterol medicine is working for me 
I sometimes skip my cholesterol medicine to see if it is still needed 
I am concerned about possible side-effects from my cholesterol medicine 
I am concerned about long term effects from my cholesterol medicine 
I had difficulty opening the container 
I had difficulty swallowing my cholesterol medicine 
I didn’t have my cholesterol medicine because the pharmacy was out of this medicine 
I didn’t have my cholesterol medicine because I didn’t have a ride to the pharmacy 
I am not sure how to take my cholesterol medicine 
I have trouble managing all the medicines I have to take 
I would have taken it but simply missed it 
I would have taken it but missed it because of busy schedule 
I would have taken it but have problems forgetting things in my daily life 
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I do not consider taking my cholesterol medicine as a high priority in my daily life 
Please let us know your intention of taking your cholesterol medication as prescribed during the 
next 2 weeks.  
5. I intend to take my cholesterol medication as prescribed during the next 2 weeks: 
1 = strongly disagree  
2 = disagree  
3 = neither disagree/agree 
4 = agree  
5 = strongly agree  
 
Thank you for your participation in this survey! 












C. PROCESS Analysis Model  
The conditional process analysis model is used when the analytical goal is to describe and 
understand the conditional nature of the mechanisms by which a variable transmits its effect on 
another. Mediation analysis establishes to what extent a causal variable X influences an outcome 
Y through a mediation variable. Moderation analysis on the other hand, determines whether the 
sign or size of the effect of the causal variable X on outcome Y depends on a third moderation 
variable. The mediation and moderation analyses are combined into a moderated mediation 
analysis, termed as conditional process analysis.   
The mechanisms linking X to Y can be said to be conditional if the indirect effect of X on 
Y through M is contingent on a moderator. There are many ways this could happen. We 
considered two in this research.  
1. The indirect effect of X is conditional on W through moderation of M on Y. W 
moderates the indirect effect through its moderation effect of X on M. The equations are: 
                                                    M= i1+ a1X + a1W + a1XW + eM                                               (1) 
                                                              Y = i2+ b1M + eY                                                                                           (2) 
X exerts its effect on Y through both direct and indirect pathways. The direct effect links X to Y 
independent of M and the effect of X on Y through M, is the products of paths linking X to Y 
through M. The first of these components of the indirect effect is the path from X to M, where 
the effect of X on Y is a function of W, estimated by equation 1. The second component is the 
path from M to Y, estimated by equation 2.  
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2. The indirect effect of X is conditional on V through moderation of M on Y effect by V. 
The equations are: 
                                                          M= i1+ a1X + eM                                                                                                   (3) 
                                        Y = = i2+ c’1X + b1M+ b2V + b3Mv + eY                                                                     (4) 
X exerts its effect on Y through both direct and indirect pathways. The direct effect links X to Y 
independent of M and the effect of X on Y through M, is the products of paths linking X to Y 
through M. The first of these components of the indirect effect is the path from X to M, 
estimated by equation 3, and the second component is the path from M to Y, where the effect of 
M on Y is a function of V, estimated by equation 4.  
Reference 
Hayes, A.F. (2013). Introduction to mediation, moderation, and conditional process analysis: a 
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 Subject:Initial Study Approval for [HUM00078405] 
SUBMISSION INFORMATION: 
Study Title: The moderated mediation of regulatory focus and fit on statin adherence  
Full Study Title (if applicable): 
Study eResearch ID: HUM00078405  
Date of this Notification from IRB:11/22/2013  
Review:Expedited  
Initial IRB Approval Date: 11/22/2013 
Current IRB Approval Period:11/22/2013 - 11/21/2014  
Expiration Date: Approval for this expires at 11:59 p.m. on 11/21/2014 
UM Federalwide Assurance (FWA): FWA00004969 (For the current FWA expiration date, 
please visit the UM HRPP Webpage)  




Approved Risk Level(s): 
Name Risk Level 
HUM00078405 No more than minimal risk 
 
NOTICE OF IRB APPROVAL AND CONDITIONS: 
The IRBMED has reviewed and approved the study referenced above. The IRB determined that 
the proposed research conforms with applicable guidelines, State and federal regulations, and the 
University of Michigan's Federalwide Assurance (FWA) with the Department of Health and 
Human Services (HHS). You must conduct this study in accordance with the description and 
information provided in the approved application and associated documents. 
APPROVAL PERIOD AND EXPIRATION: 
The approval period for this study is listed above. Please note the expiration date. If the approval 
lapses, you may not conduct work on this study until appropriate approval has been re-
established, except as necessary to eliminate apparent immediate hazards to research subjects. 
Should the latter occur, you must notify the IRB Office as soon as possible. 
IMPORTANT REMINDERS AND ADDITIONAL INFORMATION FOR INVESTIGATORS 
APPROVED STUDY DOCUMENTS: 
You must use any date-stamped versions of recruitment materials and informed consent 
documents available in the eResearch workspace (referenced above). Date-stamped materials are 
available in the “Currently Approved Documents” section on the “Documents” tab. 
RENEWAL/TERMINATION: 
At least two months prior to the expiration date, you should submit a continuing review 
application either to renew or terminate the study. Failure to allow sufficient time for IRB review 
may result in a lapse of approval that may also affect any funding associated with the study. 
AMENDMENTS: 
All proposed changes to the study (e.g., personnel, procedures, or documents), must be approved 
in advance by the IRB through the amendment process, except as necessary to eliminate apparent 
immediate hazards to research subjects. Should the latter occur, you must notify the IRB Office 
as soon as possible. 
AEs/ORIOs: 
You must inform the IRB of all unanticipated events, adverse events (AEs), and other reportable 
information and occurrences (ORIOs). These include but are not limited to events and/or 
information that may have physical, psychological, social, legal, or economic impact on the 
research subjects or other. 
Investigators and research staff are responsible for reporting information concerning the 
approved research to the IRB in a timely fashion, understanding and adhering to the reporting 
guidance (http://www.med.umich.edu/irbmed/ae_orio/index.htm), and not implementing any 
changes to the research without IRB approval of the change via an amendment submission. 
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When changes are necessary to eliminate apparent immediate hazards to the subject, implement 
the change and report via an ORIO and/or amendment submission within 7 days after the action 
is taken. This includes all information with the potential to impact the risk or benefit assessments 
of the research. 
SUBMITTING VIA eRESEARCH: 
You can access the online forms for continuing review, amendments, and AEs/ORIOs in the 
eResearch workspace for this approved study (referenced above). 
MORE INFORMATION: 
You can find additional information about UM’s Human Research Protection Program (HRPP) 
in the Operations Manual and other documents available at: www.research.umich.edu/hrpp. 
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Subject:  Scheduled Continuing Review [ CR00059639 ] Approved for [ HUM00078405 ] 
SUBMISSION INFORMATION: 
Study Title: The moderated mediation of regulatory focus and fit on statin adherence  
Full Study Title (if applicable):  
Study eResearch ID: HUM00078405  
SCR eResearch ID: CR00059639  
SCR Title: HUM00078405_Continuing Review - Wed Jan 25 11:16:15 EST 2017  
Date of this Notification from IRB:2/1/2017  
Review: Expedited     
Date Approval for this SCR: 2/1/2017  
Current IRB Approval Period: 2/1/2017  - 1/31/2018  
Expiration Date: Approval for this expires at 11:59 p.m. on 1/31/2018  
UM Federalwide Assurance:FWA00004969 (For the current FWA expiration date, please visit 
the UM HRPP Webpage)   
OHRP IRB Registration Number(s): IRB00000244 
Approved Risk Level(s) as of this Continuing Report: 
Name Risk Level 
HUM00078405 No more than minimal risk 
 
NOTICE OF IRB APPROVAL AND CONDITIONS: 
The  IRBMED has reviewed and approved the scheduled continuing review (SCR) submitted for 
the study referenced above.  The IRB determined that the proposed research continues to 
conform with applicable guidelines, State and federal regulations, and the University of 
Michigan's Federalwide Assurance (FWA) with the Department of Health and Human Services 
(HHS). You must conduct this study in accordance with the description and information 
provided in the approved application and associated documents. 
APPROVAL PERIOD AND EXPIRATION DATE: 
The updated approval period for this study is listed above. Please note the expiration date. If the 
approval lapses, you may not conduct work on this study until appropriate approval has been re-
established, except as necessary to eliminate apparent immediate hazards to research subjects or 
others. Should the latter occur, you must notify the IRB Office as soon as possible. 
IMPORTANT REMINDERS AND ADDITIONAL INFORMATION FOR INVESTIGATORS 
207 
 
APPROVED STUDY DOCUMENTS: 
You must use any date-stamped versions of recruitment materials and informed consent 
documents available in the eResearch workspace (referenced above). Date-stamped materials are 
available in the “Currently Approved Documents” section on the “Documents” tab. 
In accordance with 45 CFR 46.111 and IRB practice, consent document(s) and process are 
considered as part of Continuing Review to ensure accuracy and completeness. The dates on the 
consent documents, if applicable, have been updated to reflect the date of Continuing Review 
approval. 
RENEWAL/TERMINATION: 
At least two months prior to the expiration date, you should submit a continuing review 
application either to renew or terminate the study. Failure to allow sufficient time for IRB review 
may result in a lapse of approval that may also affect any funding associated with the study. 
AMENDMENTS: 
All proposed changes to the study (e.g., personnel, procedures, or documents), must be approved 
in advance by the IRB through the amendment process, except as necessary to eliminate apparent 
immediate hazards to research subjects or others. Should the latter occur, you must notify the 
IRB Office as soon as possible. 
AEs/ORIOs: 
You must continue to inform the IRB of all unanticipated events, adverse events (AEs), and 
other reportable information and occurrences (ORIOs). These include but are not limited to 
events and/or information that may have physical, psychological, social, legal, or economic 
impact on the research subjects or others. 
Investigators and research staff are responsible for reporting information concerning the 
approved research to the IRB in a timely fashion, understanding and adhering to the reporting 
guidance ( http://medicine.umich.edu/medschool/research/office-research/institutional-review-
boards/guidance/adverse-events-aes-other-reportable-information-and-occurrences-orios-and-
other-required-reporting), and not implementing any changes to the research without IRB 
approval of the change via an amendment submission. When changes are necessary to eliminate 
apparent immediate hazards to the subject, implement the change and report via an ORIO and/or 
amendment submission within 7 days after the action is taken. This includes all information with 
the potential to impact the risk or benefit assessments of the research. 
SUBMITTING VIA eRESEARCH: 
You can access the online forms for continuing review, amendments, and AE/ORIO reporting in 
the eResearch workspace for this approved study, referenced above. 
MORE INFORMATION: 
You can find additional information about UM’s Human Research Protection Program (HRPP) 




























Table A-E. Differences between Respondents and Non-respondents 
Variables Respondents to both 
Questionnaires 
(N=326) 





SMA baseline 95.67 (14.21) 95.49 (14.06) p=.894 
Behavioral intentions 4.86 (.46) 4.82 (.52) p=.359 
Motivational intensity 4.30 (.80) 4.28 (.81) p=.770 
Self-efficacy 3.35 (.98) 3.34 (1.00) p=.992 
Outcome expectations 3.44 (.96) 3.50 (.95) p=.500 
Optimism 22.41 (4.04) 22.60 (3.87) p=.627 
RFocus 
   Promotion 










Number of Rx 4.73 (3.19) 5.44 (4.25) p=.060 
Number of Non-Rx 2.53 (2.20) 2.60 (2.33) p=.739 
Time on statin 9.45 (6.09) 9.60 (6.88) p=.809 
Statin Insurance 
   Yes 








Age 64.19 (10.14) 64.34 (10.44) p=.881 
Gender 
   Female 









   White 









   <19k/y 
   20-39k/y 
   40-59k/y 
   60-79k/y 
   80-99k/y 

















   Excellent 
   Very good 
   Good 
   Fair 




















Table A-F. Baseline Data for all Respondents  
Variable Average Standard 
Deviation 
Behavioral Intentions 4.86 .46 
Motivational Intensity 4.30 .80 
Self-efficacy 3.34 .98 
Outcome Expectation 3.43 .96 
Optimism 22.41 4.04 
Statin Medication Adherence 95.67 14.21 
 
N=326 
 
 
 
 
 
